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ABSTRACT
Antibody-mediated feedback suppression o f immunoglobulin 
production was investigated in early RA using the Facb fragment o f 
rabb it IgG. Suppression o f the PWM-stimulated IgG response in  early 
seropositive and palindromic RA patients was s im ila r to  tha t observed 
in normal con tro ls , but impaired suppression was observed in 
established RA subjects. There are also indications th a t early 
seropositive and seronegative disease may d if fe r  from each other with 
regard to  th is  control mechanism. The degree o f Facb suppression 
produced was found not to  corre late with any c lin ic a l indices of 
disease a c t iv ity .  Data also suggest tha t FacbR expression may be a 
marker fo r c e ll ac tiva tion  rather than an ind ica tor o f the a b i l i ty  to 
suppress.
The e ffe c t o f Facb on IgM RhF production was also examined. The 
k ine tics  o f suppression were d iffe re n t from those observed with IgG. 
The p o s s ib ility  tha t the Facb behaved as an antigen rather than an
FcR modulating ligand cannot be excluded.
Prelim inary studies using the multi valent ligand, Hagg, as an
FcR ligand were also carried out and IgG and IgM RhF responses
examined. Again, defective feedback suppression was observed in 
established RA patients compared to  contro ls.
The relevance o f the above observations to  the 




The work presented in th is  thesis concerns the in  v itro  
modulation o f the humoral immune response by mononuclear FcR+ ce lls  
in  rheumatoid a r th r i t is .  In p a rtic u la r, FacbR+ ce lls  have been 
investigated w ith regard to  th e ir  immunoregulatory ro le  in  early 
disease. This chapter is  therefore divided in to  three sections:-
1. Rheumatoid a r th r i t is  -  i t s  c lin ic a l course, pathology, patho­
genesis, aetiology and an assessment o f immunoregulatory 
pathways.
2. Antibody-mediated suppression and FcR+ c e lls .
3. FacbR+ ce lls  in  RA; aims o f the p ro jec t.
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SECTION 1 RHEUMATOID ARTHRITIS
Rheumatoid a r th r it is  (RA) is  a chronic inflammatory disease o f 
unknown aetiology which a ffects  p rim arily  the synovial jo in ts .  I t  is  
characterised by synovial p ro life ra tio n  and ju x ta -a rtic u la r erosions 
which lead to  progressive jo in t  damage and d is a b il ity .  The disease 
is  systemic in  nature and in  severe cases a ll major systems o f the 
body are affected, giving r is e  to  e x tra -a rticu la r features such as 
v a s cu lit is , nodules, sicca syndrome and lymphadenopathy. In a small 
number o f patients, where splenomegaly and neutropenia are associated 
features, the disease is  termed 'F e lty 's  syndrome1.
Some 2% o f the population is  affected by RA, the incidence being 
three times greater in  women than in  men (Currey, 1983). I t  has a 
worldwide d is tr ib u tio n  and although onset may occur a t any age, the 
disease generally develops between the ages o f 30 -  50 years. The 
onset may be acute, insid ious or palindromic. Patients present with 
jo in t  pain, s tiffness  and swelling. Prodromal features include low 
grade fever, weight loss and fa tigue . With acute onset jo in t  
symptoms appear w ith in  a few days or weeks, a ffecting  many jo in ts  in 
a symmetrical fashion. Most patients, however, have an insid ious 
onset where symptoms emerge over several months, gradually involving 
more jo in ts  in  a roughly b ila te ra l d is tr ib u tio n . With palindromic 
onset, symptoms f l i t  between jo in ts , las ting  fo r only a few hours or 
days each time over a period o f several weeks or months before 
becoming persistent in  nature. The disease follows a cha rac te ris tic  
rem itting-re lapsing course and although in  some patients i t  may rem it 
spontaneously, in  most there is  a gradual de te rio ra tion , w ith 50% o f 
patients s ig n if ic a n tly  disabled 10 years a fte r onset (Hardin Or 
(1985).
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The f i r s t  jo in ts  affected are usually the small jo in ts  o f the 
hands, w ris ts  and fee t and also the knees. As the disease progresses 
large jo in ts  become involved, including the elbows, shoulders, hips, 
ankles, subtalar and sternoclavicular jo in ts .  Spinal involvement is  
lim ited  to  the upper cervical region. The changes which occur in  the 
jo in t  during the disease process are described below, fo llow ing the 
description o f the normal jo in t .
1. Structure of the normal jo in t
The synovial jo in t  consists o f two a rticu la tin g  ends o f bone 
covered by hyaline ca rtilage  and enclosed in  a jo in t  capsule (Figure 
1). The la t te r  is  composed o f dense fibrous tissue and contains 
numerous nerve fib re s . The capsule is  lined by a synovial membrane 
(synovium), the innermost (in tim a l) layer o f which consists o f two 
main types o f c e lls , or synoviocytes. These form a discontinuous 
layer one to  three ce lls  th ic k . Type A ce lls  are phagocytic and 
involved in  the removal o f material from the jo in t ;  type B ce lls  
produce protein and hyaluronate. I t  is  thought tha t these two types 
o f synoviocyte represent d iffe re n t functional states o f the same ce ll 
(Ghadially, 1983). An intermediate type C ce ll has also been 
observed. The intim al layer lie s  on a layer o f loose vascular, 
ace llu la r connective tissue, called the subsynovium, which merges 
with the periosteum o f the bone. The synovium does not cover the 
hyaline ca rtila ge .
The hyaline ca rtilage  appears macroscopically as a smooth, 
g lis ten ing  structure which covers the bone. I t  consists o f ce lls  
called chondrocytes which synthesise the other two components o f 
ca rtilage  -  the fib res  and the m atrix. The fib res  are made o f type I I
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collagen which is  composed o f three coiled polypeptide chains 
arranged in to  a t r ip le  he lix  configuration. These molecules are 
quarter staggered to  each other to  form f ib r i l s  which in  turn form 
the fib re s . The la t te r  vary in  thickness and d is tr ib u tio n  w ith in  the 
ca rtilage  (Z v a ifle r , 1977). The matrix consists o f proteoglycans, 
which comprise repeating disaccharide subunits linked covalently to  a 
protein core (Z v a if le r , 1977) and contain mainly chondratin sulphate 
A and C and keratan sulphate. These are attached via a lin k  protein 
to  hyaluronate forming large aggregates which are trapped in the 
collagen network. The proteoglycans are viscous and hydrophilic . 
They absorb water causing the collagen network to  swell, thus giving 
ca rtilage  i t s  firmness and e la s t ic ity .  The chondrocytes have lo s t 
much o f th e ir  a b i l i t y  to  undergo m ito tic  d iv is io n , so regeneration is  
lim ite d . Though m etabolically active , the hyaline ca rtilage  contains 
no blood vessels or nerves. Nutrients are derived from the synovial 
f lu id  by d iffu s io n .
The jo in t  cav ity  is  normally f i l le d  with a small amount o f f lu id  
which is  c lear, colourless and does not c lo t ,  due to  the absence of 
fibrinogen. This is  the synovial f lu id  (SF). I t  is  often described 
as a dialysate o f plasma (Sandson and Hamerman, 1962) but which 
contains some 2 % o f hyaluronate, giving i t  i t s  cha racte ris tic  
v iscos ity . SF lubrica tes the load-bearing surfaces, allowing them to 
move more easily  over each other. I t  also allows transport o f 
nutrien ts to  the ca rtila ge , as mentioned above, as well as carrying 
material resu lting  from the da ily  wear and tear w ith in  the jo in t  to 
type A ce lls  fo r  removal by phagocytosis. The SF contains very few 
c e lls . Those tha t are present are thought to  be derived from the 
1 in ing .
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2. Pathology of the rheumatoid jo in t
In RA, the e a rlie s t lesions observed are vascular. This comes 
from the work o f Kulka e t al (1955) and Schumacher and K itridou 
(1972) who analysed biopsies taken from patients with disease o f only 
s ix  weeks' duration. These authors found signs o f an increased blood 
flow and enhanced vascular permeability producing oedema. All 
samples exhibited microvascular in ju ry  as evidenced by extravasation 
o f red blood ce lls  (RBC), vascular occlusion, the presence o f gaps 
between endothelial ce lls  and endothelial ce ll damage. Lymphocytes 
and polymorphonuclear ce lls  (PMN) were found in f i l t r a t in g  the 
superfic ia l synovial membrane and also observed perivascu larly. No 
plasma ce lls  were seen. Mild p ro life ra tio n  o f synoviocytes was also 
observed, with both type A and B ce lls  being affected. There was 
also some evidence o f phagocytosis. Mononuclear ce lls  (MNC) were 
found to  be the predominant ce ll in  the SF, although some PMN were 
also present. A ll changes were focal so tha t depending on where the 
biopsy was taken, some areas appeared normal.
Whilst reports o f early changes in RA are scarce because o f the 
d i f f ic u l ty  in  accurately diagnosing the disease at th is  stage, 
descriptions o f established disease are abundant. Most authors 
(Sokoloff, 1979; Harris Or, 1985; Z va ifle r and S ilve r, 1985) agree on 
the fo llow ing course o f events.
Progressive disease produces a highly characte ris tic  oedematous 
and hypertrophied synovial l in in g . The synoviocytes are present in  a 
layer which may well reach a depth o f some 1 0  -  2 0  ce lls  and the 
lin in g  ce lls  may e xh ib it hyperplasia. Multi nucleate c e lls , thought to 
be derived from type A ce lls  (Ghadially and Roy, 1969), may also be 
seen in  the intim al layer. More common, however, are the 
in te rd ig ita tin g  ce lls  which occur in  s ig n if ic a n tly  greater numbers in
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the RA synovium compared to  those from normal or non-RA inflammatory 
jo in ts  (Oanossy e t a l , 1981). These c e lls , which have long branching 
processes, lack macrophage, lymphocyte or fib ro b la s t characte ris tics, 
but are strongly DR+. Oust beneath the lin in g  there is  a rich  
ca p illa ry  network. Many o f these blood vessels have fenestrations 
such as those observed in  glomeruli. As well as the formation o f new 
blood vessels, vascular lesions observed in early disease are exag­
gerated. Thus, venous distension, ca p illa ry  occlusion, a rte r ia l wall 
in f i l t r a t io n  by neutrophils, areas o f thrombosis and perivascular 
haemorrhage are regular findings in  established disease.
Most typ ica l o f established RA, however, is  the intense i n f i l ­
tra tio n  o f the subsynovium by MNC, mainly lymphocytes and plasma 
c e lls . These co lle c t in  aggregates or fo l l ic le s ,  especially around 
small blood vessels (Gardner, 1965). True germinal centres, however, 
are not frequently seen and when present usually occur in 
longstanding RA (Sokoloff, 1979).
Immunofluorescence studies have shown tha t the principal i n f i l ­
tra tin g  ce ll is  the T lymphocyte (Abrahamsen, 1975; Van Boxel and 
Paget, 1975), although B ce lls  are also present but in lower 
percentages than those observed in the corresponding blood 
(Abrahamsen et a l , 1975; Van Boxel and Paget, 1975). Three types o f 
d is tr ib u tio n  o f the lymphoid ce lls  may be observed: lymphocyte rich  
areas, plasma ce ll r ich  regions and tra ns itio na l areas where 
macrophages, lymphocytes and plasma ce lls  are intermixed (Ishikawa 
and Z i f f ,  1976). T ce lls  are found perivascularly and B ce lls  are 
located in  centres o f lymphoid fo l l ic le s  (Konttinen e t a l , 1981). 
In some patients the various lymphoid ce lls  are scattered throughout 
the synovial tissue.
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In contrast to  early disease the predominant ce ll in  the SF is 
the PMN, with ce ll numbers ranging from a few thousands to  tens of 
thousands per mm3  in  severe active disease (Harris Or, 1985). This 
high c e llu la r ity  gives synovial f lu id  i t s  tu rb id  appearance 
macroscopically. MNC are also present but these are in  the m inority. 
As the inflammation progresses the connective tissue ce lls  and 
vasculature o f the synovial stroma undergo a marked p ro life ra tio n  to 
produce an aggressive granulation tissue known as 'pannus'. This 
grows from the jo in t  margins to  cover and digest the ca rtilage . The 
greatest amount o f a r tic u la r  destruction occurs a t the periphery of 
the ca rtila ge . I t  is  thought tha t the e a rlie s t process is  brought 
about by immature synovial c e lls  (before pannus formation) which 
arise from the recesses a t the margin o f the jo in t  and creep across 
the surface o f the ca rtila ge . These ce lls  appear to  digest the 
proteoglycans enzymically and inse rt themselves between the collagen 
fib re s . Loss o f ground substance is  also observed in  areas away from 
the advancing margins o f the p ro life ra tin g  synovium, ind icating the 
importance o f soluble factors.
Cartilage destruction appears to  occur in  waves, each followed 
by maturation o f the granulation tissue . Kobayashi and Z i f f  (1975) 
described three types o f pannus: the f i r s t  resembles the synovium and 
contains p ro life ra tin g  blood vessels and perivascular mononuclear 
c e lls ; the second resembles granulation tissue and consists o f 
monocytic c e lls  and fib rob la s ts ; the th ird  varie ty  consists o f dense 
avascular, ace llu la r fibrous tissue which attaches strongly to  the 
ca rtilage . I t  is  not known whether each kind progresses to  the next 
or whether they develop separately. Coverage o f the ca rtilage  by the 
pannus may also promote damage through interference with the 
n u tr it io n  o f the former.
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Bone destruction appears f i r s t  as a marginal or ju x ta -a rticu la r 
erosion, where the bone is  not covered by ca rtila ge . This gives the 
a rticu la tin g  end a 'chewed-out' appearance ra d io lo g ica lly . Further 
destruction occurs with the pannus burrowing through the d is­
in tegra ting  ca rtilage  to  the bone. Osteoclasts may be involved. The 
synovial f lu id  is  greatly  increased in  volume and quite watery and 
therefore no longer able to  provide adequate lub rica tion  o f the 
a rticu la tin g  surfaces. This also resu lts  in  a high in tra -a r tic u la r  
pressure which may be instrumental in  producing damage to the 
ca rtilage  and bone. Furthermore, i t  is  believed to  be responsible 
fo r extrusion o f the jo in t  cavity  in to  the neighbouring so ft tissues, 
causing much o f the pain experienced by the patient upon movement. 
The fibrous collagenisation which occurs with pannus maturation leads 
to  the shrinking o f the capsule and the increasing approximation o f 
the ends o f opposing bones. Subluxation is  observed in some cases 
where the bone ends impinge upon each other with complete elim ination 
o f the jo in t  space. Weakening o f capsular and ligamentous supports 
by inflammation and tendon contracture and rupture are also thought 
to  be important in  producing jo in t  deform ities.
A ll these changes lead to  progressive loss o f jo in t  function and 
in  turn are believed to  be responsible fo r muscle atrophy and 
contracture (Maini, 1977). The patient is  thus le f t  h ighly disabled 
and in  pain and probably has complications o f e x tra -a rticu la r (EA) 
disease as described below.
3. Extra-articular manifestations of RA
These are found mainly in  seropositive disease which tends to  be 
more severe. S eropositiv ity  re fers to  the presence o f an IgM 
autoantibody known as 'rheumatoid fa c to r ' (RhF) in  the patients '
10
sera. This is  directed against determinants on the Fc portion o f IgG 
and was o r ig in a lly  thought to  occur only in  RA, hence the 
nomenclature. This, however, is  not true since rheumatoid factors 
have been demonstrated in  a varie ty o f other diseases and also occur 
in  a small percentage o f the normal population (reviewed Koopman and 
Schrohenloher, 1985). Anti-IgG a c t iv ity  has also been demonstrated 
in  other classes o f immunoglobulin, except IgD. These RhF, however, 
are not rou tine ly  measured in  the laboratory.
Table 1 l is t s  the various forms which e x tra -a rticu la r disease 
may take. Nearly a ll systems o f the body may become involved, but 
only in  a very small percentage o f patients do life -th rea ten in g  
conditions develop. Seventy f iv e  percent o f RA patients are believed 
to  e xh ib it one or more manifestations o f EA disease (Dieppe e t a l ,
1985). Among the commonest features o f systemic disease are
rheumatoid nodules and v a s c u lit is . The la t te r  is  in  fa c t thought to  
be responsible fo r many o f the other manifestations o f EA disease. 
However, o f p a rticu la r relevance to  the current work is  the
occurrence o f F e lty 's  syndrome in  about 1% o f RA patients (Short e t 
a l , 1957). This variant o f chronic RA was f i r s t  described in 1924 
and represents a very severe form o f rheumatoid disease which is  
associated with splenomegaly and neutropenia (Fe lty , 1924). Skin 
hyperpigmentation, leg u lcers, anaemia, thrombocytopenia and
generalised lymphadenopathy may also be accompanying features
(Z v a ifle r , 1977). The a r th r i t is  is  usually a t an advanced stage with 
numerous jo in t  deform ities and appears frequently as a burnt-out 
disease. I t  may also present as severely active disease. High 
RhF t i t r e s  are often observed in  these patients.
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Bland e n d a rte ritis ; necrotizing a r te r i t is ,  
serious; rheumatoid nodules 
Mainly p e rica rd itis  
P leurisy; fib ro s is
Symmetrical sensory, m ild; patchy motor and 
sensory, serious.
Dryness (Sjogren's syndrome), common;
s c le r it is  rare , ominous
Not rare; local or general
Rare; with leucopenia = F e lty 's  syndrome
Mainly amyloid, or drug induced
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4 . Pathogenesis o f RA
Much o f the damage seen in RA is  immunologically mediated. This 
is  evident not only from the jo in t  pathology, where a ll manner of 
lymphoid ce lls  and th e ir  products have been demonstrated, but also 
from in  v it ro  and c lin ic a l studies. For example, Stastny e t al 
(1975) reported tha t explants o f rheumatoid synovium were capable o f 
generating both antibody and lymphokines in  v i t r o , supporting the 
description o f the rheumatoid synovium as an ectopic lymphoid organ 
(Z v a ifle r, 1973). C lin ica l studies have shown tha t removal o f 
c ircu la tin g  lymphocytes via the thoracic duct produces symptomatic 
r e l ie f  in  patients with active disease, w h ils t in jec tin g  these ce lls  
back in to  the subject exacerbates the disease process (Pearson e t a l, 
1975).
Figure 2 summarises the sequence o f events which is  thought to 
be responsible fo r the various pathological changes w ith in  the jo in t  
and which leads u ltim a te ly  to  i t s  destruction.
The main destructive elements in  rheumatoid disease are 
lysosomal enzymes and oxygen free rad ica ls . Lysosomal enzymes are 
released from PMN and macrophages e ithe r during the process of 
phagocytosis or fo llow ing ce ll death. They contain elements which 
are able to  degrade both components o f ca rtila ge , ie  the proteo­
glycans and the collagen framework. The e a rlie s t ca rtilage  damage 
observed is  the loss o f ground substance. This is  seen h is to ­
lo g ic a lly  as an absence o f metachromatic sta in ing . The aggregates o f 
proteoglycan are broken down by the PMN serine neutral proteases 
elastase and cathepsin 6 , which act on the protein core and the lin k  
p ro te in . The soluble components are then degraded in tra c e llu la r ly  by 
the ac id ic  cathepsin B and D. RA patients are also found to  possess
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LEGEND TO FIGURE 2
I t  is  currently  believed tha t the in it ia t in g  antigen may become 
localised in the a rtic u la r  cav ity , where local macrophage/dendritic 
ce lls  process and present the antigen to  T c e lls . There is  release 
o f IL-1 from the macrophages, activa ting  a subpopulation o f T ce lls  
to  generate IL-2. This lymphokine produces p ro life ra tio n  and 
d iffe re n tia tio n  o f other T ce ll populations. Thus inducer T ce lls  
are generated which through the medium o f helper factors stimulate B 
ce lls  to  immunoglobulin synthesis. Immune complexes are formed and 
complement fixed , producing a number o f anaphylactic and chemotactic 
fac to rs . These increase the local blood flow and vascular perme­
a b i l i t y ,  leading to  an in flu x  o f PMN and large molecular weight 
proteins such as fibrinogen and kininogen. The la t te r  are activated, 
generating factors which fu rthe r enhance the inflammatory process. 
Phagocytosis by both micro and macrophages resu lts  not only in the 
e x tra ce llu la r release o f lysosomal enzymes capable o f digesting 
a r tic u la r  tissues, but also in  the production o f pro-inflammatory 
arachidonic acid metabolites and oxygen free rad ica ls . These, 
together with ce ll ac tiva tion  products, set up a series o f highly 
complex, in te r-re la te d  positive  feedback networks which lead 
u ltim a te ly  to  the destruction o f the jo in t .
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high levels o f enzymes which are capable o f digesting the 
polysaccharide side chains o f chondrotin sulphate and keratan 
sulphate (Harris Or, 1985). Once the proteoglycan is  removed, not 
only is  the ca rtilage  less able to  re s is t a deforming force and 
therefore at a greater r is k  o f mechanical d isruption , but i ts  
in fras truc tu re  is  also now open to  p ro te o ly tic  attack (Z va ifle r, 
1977). Elastase and cathepsin G so lu b ilize  the collagen by attacking 
the non-helical regions o f the molecule and breaking down the 
interchain cross linkages. At 37°C the polypeptide chains unwind and 
are now susceptible to  p ro teo ly tic  attack by spec ific  collagenase. 
This enzyme is  elaborated by both the macrophages and the dendritic  
c e lls  o f the pannus (Mizel e t a l , 1980) and by the chondrocytes 
(Gowan e t a l , 1984) in response to  in te rleuk in  1 (IL -1 ). So collagen 
breakdown occurs from above as well as from w ith in  the ca rtila ge . 
Collagenase cleaves the polypeptide chains in to  two fragments which 
are fu rth e r degraded to  ge la tin  by a va rie ty  o f natural proteases 
including specific  'gelatinases 1 (Harris Or, 1985). In severe 
aggressive synovitis , f ib r i ls  may be phagocytised whole by activated 
macrophages.
Although protease in h ib ito rs  such as a  2  macroglobulin and a-1  
a n titryps in  are present w ith in  the jo in t ,  i t  is  probable th a t these 
are saturated, since free collagenase has been demonstrated in  RA 
effusions (Harris Or, 1985). Although th is  enzyme is  released in an 
inactive  form (Werb e t a l , 1977), the synovial f lu id  contains factors 
which are able to  activa te  i t .  These include p ro teo ly tic  enzymes and 
plasmin. Plasmin is  generated from plasminogen in  SF by plasminogen 
a c tiva to r. This is  secreted by rheumatoid synovial c e lls  (Werb et 
a l , 1977) as well as the endothelial ce lls  o f small blood vessels in 
the pannus.
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Oxygen free radicals (Ros) fu rthe r enhance p ro teo ly tic  attack by 
inac tiva ting  protein enzyme in h ib ito rs  (Carp and CJanoff, 1980). 
These radicals are generated by phagocytic ce lls  fo llow ing a 
resp ira to ry  burst which can be stimulated e ithe r by phagocytic 
a c t iv ity  or when immune complexes (ICs) or chemotactic factors are 
bound to  the ce ll surface. Perturbation o f the ce ll membrane by such 
s tim u li leads to  an increase in oxygen consumption, enhanced a c t iv ity  
o f the hexose monophosphate shunt and the generation o f h ighly 
reactive species o f oxygen. These include superoxide anion, hydrogen 
peroxide and hydroxyl rad ica ls . The la t te r  are amongst the most 
reactive chemical species known and are generated in an iron - 
catalysed reaction from superoxide anion and hydrogen peroxide 
(H a lliw e ll, 1978). This is  known as the Haber-Weiss reaction and may 
be enhanced in the rheumatoid jo in t  since increased levels o f iron 
are available fo llow ing micro-haemorrhage in  the synovial tissue 
(Harris Or, 1985).
Large quantities o f these oxygen derivatives are released 
e x tra ce llu la r ly  (Rosen and Klebanoff, 1979) where they have the 
potentia l fo r much tissue damage. For example, H2 02  is  reported to  
be d ire c tly  to x ic  to  ce lls  including endothelial ce lls  o f blood 
vessels (Weiss et a l , 1981) and OH radicals are able to  d is rupt ce ll 
membranes by l ip id  peroxidation and the breakdown o f fa t ty  acids. 
Oxygen free radicals also have the a b i l i ty  to  degrade hyaluronic acid 
(McCord, 1974), thereby reducing the v iscos ity  o f the synovial f lu id  
and diminishing i t s  lub rica ting  properties. These data come la rge ly  
from in  v it ro  studies since d ire c t evidence o f Ros involvement is  
d i f f i c u l t  to  obtain due to  the rapid disappearance o f these radicals 
from the jo in t .  However, Lunec et al (1981) demonstrated increased 
levels o f free radical induced l ip id  breakdown products in  RA
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synovial f lu id  compared to  OA effusions. In v it ro  studies by Oasin 
(1983) have shown tha t Ros damage IgG molecules producing structura l 
changes which are s im ila r to  those observed in  immunoglobulins 
obtained from rheumatoid samples (Wickens and Dormandy, 1982). Such 
damage may expose new antigenic s ites or lead to  protein aggregation.
The potentia l fo r oxidative damage in  the RA jo in t  is  enhanced 
by an absence o f enzymes such as superoxide dismutase and catalase 
(Blake et a l , 1981), which protect against free radical damage, and 
the depressed levels o f ex tra ce llu la r scavengers such as SH groups 
(Hall e t a l , 1984). The la t te r  are thought to  be oxidised by 
chloramines which are generated by PMN ch lorination o f endogenous 
amines in the presence o f H2 O2  and myeloperoxidase. SH groups are 
also important fo r the a c t iv ity  o f certa in  proteins and fo r normal 
accessory ce ll function (McKeown e t a l,  1984).
As well as th e ir  destructive e ffects  on the rheumatoid jo in t ,  
lysosomal enzymes and oxygen free radicals are also able to  promote 
the inflammatory reaction. For instance, the former are able to 
cleave components o f complement (Goldstein and Weissman, 1974) 
w h ils t the la t te r  through non-specific ce ll damage activate the 
membrane enzyme phospholipase ^  ^ i s  enzyme is  found in a varie ty 
o f ce ll types and activa tion  by a wide range o f s tim u li, which 
include bacteria l ce ll products, immune complexes and chemotactic 
peptides, leads to  the release o f fa t ty  acids from the plasma 
membrane. Of these, arachidonic acid (AA) is  the most important. 
This can be metabolised by two enzymatic pathways, generating two 
main classes o f inflammatory mediators -  the prostaglandins (PGs) and 
the leukotrienes (LTs). PGs are generated via the cyclo-oxygenase 
pathway, where AA is  converted f i r s t  to  PGG2  and then PGH2. From the 
la t te r  are produced the stable prostaglandins PGE2» PGE2  and D2
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(Pelus and Strausser, 1977). In p la te le ts  PGH2  is  converted to 
thromboxane and in  vascular endothelial ce lls  to  prostacyclin. These 
mediators cause vasodilation and potentiate the pain produced by 
other inflammatory agents such as bradykinin and histamine (H all,
1986). PGE2  is  also known to  promote bone resorption (Robinson et 
a l , 1975), a process involving osteoclasts stimulated by IL-1. PGs, 
in p a rticu la r those o f the E series, have been shown to  possess 
immunomodulatory properties (Goodwin e t a l , 1984). This is  to  be 
discussed in greater de ta il in  a la te r  section.
The lipoxygenase pathway, which has been best investigated in 
neutrophils, gives r ise  to  leukotrienes. These arise from the 
conversion o f AA to  5HPETE which can be processed to  5HETE or to the 
leukotriene LTA4 . The la t te r  may be converted to  LTB4  or to  LTC4 , 
LTD4  or LTE4 , which together form the slow reacting substance of 
anaphylaxis (SRS-A). Not only is  LTB4  a powerful chemotactic factor 
fo r PMN (Ford-Hutchinson e t a l , 1980) but i t  also prolongs the 
increased vascular permeability produced by other mediators (eg C5a). 
I t  has also been found to  stimulate the release o f oxidative products 
from activated neutrophils (Goetzl and P ickett, 1980). This, 
together with raised levels o f LTB4  reported by Rae e t al (1982) 
probably serves to  enhance the inflammatory response w ith in  the RA 
jo in t .
Phagocytic ce lls  which are the source o f these destructive and 
inflammatory mediators (lysosomal enzymes, AA metabolites, Ros) are 
lured to  the s ite  o f inflammation by chemotactic fac to rs . Here, 
th e ir  entry is  fa c il ita te d  by anaphylotoxins which enhance the 
vascular perm eability. They also cause vasodilation thus increasing 
the number o f ce lls  gaining entry to  the tissues. Most o f these 
e ffec to r molecules are generated during the process o f complement
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f ix a tio n  and arise mainly from the cleavage o f complement (C1) 
components C3 and C5. Thus, C3a and C5a behave as anaphylotoxins. 
These, through d ire c t action (C5a) or in d ire c tly  through mast ce ll 
ac tiva tion  (C3a, C5a) -  which causes release o f the vasoactive amines 
histamine and serotonin -  bring about the vascular changes described 
above. C5a is  also cast in  the ro le  o f main PMN chemotactant. I t  is  
a potent substance which can increase PMN adhesiveness to  the 
endothelium o f blood vessels as well as in c ite  these ce lls  to 
oxidative metabolism, lysosomal enzyme release and the generation o f 
AA derivatives. Other chemotactants include those derived from mast 
c e lls , and the activated complex C5b67. The la t te r  is  also involved 
in  'bystander attack' (Lachman, 1980). Although most o f th is  complex 
is  membrane bound, some may be found free in  the in te r s t i t ia l  f lu id .  
Here i t  binds to  'innocent c e lls ' in  the v ic in ity  and completes the 
complement cascade by f ix in g  the remaining C8  and C9 components o f 
C '. This resu lts  in  ce ll ly s is  due to  osmotic shock. I t  is  believed 
tha t many o f the va scu litic  lesions produced w ith in  the rheumatoid 
jo in t  and elsewhere in the body are due to  the deposition o f ICs in 
the blood vessels, which then bind C' with a ll i t s  attendant e ffec ts . 
RA has in  fac t been described as an 'extravascular immune complex 
disease' by Z va ifle r (1974).
Both alternate and classical pathways o f complement are 
activated in RA. This is  indicated by s ig n if ic a n tly  lower 
concentrations o f C4, C2 and C3, and factors B and P in RA effusions 
compared to  those obtained from subjects with non-RA disease (Ruddy 
and Austen, 1970; Ruddy e t a l, 1975). This decrease is  greater in  
seropositive disease, probably due to  a more aggressive disease. 
Serum C' leve ls, however, are w ith in  the normal range or increased 
(Schur, 1985). A high local consumption o f C' is  probably due to the
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large quantities o f ICs which are present in  the RA jo in t .  These 
have been demonstrated in  the SF and in  the menisci and the ca rtilage  
o f RA patients using immunofluorescence techniques (Cooke e t a l , 
1975). Entrapment in  the la t te r  jo in t  tissues may be due to  charge 
differences between the macromolecules o f ca rtilage  and 
immunoglobulins (Harris Or, 1985). Analysis o f immune complexes have 
shown tha t although ICs containing anti nucle ic, anti collagen and 
anti fibrinogen antibodies are present, most o f the ICs w ith in  the 
rheumatoid jo in t  contain rheumatoid fac to r (Z va ifle r, 1977). These 
may be complexes o f IgM RhF and IgG or intermediate sized complexes 
formed from molecules o f se lf-associating IgG RhF. Much o f th is  RhF 
is  believed to be generated lo c a lly , since up to  90% o f the plasma 
ce lls  present in  the rheumatoid synovium are reported to  be committed 
to  anti-IgG antibody production (Munthe and Natvig, 1972; Youinou e t 
a l , 1984a). In te res ting ly , the synovia o f seronegative RA patients 
have also been shown to be engaged in  rheumatoid fac to r formation 
(Munthe and Natvig, 1972). Although IgM RhF is  more frequently found 
in the synovial tissues o f seropositive patients compared to  
seronegative subjects, IgG RhF is  found to  be the predominant class 
generated (Natvig and Munthe, 1975). This exuberant synthesis o f 
autoantibody is  probably greatly  aided by the presence o f large 
numbers o f Class I I  pos itive  antigen presenting ce lls  and T helper 
ce lls  with which they are in  close association (Oanossy e t a l , 1981). 
Immunofluorescence has revealed tha t many o f these T ce lls  are 
activated. This is  probably a consequence o f IL-1 a c t iv ity  which 
also activates B c e lls . This in te rleuk in  has been demonstrated in  
the synovial f lu id s  o f RA patients (Fontana e t a l , 1982; Wood e t a l,  
1983). I ts  production by both c ircu la tin g  and synovial RA ce lls  in  
v it ro  is  reported to  be s ig n if ic a n tly  higher compared to  tha t
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observed with normal PBMNC (Nouri e t a l , 1985). I t  probably has a
profound e ffe c t on the inflammatory process in RA since i t  has been 
reported to  stimulate synoviocytes to  secrete collagenase and PGs. 
I t  induces fib ro b la s t p ro life ra tio n  and activates chondrocytes to 
induce ca rtilage  destruction and stimulates bone resorption. 
Neutrophilia, pyrogenicity and the acute phase response (hence the 
fever observed in the patient and the raised CRP etc o f the c lin ic a l 
p ro file )  are also a ttribu ted  to  th is  cytokine (reviewed Ta la l, 1985). 
What in it ia te s  the immune response in  the jo in t  is  not clear, 
although several p o s s ib ilit ie s  e x is t. These are described below.
5. Aetiology
Despite intensive research the cause o f RA remains unknown. 
However, p o s s ib ilit ie s  include an in fectious aetio logy, genetic 
predisposition to  the disease and abnormalities o f immunoregulation.
That RA may have an in fectious aetiology has a basis in  the 
observation tha t some in fectious diseases in  both man and animals may 
produce a r th r i t is .  Organisms such as Streptococci, Diphtheria 
b a c i l l i ,  Mycoplasma and slow acting viruses have a ll been implicated 
at various times (reviewed by Harris Or, 1981). More recently, Lyme 
disease in man has been described. This produces synovial changes 
s im ila r to  those observed in  RA and is  thought to  be caused by a 
spirochaete (Burgdorfer e t a l , 1982). In swine, the Erysiopelothrix 
organisms produce a r th r i t is  which closely resembles the human disease 
and c la s s ica lly , subacute bacteria l endocarditis is  accompanied by 
RhF production, levels o f which fa l l  o f f  once the disease is  
resolved. Johnson e t al (1985) have suggested th a t the anti-IgG 
a c t iv ity  may arise as a re su lt o f c ross-reac tiv ity  w ith bacterial 
antigens. More recently , Mouritsen (1986) has suggested tha t the
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autoantibody is  a n ti- id io ty p ic  fo r v irus induced anti-Fc antibody.
V ira l in fe c tio n , in  p a rticu la r by EBV, has recently featured 
prominently in  the aetiology o f RA. Alspaugh and co-workers (1976, 
1978) showed tha t some 67% o f patients with RA carried antibodies to 
EBV associated nuclear antigens (RANAs), w h ils t only 8 % o f normal 
subjects were p os itive . Furthermore, EBV is  also known to  be a 
polyclonal ac tiva to r o f human B ce lls  (Rosen e t a l , 1977) and can 
induce rheumatoid facto r production in v it ro  (Slaughter e t a l , 1978). 
This would explain the B ce ll hyperactiv ity  observed in  RA. However, 
anti-RANA antibodies also occur in  other diseases and therefore data 
are inconclusive regarding the importance o f EBV in RA.
Although some o f the above agents (eg bacteria l ce ll wall 
peptidoglyeans and mycoplasma containing complete Freund's adjuvant) 
have been used successfully in  generating models o f RA in laboratory 
animals, attempts to  iso la te  these organisms from the synovial 
tissues o f RA patients have proved u n fru itfu l (Harris Or, 1981). At 
present, there is  in s u ff ic ie n t evidence to  cast any o f the above 
micro-organisms in  an aetio log ica l ro le .
However, given tha t such a wide va rie ty  o f agents may produce 
a r th r i t is ,  i t  is  obvious tha t other factors must be involved in  
allowing the fu l l  expression o f rheumatoid disease.
In 1973, Brewerton e t al showed tha t a large percentage o f 
patients with ankylosing spondylitis  carried the HLA-B27 haplotype, 
suggesting tha t possession o f certa in  h is tocom patib ility  antigens may 
be linked with su sce p tib ility  to  p a rticu la r diseases. Since then a 
whole series o f associations between disease types and HLA antigens 
has been described, including the lin k  between RA and HLA-DRw4 
(Stastny, 1978). DR antigens are s im ila r to  murine la antigens which 
are encoded fo r by the immune response genes. These control T-B ce ll
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co-operation, suppression o f the immune response and antigen-induced 
antibody production (S ilve r and Z va ifle r , 1985). This led to  the 
proposal tha t RA might re su lt from an abnormal immune response in a 
gene tica lly  susceptible individual to  a perfectly  normal pathogen. 
However, i t  has been shown tha t the increased incidence o f HLA-DR4 is  
only observed in seropositive disease and tha t patients with 
seronegative RA do not d if fe r  from normal healthy controls (Alarcon 
e t a l , 1982). Thus, possession o f the DR4 haplotype is  thought to  be 
re la ted  only to  the degree o f disease severity and not to  the 
in d iv id u a l's  su sce p tib ility  to  RA (Jones e t a l,  1983). This is  
supported by the observation tha t some 95% o f F e lty 's  subjects are 
HLA-DR4 positive  (Alarcon, 1986).
Abnormalities o f immunoregulation have long been considered 
important in  the aetiopathogenesis o f RA. Whilst these may not 
in i t ia te  the disease, ce rta in ly  th e ir  importance in  allowing the 
establishment and the perpetuation o f the disease process cannot be 
understated. Inflammation is  usually a s e lf- lim it in g  process but i t  
is  c lear from the sections above tha t the immune system in RA is  
unable to  contain the various inflammatory processes occurring in  the 
jo in t  and elsewhere in  the body. This is  e ithe r because the immune 
system is  unable to  e ffe c tive ly  elim inate the in it ia t in g  antigen or 
to  adequately regulate a normal immune response to  the causative 
agent. In both s itua tions chronic inflammation is  produced. 
Furthermore, autoimmune phenomena are h igh ly cha racte ris tic  o f RA, 
where some 70% o f patients are seropositive (Z va ifle r, 1977). In 
normal subjects, response to  se lf-antigen is  suppressed or eliminated 
by regulatory pathways.
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In view o f the above, i t  is  probable tha t RA has a m ulti - 
fa c to r ia l aetiology which in  subjects w ith defective immunoregulation 
leads to  the development o f a common pathway o f inflammation which we 
term 'rheumatoid disease'. This concept has led to  the examination 
o f immunoregulatory pathways in RA. These are reviewed in Section7 .
6. Treatment of RA patients
RA occurs not as a single e n tity  but as a spectrum o f disease 
a c t iv it ie s ,  ranging from inactive or mild to  severely active erosive 
disease. This necessitates the use o f individual treatment regimes 
in  each patient depending on the severity o f illn e s s . The 
chemotherapy may modify the disease process or control spec ific  
manifestations o f i t ,  but i t  is  not curative , although in  some 
patients the disease may rem it.
The drugs used in RA may be divided in to  the fo llow ing 
categories:-
1. Non-steroidal anti-inflammatory drugs (NSAIDs)
2. Corticosteroids
3. Second lin e  or disease modifying drugs
4. Third lin e  or cytotoxic drugs.
Agents w ith in  each group may be used singly or more usually in  
combination with those from other groups. In i t ia l  therapy may begin 
w ith NSAIDs (asp irin , phenylbutazone, indomethacin and phenylalkanoic 
acids eg ibuprofen and naproxen) to  a lle v ia te  pain, fever and jo in t  
sw elling. These manifestations o f RA are caused by inflammatory 
mediators such as PGs, k in ins , acute phase proteins and by increased 
vascular permeability and enhanced blood flow . NSAIDs act by 
in h ib it in g  PG synthesis which in  v it ro  occurs by suppression o f 
cyclo-oxygenase a c t iv ity  (Vane, 1971). The use o f such agents in RA
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is  questionable in  the l ig h t  o f some PG data (see Section 1 (7.B)) 
which suggest tha t they may suppress the immune response in  the
jo in t .  However, not a ll NSAIDs are found to  be equally e ffec tive  in 
suppressing cyclo-oxygenase a c t iv ity  in  v i t r o , although c lin ic a lly  
they are equally potent. C learly, other mechanisms are involved and 
these are thought to  centre on the in h ib it io n  o f PMN function. Both 
lysosomal enzyme release (Smith and Iden, 1980) and oxidative 
metabolism (Smolen and Weismann, 1980) have thus been shown to  be
suppressed in v it ro  by NSAIDs. The main problems with using NSAIDs
are those o f asp irin  hypersensitiv ity  and, more im portantly, the
tox ic  si de-effects these drugs have on the GI tra c t (reviewed, Ward 
and Samuel son, 1981).
Patients examined in  the current study were e ithe r receiving no 
medication at the time o f investigation or only NSAIDs therapy. 
Other drug regimes are thus not d ire c tly  relevant to  the present 
investigation and therefore are only b r ie f ly  discussed. Their 
e ffects on the immune system are summarised in  Table 2.
In subjects whose disease a c t iv ity  is  not adequately controlled 
by NSAIDs, a more potent c.ass o f anti-inflammatory drug is  employed. 
These are the co rticoste ro ids, which in h ib it  the generation of a ll 
arachidonic acid derivatives by preventing activa tion  o f phospho- 
lipase A2. This is  thought to  occur through the generation o f an 
anti-phospholipase A2  prote in called lipocortin ,w hich is  believed to 
e ither block the active s ite  on the enzyme or reduce a v a ila b ility  o f 
i t s  substrate. Other e ffec ts  o f steroids on the immune system have 
also been reported (see Table 2)
Where disease a c t iv ity  remains unchecked by anti-inflammatory 
agents or NSAIDs, second lin e  therapy is  introduced. These drugs are 
often referred to  as slow acting or disease modifying agents. This
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TABLE 2 TREATMENT REGIMES IN RA, EXCLUDING NSAIP THERAPY
THERAPY EFFECT (most data derived from In vitro  studies) ADVERSE REACTION
Corticosteroids: eg hydrocortisone, Strongly anti-inflammatory; |  phosphollpase Peptic ulcers; Adrenal
prednisolone a c tiv ity ; |  T ce lls  and monocyte numbers suppression; Thin and frag ile
|T  ce lls  and monocyte numbers skin, delayed wound healing
Second lin e  drugs
i .  Gold eg sodium thiomalate, 1  phagocytic a c tiv ity ; |  chemotactic response; Protei nur1a; Thrombotytopeni a;
auranofin 1 PMN function; |  complement cascade 
+ 1n v itro  lvmDhocvte resDonses 
in vivo lymphocyte responses normal
Type 1 hypersensitivity
i i .  D-penici11 amine | T h a c tiv ity  1n presence o f CuS04 Thrombocytopeni a; Nephroti c
Free radical scavenging; Inh ib its  formation of syndrome; Erythematous rashes
IgG aggregates; Normalises accessory ce ll function
i i i .  Antimalarials eg chloroquine Lysosomatropic effects; |  Collagen degradation; Reti nopathy
hydroxychloroqui ne 1 IL-1 production
iv . Sulphasalazine 1  acute phase response - possible action on 
IL-1 production
Colon ulceration
Third lin e  drugs: Cytotoxic drugs eg In h ib it DNA replication Active against a ll actively
chlorambucil, cyclophosphamide, Cell deprivation of DNA precursor dividing ce lls  in the body eg in
azathioprine, methotrexate GI tra c t, gonads and bone marrow
is  because f i r s t l y  th e ir  e ffects  may not be apparent u n til a fte r 4 - 
6  months o f continued therapy. Secondly, these drugs appear to  be 
able to  h a lt or slow down the tissue destruction by a lte ring  the 
immune re a c tiv ity . Improvement in  c lin ic a l status can be assessed 
ra d io log ica lly  and by c lin ic a l (eg R itchie Index) and laboratory 
parameters (eg ESR, CRP and RhF le ve ls ). This group includes drugs
such as gold compounds, the SH-containing drug D-penici11 amine, the
antim alaria ls -  chloroquine and hydroxychloroquine, and sulpha- 
salazine. Gold and D-penici11 amine are most commonly used in 
trea ting  RA. Of the various e ffects these drugs may have on the 
immune system, one o f the most in te resting  observations in  recent 
years is  tha t mixtures o f CuS04  and D-penici 11 amine are found to  
in h ib it  T helper ce ll a c t iv ity  in v i t r o . This is  thought to  occur 
in d ire c tly  through the generation o f hydrogen peroxide. This may 
explain the reduction o f the serum immunoglobulin (Ig ) and RhF levels
seen in  patients treated with th is  agent.
Where disease a c t iv ity  is  not curbed by the use o f even second
lin e  drugs, th ird  lin e  agents are employed as a fin a l attempt to
pacify the aggressive disease process. These drugs are cytotoxic and 
produce th e ir  e ffects  by preventing d iv id ing  ce lls  from re p lica ting  
th e ir  DNA or by depleting the ce ll o f DNA percursors. These drugs 
are not selective fo r activated lymphocytes but act against a ll
ac tive ly  d iv id ing  ce lls  in  the body, namely those o f the GI tra c t ,  
bone marrow and gonads. The seriousness o f the risks  o f such 
treatment is  obvious.
Alongside the chemotherapy, RA management involves physiotherapy 
and programmes o f re s t and exercise. Where erosive disease has
produced destruction o f the jo in t ,  surgery may improve jo in t  function 
by replacement therapy, eg hip replacement.
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7. Imnunoregulation in RA
A. T cell subsets in RA
The e a rlie s t attempts a t investiga ting  immune function in  RA 
involved only the very basic analysis o f T and B ce ll responses to  
skin sensitis ing agents and mitogens. I t  was found th a t T ce ll 
responses were impaired w h ils t B c e lls  were h ighly activated 
(reviewed Hall and Bacon, 1981). The la t te r  was indicated by 
spontaneous Ig production by B ce lls  in  the peripheral blood and the 
synovial tissues (Al-Balaghi e t a l , 1982) as well as by enhanced 3 H- 
thymidine incorporation (Horwitz e t a l , 1970; Stratton and Peter, 
1978). More recently a decrease in the number o f mouse RBC rosetting  
ce lls  has been reported (Youinou et a l , 1984b), a fu rthe r ind ica tion  
o f B ce ll ac tiva tion . The absence o f T lymphocyte responses was 
a ttribu ted  to  p r io r committment o f these ce lls  to  an ongoing immune 
response. Enumeration o f to ta l T and B ce lls  by rosetting  techniques 
and immunofluorescent la b e llin g  fo r surface Ig respectively showed 
tha t the re la tive  percentages o f these ce lls  in  the peripheral blood 
o f patients were w ith in  the normal range.
In the early 1970's, i t  became apparent tha t the immune system 
is  regulated by subsets o f T helper and suppressor c e lls . C learly, 
an overproduction o f Ig may occur e ithe r through excessive T ce ll 
help or a lack o f suppressor influences. The la t te r  may also allow 
the development o f autoimmune phenomena.
T helper and suppressor c e lls  each carry spec ific  antigens which 
are used as markers fo r the p a rticu la r subset. These can be detected 
by monoclonal antibodies (McAbs). T helper ce lls  (TH) thus express 
the CD4+ antigen and T suppressor/cytotoxic (T$/q) c e lls , CD8 +. 
This delineation, however, is  not s t r ic t ly  accurate since these 
populations are heterogeneous in  function.
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Assessment o f T ce ll immunoregulatory pathways in  RA has 
involved both phenotypic and functional analysis o f these ce ll types,
i )  Phenotypic analysis o f T c e ll subsets
a) Peripheral blood
Analysis o f T ce ll subsets in  RA peripheral blood has shown 
the percentage o f TH and Ts/ q ce lls  to  be w ith in  the normal 
range (Burmester e t a l , 1981; Nilsson and B ibe rfie ld , 1982;
Egeland e t a l , 1983). Some authors have found the proportions 
o f CD4+ ce lls  s ig n if ic a n tly  increased and those o f CD8 + ce lls  
s ig n if ic a n tly  reduced compared to  normal peripheral blood c e lls  
(Fox e t a l , 1982; Verdickt e t a l , 1983). This discrepancy is  
probably re lated to  disease a c t iv ity .  For example, i t  is  
reported (Veys e t a l , 1982a; Duclos e t a l , 1982; Duke e t a l , 
1983) tha t only patients whose disease is  active are found to  
have reduced percentages o f CD8 + c e lls , w h ils t those with 
inactive  disease do not d if fe r  from normal healthy contro ls.
The former patien t group may also exh ib it a reduction in
absolute numbers o f CD8 + ce lls  (Fox e t a l , 1982; Veys e t a l ,
1982a; Duke e t a l , 1983). Total T ce ll number in RA peripheral 
blood, however, remains unchanged. The d e f ic it  le f t  by the 
decrease in the CD8 + populations described above may be made up 
by an increase in  th ird  population ce lls  as described by Sharpin 
and Wilson (1977).
Another p o s s ib ility  comes from the recent observation tha t 
the CD4+ population is  fu rthe r subdivided in to  helper inducer 
(HI) and suppressor inducer (SI) subsets (Reinherz e t a l , 1982). 
These are detected by McAbs, anti-4B4 and anti-2H4 respective ly. 
Thus, in  v it ro  CD4+4B4+ ce lls  are reported to  augment Ig 
production (Morimoto e t a l , 1985a) w h ils t CD4+2H4+ induce CD8 +
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ce lls  (Morimoto e t a l , 1985b). Analysis o f these subsets in RA 
has shown there to  be a reduction in SI ce lls  compared to normal 
healthy controls and patients with other a r tic u la r  diseases 
(Emery e t a l , 1987). This might explain the d e f ic it  o f CD8 + 
c e lls  reported by some o f the above authors.
In vivo ac tiva tion  o f peripheral blood T ce lls  in  RA has 
been reported to  be normal (Forre e t a l , 1982a; Duke e t a l , 
1983) or increased (Yu e t a l , 1980; Burmester et a l , 1981) as 
indicated by the expression o f Class I I  antigens. Burmester et 
al (1981) reported tha t the activated ce lls  belonged 
predominantly to  the CD8 + population. Using a decrease in 
lymphocyte density as an ind ica to r fo r ce ll ac tiva tion , 
Papadimitriou e t al (1982) found tha t increased numbers o f low 
density lymphocytes occurred only in  patients with active 
synovitis  but not in  those with active e x tra -a rticu la r disease,
b) Synovial f lu id
Most authors agree tha t the percentage o f CD8 + ce lls  is  
enhanced in the SF o f RA patients (Burmester e t a l,  1981; Duel os 
e t a l , 1982; Fox e t a l , 1982; Veys e t a l , 1982b), w h ils t tha t 
o f CD4+ ce lls  may be normal (Duke e t a l , 1983) or reduced 
(Burmester et a l , 1981; Duel os e t a l , 1982; Fox e t a l , 1982; 
Veys e t a l , 1982b) in comparison to  peripheral blood. Lydyard et 
al (1982) correlated th is  increase in CD8 + ce lls  with disease 
a c t iv ity .
The observations in  SF are surprising in  view o f the 
markedly depressed levels o f CD4+2H4+ ce lls  in  the SF (Emery et 
a l , 1987). Fox e t al (1982) have suggested tha t the increase in 
CD8 + ce lls  in  the SF and the re la tive  lack o f th is  phenotype in 
the peripheral blood is  probably due to  the migration of
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peripheral blood CD8 + ce lls  to  the SF where they become 
activated. Many o f the ce lls  in  the synovial f lu id  are reported 
to  be activated (G a li1i e t a l, 1981; Burmester e t a l,  1981; Fox 
e t a l , 1982; Duke e t a l , 1983). Duke e t al (1983) reported tha t 
though both CD4+ and CD8 + ce lls  bore Class I I  antigens, the 
m ajority belonged to  the former subset. This contrasts with 
others (Burmester e t a l , 1981; Fox e t a l , 1982) who reported 
tha t most o f the activated ce lls  carried the Ts/q phenotype,
c) Synovial membrane (SM)
Reports o f the proportions o f T ce ll subsets in  the SM have 
been c o n flic t in g . Whilst most investigators have demonstrated a 
preponderance o f CD4+ ce lls  in the SM, with ra tio s  o f CD4+:CD8+ 
ranging from 4:1 to  14:1 (reviewed Z va ifle r and S ilve r, 1985), 
reports o f normal proportions (Forre e t a l , 1982b) or reduced 
numbers (Egeland e t a l , 1983) o f these ce lls  are also to  be 
found. This is  probably due to  varia tions in  sampling, as in d i­
cated by studies conducted by Kurosaka and Z i f f  (1983). Using 
an immunoelectron microscopic technique these authors reported 
th a t in  lymphocyte r ich  areas CD4+ ce lls  were predominant, 
w h ils t in  tra n s itio n a l areas CD8 + ce lls  were in  the m ajority . 
Here these CD8 + c e lls  had the appearance o f b last c e lls  and were 
reported to  be in  close contact w ith macrophage-like c e lls . The 
la t te r  were also found in  CD4+ areas but in  smaller numbers.
Prelim inary studies by Salmon e t al (1987) have reported a 
reduction in  the numbers o f suppressor-inducer ce lls  in  the RA 
synovium, which might in  turn explain the diminished levels of 
CD8 + c e lls  in  th is  tissue . They also report tha t the principal 
in te rleuk in -2  (IL-2) producers are CD4+ 2H4+ cells.
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The in te rleuk ins 11-1 and 11-2 may also be important in 
determining the percentages o f c e lls  expressing the CD4+ and 
CD8 + phenotypes. 11-1 is  reported to  activate mainly CD4+ 
c e lls , which in  turn generate IL-2 , causing stim ulation o f CD8 + 
ce lls  (Alarcon-Segovia e t a l , 1985). Whilst production o f the 
former is  reported to  elevated in  RA (Nouri e t a l , 1985), tha t 
o f the la t te r  is  found to be reduced (Alcocer-Varela e t a l, 
1984; Miyasaka e t a l , 1984; Combe e t a l, 1985). Furthermore, T 
ce lls  from the rheumatoid synovium are found not to  respond to 
exogenous IL-2 (Miyasaka e t a l , 1984; Combe e t a l , 1985). This 
has been explained by p r io r a c tiva tio n . An average o f 40% o f T 
ce lls  in  the RA synovium are activated (reviewed Z va ifle r and 
S ilve r, 1985). Whilst some authors reported CD4+ c e lls  as HLA 
DR+ (Meijer e t a l , 1982a), others found CD8 + T ce lls  to  be 
carrying Class I I  antigens (Burmester e t a l , 1981). This again 
may be due to  sampling differences or as suggested by the 
findings o f Pincus e t al (1985) th a t T ce lls  can express both 
phenotypes follow ing activa tion .
Whatever the explanations fo r the differences in  the CD4+ 
and CD8 + ce ll representation in  the synovium, i t  has clear 
im plications fo r the immunological a c t iv ity  in  the RA jo in t .  
For example, Meijer e t al (1982b) found tha t in  synovial samples 
where Ts/ C ce lls  were present in  s im ila r proportions to  those of 
Th c e lls , fo l l ic u la r  arrangements were rare and the d iffe re n t 
ce ll types were d is tribu ted  d iffu se ly  throughout the synovium. 
Only in  samples where T$/c numbers were low was there a 
gathering o f ce lls  in to  fo l l ic le s .
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Phenotypic analysis, however, forms only an in i t ia l  assessment 
o f the regulatory pathways. I t  is  more important to  determine 
whether or not the ce lls  function in  th e ir  phenotypic ro le .
i i )  Functional analysis o f T c e ll subsets in  RA
In view o f B ce ll hyperactiv ity  in RA, much emphasis has been 
placed on the measurement o f suppressor T ce ll function, since i t  is  
generally believed the d e f ic it  is  more l ik e ly  to  be here,
a) Suppressor ce ll function in RA
Both spontaneous and Con A-induced suppressor a c t iv it ie s  
have been investigated in RA.
Peripheral blood. Suppressor a c t iv ity  in  RA peripheral 
blood has been found to  be normal (Patel e t a l , 1982; Romain e t 
a l , 1982) or depressed (Abdou e t a l , 1981a; Sakane e t a l , 1982) 
compared to  tha t observed in  normal blood. For example, Patel 
e t al (1982) found no difference in  Con A-induced suppressor 
a c t iv ity  between RA and control peripheral blood c e lls . 
However, Sakane et al (1982) who divided th e ir  RA patients in to  
various disease groups, discovered tha t there were d is t in c t 
differences between these subgroups. They found tha t in 
patients with early active disease (< 3 months duration), i t  was 
not possible to  generate Con A suppressor a c t iv ity  and th is  
correlated wiuth a reduction in  the number o f c ircu la tin g  T5 /Q 
c e lls . Anti-T lymphocyte antibodies were detected in the sera 
o f these patients and these were found to  be directed against 
CD8 + c e lls . Furthermore, ce lls  obtained from patients with 
early active disease were not responsive to  signals generated by 
normal Con A-induced suppressor c e lls . S im ilar resu lts  were 
obtained using PBMNC from patients with chronic active RA,
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although peripheral blood ce lls  from these subjects could be 
induced by Con A to exh ib it suppressor a c t iv ity .  Patients with 
inactive  disease behaved as normal con tro ls . S im ilar data were 
obtained by Abdou et al (1981) who examined suppression o f Ig 
synthesis and i t s  secretion. These authors, however, reported B 
ce ll function in  both early and chronic active RA to  be normal.
T ce lls  from RA patients have frequently been found to be 
unresponsive to  Con A, so i t  is  possible th a t th is  is  one reason 
why Con A-induced suppression may be defective in  patients with 
RA. However, antigen spec ific  suppression has also been found 
to  be s ig n if ic a n tly  reduced in these ind iv idua ls (Keystone et 
a l , 1980; Tosako e t a l , 1981).
Synovial jo in t .  In the jo in t  i t  is  generally accepted tha t 
unfractionated T suppressor ce ll function is  defective. Thus 
Chattopadhyay e t al (1979 a and b) reported the in a b il i ty  o f 
synovial tissue lymphocytes (STL) to  suppress p ro life ra tio n  and 
immunoglobulin synthesis in Con A-induced and spontaneous 
suppressor ce ll assays respective ly. In both assay systems STL 
were found to  enhance the immune response. S im ilar data were 
obtained by Romain e t al (1982) who examined the a b i l i ty  o f 
mainly SF lymphocytes (SFL) to  suppress d iffe re n tia tio n  o f auto­
logous peripheral blood c e lls . Deeming the lack o f suppression 
to  be due to inadequate helper a c t iv ity ,  these authors co­
cultured SFL with peripheral blood T ce lls  (which inc iden ta lly  
behaved as normal ce lls ) only to  fin d  tha t Ig synthesis was 
enhanced. This was surprising since most o f the SFL expressed 
the CD8 + phenotype. C learly, there was a discrepancy between 
phenotype and function. Romain e t al (1982) referred to  th is  
enhancement as ‘ helper augmentation’ and suggested tha t synovial
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CD8 + ce lls  may be analogous to  the murine contra-suppressor 
ce lls  described by Gershon e t al (1981). Egeland e t al (1983) 
obtained s im ila r data using a p u rifie d  CD8 + Leu 3a and B ce ll 
population.
However, in  studies where isolated CD8 + ce lls  have been 
examined, these ce lls  have been reported to  be very e f f ic ie n t  
suppressors (Egeland e t a l , 1983; Nilsson e t a l , 1986b). Thus, 
Nilsson e t al (1986b) found tha t SF CD8 + ce lls  could suppress 
PWM-induced Ig synthesis as well as control peripheral blood 
CD8 + c e lls . However, these authors found tha t choice o f mitogen 
may a ffe c t the outcome o f these functional assays since SF and 
blood CD8 + ce lls  were less able to  suppress PPD-stimulated 
cultures compared to  those stimulated by PWM. They suggested 
tha t th is  was because PWM was a much more e f f ic ie n t  generator o f 
suppressor a c t iv ity  (Nilsson e t a l , 1986a).
b) Helper a c t iv ity  in RA
Experiments analysing helper function in RA subjects have 
likewise produced co n flic tin g  data. Thus in  peripheral blood T 
helper function has been reported to  be defective (Bellamy et 
a l , 1983; Egeland e t a l , 1983), normal (Romain e t a l , 1982) or 
increased (Kluins-Neleman e t a l, 1984). Patel and Panayi (1984) 
examined spontaneous generation o f IgM RhF production in v it ro  
and reported tha t T ce lls  from RA patients produced enhanced 
help fo r autoantibody production which was not HLA re s tr ic te d . 
Thus normal as well as RA B ce lls  could be induced to  generate 
RhF when co-cultured with RA T c e lls .
In the jo in t ,  Petersen e t al (1986) reported tha t SF T 
c e lls  had a low a b i l i ty  to  co-operate with PWM-induced RhF
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secretion. Chattopadhay e t al (1979a), examining Ig production, 
found tha t synovial tissue lymphocytes did not d if fe r  from 
normal peripheral blood lymphocytes in  helper a c t iv ity ,  w h ils t 
Romain e t al (1982) found th is  to  be impaired compared to 
autologous peripheral blood T c e lls , which did not d if fe r  from 
normals. In studies examining isolated CD4+ c e lls , contra­
d ic to ry  data have been obtained. Whilst Egeland e t al (1983) 
found Leu 3a+ ce lls  to  be weak augmentors o f the antibody 
response, Nilsson e t al (1986) reported tha t SF CD4+ c e lls  alone 
were better augmentors o f PWM-induced help than the 
corresponding unfractionated T c e lls . This, they explained, was 
due to  suppression by PWM-stimulated CD8 + o f CD4+ function in 
the unfractionated preparation.
The functional assays have c le a rly  produced much co n flic tin g  
data. This is  probably because investigators have tr ie d  to  analyse a 
complex regulatory system with re la tiv e ly  simple frac tiona tion  or 
cu ltu re  systems. More and more evidence is  accumulating regarding 
the heterogeneity o f the two main CD4+ and CD8 + T ce ll subsets. 
Ballieux and Heijnen (1983) who recently re-evaluated the usefulness 
o f FcR on T ce lls  as subset markers in  conjunction with McAb 
analysis, have indicated a much greater degree o f heterogeneity than 
previously appreciated in , fo r instance, the CD8 + subset. For 
example, they postulate the existence o f suppressor precursor T 
c e lls , suppressor ac tiva to r and e ffec to r T c e lls . They also suggest 
tha t suppressor inducer a c t iv ity  does not e x is t in  unprimed T ce lls  
(Heijnen e t a l , 1982) w h ils t Thomas et al (1981) believe i t  does. 
These differences may be due to the former group using an antigen to  
examine such in te ractions, w h ils t the la t te r  used PWM.
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U ntil T ce ll populations are more c le a rly  defined and the 
various in te r-re la tionsh ips  better established, i t  is  probable tha t 
contradicting data w ill continue to  emerge from various laboratories 
examining T ce ll regulatory pathways in  RA. Whilst T ce lls  are 
frequently considered to  be the main proponents o f immunoregulation, 
there e x is t other ce lls  and mediators which are also important in 
maintaining the homeostasis o f the body's defence system. These 
include prostaglandins, a n ti- id io ty p ic  (a n ti- id )  antibodies, natural 
k i l le r  (NK) ce lls  and the immunoglobulin molecules themselves. The 
immunomodulatory actions o f these various components on immune 
function are considered below.
B. Prostaglandins
Prostaglandins are a fam ily o f 20 carbon a lip h a tic  unsaturated 
fa tty  acids, which are generated by every tissue in  the body except 
fo r the red blood ce lls  (Goodwin e t a l , 1984). They were o r ig in a lly  
described as smooth muscle stimulants (Pelus and Strausser, 1977) but 
have since been found to  be potent immunoregulators, especially o f 
c e llu la r  immunity. PGs thus in h ib it  T ce ll mitogenesis in  response 
to  PHA and Con A (Goodwin et a l , 1977). They in h ib it  E rosette 
formation (Venza-Teti e t a l,  1980), the generation o f cytotoxic ce lls  
in  MLR (Darrow e t a l,  1980) and the formation o f T ce ll colonies in 
v itro  (Bockman and Rothschold, 1977). Gamma 1FN production is  also 
reported to  be inh ib ited  by prostaglandins, and th is  in  turn is  
thought to  be responsible fo r the continued growth o f EBV transformed 
ce lls  from RA patients rather than defects o f suppressor ce ll 
a c t iv ity  (Hasler e t a l , 1983).
A number o f investigators believe th a t some o f the above effects 
may be achieved through PG action on IL-2 synthesising c e lls , since
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they are reported to  be inh ib ited  by PGE2  in  both animals (Gordon et 
a l , 1976; Bray e t a l , 1978; Baker e t a l , 1981) and humans (Rappaport 
and Dodge, 1982; Tilden and Balch, 1982). Furthermore, PG may also 
prevent ce lls  from responding to  IL-2. For instance, Tilden and 
Balch (1982) found tha t i t  inh ib ited  the p ro life ra tio n  o f I I n ­
dependent T ce ll lines in response to exogenous IL-2. Although the 
in h ib ito ry  e ffects  o f PG and IL-2 production are believed to  occur 
through d ire c t action by some authors (Baker et a l , 1981; Tilden and 
Balch, 1982), others (Chouaib and F rade liz i, 1982) report tha t IL-2 
production is  suppressed in d ire c tly  through the induction o f a T 
suppressor c e l l .  Tilden and Balch (1982) suggest th a t the absence or 
presence o f a suppressor ce ll observed by various workers may depend 
on the concentrations of PG used in the experiments.
PGE2  has also been reported to  decrease NK and antibody 
dependent ce ll mediated cy to to x ic ity  (ADCC) a c t iv ity  (D ro lle r e t a l , 
1978; Brunda et a l , 1980). This is  in te resting  in view o f the report 
by Burchiel and Warner (1980) who found th a t PGE1 increased FcR 
expression. NK a c t iv ity  is  reported to  be diminished in RA (S ilver 
e t a l , 1982; Combe et a l , 1984) and PGE2  a c t iv ity  may be one o f the 
contributory factors.
Modulation o f humoral response by prostaglandins has produced 
variable re su lts . In man, the p ro life ra tiv e  response to PWM is  not 
affected by PG (Goodwin e t a l , 1977; S ta ite  and Panayi, 1982; 
Thompson e t a l , 1984) a t physiological concentrations, w h ils t tha t 
induced by Staphylococcus aureus (SA) was found to  be suppressed. 
This suggests th a t d iffe re n t B ce ll subsets may vary in  th e ir  
su s ce p tib ility  to  PG-mediated regulation.
Effects o f PG on antibody responses have also been studied and 
produced some co n flic tin g  data. Deli nek e t al (1985) reported tha t
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PGE2  could cause dose-dependent in h ib it io n  o f Ig secreting ce lls  in 
PWM- and Staphylococcus aureus-stimulated B ce ll cu ltu res. The PGE2
was found not only to  suppress the production o f B ce ll
d if fe re n tia t io n  facto r (BCDF) from mitogen-stimulated T c e lls , but i t  
also inh ib ited  the capacity o f B lymphocytes to  respond to  BCDF.
In contrast, other authors (S ta ite  and Panayi, 1982) have found
th a t the use o f PG-synthetase in h ib ito rs  suppressed the antibody
response o f PBMNC in  man. S ta ite  and Panayi (1982) demonstrated tha t 
th is  suppression could be reversed by the addition o f low 
concentrations o f PGE2  to  the cu ltu res. They also found tha t the IgM 
response was not fu l ly  reconstituted by PG and suggested tha t other 
cyclo-oxygenase products may be more important in  modulating th is  
class o f response.
Experiments by Ceuppens and Goodwin (1982) showed tha t PGE2  did 
not act on B ce lls  or monocytes d ire c tly . I t  was probable tha t the 
e ffec ts  o f PGE2  on B ce ll responses were mediated through action on T 
helper or suppressor c e lls . These authors suggested tha t suppressor 
c e lls  which in h ib it  Ig production are themselves suppressed by PGE2. 
Thus a lack o f PGE2  through indomethacin administration releases the 
in h ib ito ry  influence on T suppressor c e lls , which can then suppress 
an ongoing antibody response. These PG-sensitive ce lls  are reported 
also to  be sensitive to  ir ra d ia tio n  and mitomycin C.
Support fo r the above hypothesis comes from e a rlie r  work by 
Goodwin e t al (1979) who found th a t T suppressor c e lls  defined by 
Fc R expression carried large numbers o f PGE2  receptors. Later 
Ceuppens and Goodwin (1982), using the CD8 + marker, found tha t 
removal o f these ce lls  decreased the amount o f suppression o f Ig 
synthesis observed w ith indomethacin but i t  did not reverse i t  
completely. These authors suggest tha t th is  is  because some CD4+
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c e lls  can be induced to  become suppressor ce lls  without undergoing 
any phenotypic changes in  the process by other CD4+ ce lls  as reported 
by Thomas e t al (1981).
In reference to  RA, where large quantities o f PGE2  have been 
reported to  be present in  the SF o f these patients (Morley, 1974), i t  
is  c lear tha t th is  fa tty  acid may have profound e ffects  on the immune 
function o f the synovial tissue . F irs t ly ,  i t  would explain the 
depressed T ce ll responses seen in  the rheumatoid synovium. 
Secondly, i t  also provides an explanation fo r  the exuberant antibody 
response in these tissues. Ceuppens e t al (1982) reported tha t 
cyclo-oxygenase in h ib ito rs  decreased IgM RhF production in  normals, 
old subjects and RA patients. They suggested tha t the high level o f 
RhF in  the RA jo in t  may be due to  the suppression o f T c e lls , which 
in  normals suppressed RhF production.
Although i t  is  believed th a t PG may mediate i t s  e ffects  on 
c e llu la r  and humoral responses by a lte ring  the in tra c e llu la r  CAMP and 
CGMP leve ls , i t  should be noted tha t changes in  the concentration o f 
these nucleotides and those occurring in  ce ll function do not always 
corre la te  (Stobo e t a l , 1979; T il den and Balch, 1982).
C. Anti-idiotypic antibodies
The id iotype network theory is  one o f the c lassic hypotheses in 
the f ie ld  o f immunoregulation. In 1974, Oerne suggested tha t the 
immune system is  regulated through a network o f id io typ e -an ti- 
id iotype in te ractions. This concept is  based on the observation tha t 
antibody, as well as recognising antigen, can i t s e l f  be perceived as 
an immunogen. This is  due to  the presence o f antigenic determinants 
known as 'id io types ' which are unique to  the antigen binding s ite  of 
tha t antibody and more often than not are located in  the hyper-
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variable regions o f the Ig molecule. Idiotypes (ids) are thus to  be 
found on surface Ig ( ie  antigen receptor) o f B ce lls  as well as on 
secreted Ig . They appear also to  be present on T ce ll antigen recep­
to rs  (Stevenson, 1986) and have been demonstrated on T helper and T 
suppressor subsets (Woodland and Cantor, 1978; Owen e t a l , 1978).
Thus id io typ ic  regulation can occur a t both c e llu la r  and humoral 
leve ls .
An antigen e l ic i ts  the production o f antibody, Ab-j, which gives 
r is e  to  Ab2  (an ti- id io type ) and th is  then resu lts  in  the formation of 
Ab3  (a n ti-a n ti- id io ty p e ) and so on, establishing a network. Each 
antibody e ithe r up regulates or down regulates the a c t iv ity  o f the 
preceding component. This immunoregulatory a b i l i ty  is  reported to  be 
dependent on the dose and isotype used. For example, low doses of 
a n t i- id  can greatly enhance the expression o f the appropriate 
id io type in response to  a given antigen, w h ils t higher doses produce 
suppression (R o itt, 1984).
Early studies showed tha t w h ils t fam ilies o f Ab-j expressed 
s im ila r but not identica l antigen binding s ites  (reviewed Klinman and 
Steinberg, 1986), they could a ll be bound by one a n ti- id io ty p ic  
anti serum. This suggested tha t these Ab^  carried a 'shared1,
'p u b lic ' or 'c ross-reactive ' id iotype (CRI). This would also explain 
why Ab3  is  often found not to  express the same antigen binding
s p e c if ic ity  as Ab-j, although i t  may carry the same id iotype as Ab-j.
The occurrence o f CRIs is  found to  depend on the nature o f the 
immunising antigen and the genetic make-up o f the individual (Klinman 
and Steinberg, 1986).
I t  is  found tha t autoantibodies frequently express CRIs. Kunkel 
e t al (1973) were the f i r s t  to  demonstrate the re s tr ic te d  nature o f 
idiotypes on rheumatoid fac to r. They found th a t the m ajority o f IgM
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anti-IgG  antibodies carried the Wa id io type . More recently, Forre et 
al (1979) have reported s im ila r it ie s  between some IgG and IgM RhFs. 
Such s im ila r ity  may be explained by the recent observation in  mice 
(Manheimer, 1986) tha t autoantibodies u t i l is e  only a lim ited  number 
o f VH gene fam ilies .
The presence o f CRIs is  p a rtic u la r ly  pertinent to  autoimmunity 
since some authors believe tha t a loss o f se lf-to lerance may re su lt 
from such antigenic determinants. Furthermore, there exists much 
evidence suggesting tha t responses where CRI are prevalent are 
p a rtic u la r ly  susceptible to  id io typ ic  regu la tion. These two aspects 
o f id io typy are discussed below.
i )  Induction o f autoimmunity
I t  has been suggested (Cooke e t a l,  1983) tha t an invading 
micro-organism may e l i c i t  an antibody response, where the la t te r  
carries an id iotype which is  shared with autoreactive 
lymphocytes. Induction o f T^ spec ific  fo r the id iotype could 
then provide help fo r the autoantibody response.
Klinman and Steinberg (1986) postulate another mechanism. 
They suggest tha t during a normal immune response, immature B 
c e lls  are generated, some o f which are autoreactive. The 
induction o f tolerance requires high a f f in i ty  binding of 
immature B c e lls  to  antigen (Teale and Klinman, 1980). Low 
a f f in i t y  binding in h ib its  tolerance. Klinman and Steinberg 
(1986) suggest tha t antibody which cross reacts w ith ( ie  is  
a n ti- id io ty p ic  fo r)  antigen receptors on autoreactive B c e lls , 
does so with low a f f in i ty  and therefore could in h ib it  the 
to le r is a tio n  o f these B ce lls  and thus lead to  the production o f 
autoimmune phenomena.
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Clearly, in  both hypotheses a defect in  the 
immunoregulatory T ce ll c ir c u it  is  required fo r autoimmunity to 
arise .
Another mechanism whereby id io typy may cause loss o f s e lf­
tolerance is  through the occurrence o f 'in te rn a l image1. Anti­
id iotype and id io type are mutually inducib le, ie  Ab2  can induce 
Ab-j. This occurs because Ab2  is  believed to  carry the 'in te rna l 
image' o f the antigen, which gives r is e  to  the formation o f Ab-j. 
This idea has been used successfully in  in fectious diseases, 
where ind iv idua ls can be vaccinated against antigens which are 
h ighly in fectious or not read ily  available, by using Ab2  
(Stevenson, 1986).
I t  has been suggested tha t autoimmunity may arise i f  the 
immune response generates a n ti- id  antibodies, which carry the 
'in te rn a l image1 o f an autoantigen. Recently, Fong e t al (1984) 
carried out experiments using an a n ti- id  antibody which bore the 
in ternal image o f human IgG Fc. This was raised using IgM RhF 
from patients and was used to  show tha t in ternal image a n ti- id  
antibodies could behave lik e  antigen. Thus a p ro life ra tiv e  (but 
not secretory) response was obtained from patients with RA but 
not from a normal ind iv id u a l. Furthermore, the a n ti- id  blocked 
RhF synthesis by PBMNC but had no e ffe c t on the to ta l IgM 
response follow ing PWM stim ulation.
Such idiotypes are p o te n tia lly  powerful too ls fo r analysing 
antigenic structures,
i i ) Regulation o f the autoimmune response
A number o f investigators have reported the occurrence o f 
a n ti-id io type  antibodies in  pa tien ts ' sera coincident with 
c lin ic a l improvement. Thus, Abdou e t al (1981b) reported tha t
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the appearance o f a n ti- id  antibodies to  autologous anti-DNA was
associated with decreased disease a c t iv ity  in  SLE patien ts. In
RA, Koopman e t al (1983) reported in v itro  suppression o f
monoclonal RhF synthesis by the corresponding a n ti-id io type  
antibody and s im ila r ly , in  v ivo , Abe e t al (1984) reported 
decreased RhF a c t iv ity  in  the serum o f a female patien t with 
monoclonal IgM gammopathy fo llow ing the appearance o f an a n ti-  
id io typ ic  antibody.
Observations such as these, and the presence o f CRI, 
c le a rly  indicate an opportunity to  manipulate autoimmune 
behaviour. Although a n ti- id io ty p ic  therapy has been used with 
some success in  trea ting  human B ce ll lymphoma, the use o f such 
agents has not proved very f r u i t fu l  in  autoimmunity. This is  
because suppression o f id iotype positive  clones leads, a fte r a 
short latency period, to  the emergence o f id io type negative 
antibodies o f the same s p e c if ic ity . Furthermore, si de-effects 
such as serum sickness and immunosuppression have to be
considered.
D. Natural k ille r  cells
Over the la s t decade p ra c tica lly  a ll major ce ll types have 
been considered to  be involved in  immunoregulation to  a lesser 
or greater degree. One recent contender is  the natural k i l le r  
c e l l .  These c e lls  are large granular lymphocytes which share 
some characte ris tics  with T ce ll surface receptors and 
antigens. They have been reported to  modulate B ce ll 
d iffe re n tia tio n  (Arai e t a l , 1983) and immunoglobulin production 
(Nabel e t a l , 1982; Abruzzo and Rowley, 1983).
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There appears to  be some dispute over the exact mechanism 
whereby NK ce lls  mediate th e ir  suppressive e ffects  on B ce lls  
since TH ce lls  (Arai e t a l , 1983), antigen exposed accessory 
c e lls  (Abruzzo and Rowley, 1983) and B ce lls  (Nabel e t a l , 1982) 
have a ll been described as the ta rge t c e lls .
In the RA synovium there appears to  be a lack o f NK ce ll 
(S ilve r e t a l , 1982; Combe et a l , 1984) a c t iv ity .  This is  not 
surprising since NK function is  h igh ly dependent on ac tiva tion  
by IL-2 (Kuribayashi e t a l , 1981). In view o f i t s  e ffe c t on 
antibody synthesis, an absence o f NK ce ll a c t iv ity  in  a synovium 
already de fic ie n t in  T suppressor function would serve to  
fu rthe r enhance the B ce ll response.
E. Immunoglobulin molecules
Immunoregulation by immunoglobulin molecules has long been 
investigated. This mode o f regulation forms the subject o f th is  
thesis and w il l  be considered in  de ta il in  Section 2.
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SECTION 2 ANTIBODY MEDIATED NEGATIVE FEEDBACK SUPPRESSION AND 
FcR+ CELLS
1. Antibody-mediated feedback suppression
The mechanisms whereby the immune response is  regulated have 
been the subject o f intense investigation in  recent years. One area 
which has received considerable a tten tion  is  tha t o f immunoregulation 
by antibody molecules. This concept is  by no means new. One o f the 
e a r lie s t known observations comes from the work o f T Smith (1909) who 
found th a t by in je c tin g  varying amounts o f Diphtheria tox in  and a n ti­
to x in , the immune response could be enhanced or suppressed.
Subsequent studies revealed tha t passive adm inistration o f 
antibody was able to  suppress s p e c ifica lly  the response to  a given 
antigen (reviewed by Uhr and M oller, 1968). For instance, Moller 
(1963) found tha t when mice were in jected with ce lls  from animals of 
an H-2 incompatible s tra in , together with antibodies directed against 
these c e lls , the immune response was suppressed. Furthermore, when 
anti serum directed a t only some antigenic determinants was used, the 
response to  these p a rticu la r determinants was suppressed, w h ils t the 
res t o f the antigens on the in jected c e lls  were able to  e l i c i t  
antibody synthesis.
The response to  soluble antigens such as DNP-BG6  (Chang e t a l , 
1969) and Diphtheria tox in  (Uhr and Bauman, 1961) has s im ila r ly  been 
shown to  be suppressed w ith corresponding anti sera.
These e ffec ts , which were demonstrated both in vivo (C ero ttin i 
e t a l , 1969; S in c la ir e t a l , 1970) and in  v it ro  (Feldman and Diener, 
1972; Kappler e t a l , 1973; Lees and S in c la ir, 1973), were thought to 
be due to  the masking o f antigenic determinants by the antibody - an
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a) The F(ab ' ) 2  fragment was ju s t as e ffe c tive  in  suppressing the 
immune response as i t s  7S counterpart (TaO and Uhr, 1966; 
Feldman and Diener, 1972) and tha t
b) High a f f in i ty  antibodies were much more e ffe c tive  than those of
low a f f in i ty  (Walker and Siskind, 1968),
However, there existed evidence th a t other mechanisms might be 
involved. F irs t,  Uhr and Bauman (1961) reported tha t antibody 
in jected fiv e  days a fte r immunisation was s t i l l  capable o f 
suppressing the immune response, suggesting tha t a feedback mechanism 
operated. Second, experiments by S in c la ir  (1969) using 7SIgG and 
F(ab ' ) 2  fragment found tha t the la t te r  was 100 -  1000 fo ld  less 
in h ib ito ry  than the in ta c t IgG. I t  was concluded tha t th is  
difference lay in  the absence o f the Fc portion . This was fu rthe r 
emphasised by Kappler e t al (1973) who examined the suppressive 
e ffects  o f ra bb it 7S anti-SRBC IgG, i t s  F(ab1 ) 2  fragment and chicken 
7S anti-SRBC IgG on the humoral response o f mouse spleen ce lls  to 
SRBC. In h ib itio n  was observed with a ll three a t high concentrations, 
but only rabb it 7SIgG was capable o f suppressing the immune response 
at low concentrations. Thus i t  appeared tha t in h ib it io n  due to 
antibody operated at two levels (Hoffman and Kappler (1978). At high 
concentrations the antibody did mask antigenic determinants leading 
to  suppression, but a t low concentrations where antibody was present 
in  in s u ffic ie n t amounts the suppression was mediated by the Fc 
portion. Chicken IgG was not able to  in h ib it  the immune response 
because i t  could not bind to  mouse spleen ce ll Fc receptor (FcR)
2. Mechanisms of Fc-mediated suppression
At present there are two main schools o f thought concerning the
mechanisms whereby Fc-mediated suppression takes place. The f i r s t
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comes from the work o f Hoffman and associates (1973; 1978). These 
authors, using TNP-SRBC as antigen, showed tha t anti-SRBC antibody 
could suppress the anti-TNP response when TNP was linked to  SRBC but 
not when the hapten was attached to  burro red blood ce lls  (BRBC), 
even when the responding ce lls  were preincubated with TNP-SRBC and 
anti-TNP immune complexes. SRBC primed T ce lls  could stimulate 
production o f antibody in  response to  both SRBC and BRBC (Hoffman and 
Kappler, 1973). I t  was found tha t w h ils t anti-SRBC suppressed the 
humoral response to  SRBC, i t  did not prevent the SRBC primed T ce lls  
from helping the anti-BRBC antibody response. Thus, Hoffman and 
Kappler (1978) concluded tha t antibody induced suppression was not 
mediated via a central e ffe c t on the lymphocytes, since neither B nor 
T c e lls  were d ire c tly  blocked. I t  resulted instead from an 
interference between T-B ce ll co-operation. They suggested th a t th is  
interference could be reversed by the in troduction o f factors which 
replaced T ce ll help - a prediction which was proved true by the 
addition o f tumour necrosis serum (TNS) which is  obtained from BCG 
infected mice 2 hours a fte r in je c tion  o f 1ipopolysaccharide (LPS) and 
has been shown to provide 'T ce ll help 1 (Hoffman e t a l , 1976).
Furthermore, i t  was suggested tha t the immune response to 
soluble antigens would not require the Fc piece fo r suppression to 
occur. Evidence fo r th is  comes from the work o f Feldman and Diener 
(1972) who found tha t in  v it ro  response to  polymerised f la g e ll in  was 
suppressed equally well by the F(ab ' ) 2  fragment and the 7S IgG 
antibody.
Support fo r Hoffman's hypothesis also comes from ce ll transfe r 
experiments where lymphoid ce lls  obtained from recip ients treated 
with suppressive doses o f antibody were able to  in i t ia te  an immune
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response against the corresponding antigen a fte r trans fe r to  
incompetent hosts (reviewed Uhr and M oller, 1968).
The above find ings, however, are in  d ire c t contrast to  the 
observations o f S inc la ir (1982) and Kolsch e t al (1980), who advocate 
d ire c t blockage o f B c e lls .
In 1971 S in c la ir and co-workers proposed the t r ip a r t i t e  model o f 
Fc mediated feedback suppression. Here, antigen in  the immune 
complexes bound to  the antigen receptor on the B c e ll ,  imparting
s p e c if ic ity  to  the suppressive process, and the Fc bound to  the Fc
receptor. Cross-linking o f the two receptors was thought to  
inac tiva te  the B c e lls , a concept also supported by Kolsch e t al 
(1980). These authors, lik e  Kappler e t al (1973), used the TNP-SRBC 
model to  investigate feedback suppression. They found th a t the 
degree o f suppression depended on the concentration o f antibody in 
the complex and tha t suppression was spec ific  to  the antigen in  the
complex and did not prevent the immune response to other antigens.
Furthermore, th is  suppression could not be over-ridden by T ce ll 
replacing facto r (TRF) -  obtained from Con A-stimulated cu ltu res, nor 
by the B ce ll mitogen, LPS. A pos itive  response, ie  antibody 
synthesis, was only obtained i f  TRF interacted with B ce lls  before 
the immune complexes d id . Schimpl e t al (1977) have shown th a t TRF 
is  able to  bind to  B ce ll FcR. In h ib itio n  o f the immune response, 
Kolsch e t al (1980) suggested, occurs by immune complexes blocking 
the d iffe re n tia tio n  o f B ce lls  in to  plasma c e lls . The B c e lls  were 
instead diverted to  memory ce ll production. This might explain the 
observations o f workers in  the la s t century (reviewed by Uhr and 
M oller, 1968) who found tha t by in jec tin g  animals with an anti body- 
anti gen mixture, the primary response was suppressed, but subsequent
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challenge with antigen led to  a fu ll-b low n secondary response. More 
recen tly , Safford and Tokunda (1971) have also found tha t w h ils t 
passive administration o f antibody suppresses plaque ce ll formation, 
i t  does not suppress priming o f B c e lls  fo r  a secondary response. 
Klaus (1978) has in  fac t demonstrated th a t priming with immune 
complexes was a hundred times more e ffe c tive  than antigen alone.
At present, the c o n flic t  between these two schools o f thought 
(interference with T-B ce ll co-operation or B ce ll blockade) remains 
unresolved. I t  is  possible tha t these concepts may not be mutually 
exclusive.
3. Factors affecting feedback suppression
The nature o f Fc-mediated suppression is  fu rthe r complicated by 
a va rie ty  o f other fac to rs . For example, i t  has been found th a t the 
class or subclass used may a ffe c t the a b i l i t y  o f the antibody to 
suppress. Henry and Oerne (1968) reported tha t IgM anti-SRBC 
antibody potentiated the plaque forming ce ll (PFC) response to  SRBC, 
w h ils t 7S IgG was suppressive. S im ila rly , Collisson e t al (1983) 
found anti TNP SRBC responses to  be enhanced by IgM and where 
suppression has been observed with th is  class o f immunoglobulin, i t  
is  usually reported to  be much lower than tha t found with IgG 
(reviewed Uhr and M oller, 1968). In mice, IgG  ^ was found to  be 
suppressive at a ll doses tested, w h ils t suppression o f the SRBC 
response by IgG2  was only seen at high concentrations (Murgita and 
Vas, 1972). Low doses o f IgG2  were found to  enhance the response. 
Thus the concentration o f antibody may also influence the feedback 
process.
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In te res ting ly , a n ti- id io ty p ic  antibody has also been shown to 
require the Fc portion fo r suppression to  occur (Weigle and Berman,
1979). Like other antibodies, i t  also appears to  be subject to
varia tions produced by d iffe re n t subclasses o f immunoglobulin. For 
example, Eichman (1974) reported tha t the immune response in  mice was 
suppressed by guinea pig a n ti- id io ty p ic  antibody belonging to  the 
IgG2  class, w h ils t the use o f IgG1 resulted in enhancement.
The mechanisms whereby the immune response is  enhanced have not 
been as well researched as those producing suppression. However, 
enhancement has been observed with both pa rticu la te  and soluble 
antigens, often occurring at low concentrations o f antibody (Walker 
and Siskind, 1968; Murgita and Vas, 1972). The Fc portion appears to 
be involved. Some authors suggest th a t i t  is  the re la tiv e  
concentrations o f antigen and antibody in  the complex which d ic ta te
whether suppression or enhancement occurs (reviewed Uhr and M oller,
1968; Weigle and Berman, 1979). Furthermore, the immune status o f 
the ind iv idual may play a determining ro le  (Weigle and Berman, 1979). 
In mice immunized with Fab fragment o f human IgG in  complete Freund's 
adjuvant and th e ir  ce lls  challenged with antigen 6  weeks la te r , i t  
was found tha t the anti-Fab response was weak but th is  was enhanced 
by the addition o f Fc fragment. In another group o f immunised mice, 
which was boosted 7 days before tes ting , i t  was found tha t a strong 
anti-Fab response was obtained which was markedly suppressed by Fc 
fragment.
As well as an immunoregulatory ro le , antibody in  the form o f 
immune complexes or Fc fragment has been shown to induce 
p ro life ra tio n  in  both mouse and human c e lls  (reviewed Weigle and 
Berman, 1979), which again is  affected by class/subclass va ria tions. 
Morgan and Weigle (1983) reported tha t Fc fragment is  also able to
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act as an adjuvant in  the immune response, an e ffe c t not mediated by 
in ta c t IgG. The ad juvan tic ity  resides in  a 14,000 dal ton subfragment 
derived from the Fc fragment by macrophages.
4. Occurrence of FcR
In view o f the e ffects  tha t antibody has on the immune response, 
especia lly since the Fc portion appears necessary fo r the mediation 
o f these e ffec ts , i t  is  hardly surprising th a t many o f the ce lls  o f 
the immune system express receptors fo r  the Fc portion o f 
immunoglobulin. These include B ce lls  (D ickler and Kunkel, 1972), T 
c e lls  (Lee and Paraskevas, 1972), monocytes (Lawrence e t a l , 1977), 
macrophages (Berken and Benacerraf, 1966), PMN (Gale and Ziegelbaum, 
1975) and p la te le ts  (Becker and Henson, 1973). Fc receptors are also 
found in  placental syncytterophoblasts, yolk sac endodermal c e lls  
and neonatal entereocytes (reviewed Fornusek and Vetvicka, 1984) as 
well as on connective tissue and e p ith e lia l tumours (Kerbel and 
Davis, 1974). The ubiquitous FcR has also been demonstrated on 
Staphylococci and Streptococci (Langone, 1982). In the former group, 
the s tra in  Staphylococcus aureus is  used as a source o f protein A, 
which has a high IgG binding capacity and is  employed in  a f f in i ty  
chromatography.
The term 'Fc receptor' usually re fers to  the Fc receptor fo r  
IgG. However, FcRs have been described fo r  a ll f iv e  classes o f 
immunoglobulins (Moretta e t a l , 1976; Lum e t a l,  1979; Yodoi and
Ishisaka, 1979; Sjoberg ^ ___1980). The assay usually employed is
a rosetting  technique where the ce ll population being examined is  
mixed with ind ica tor red blood ce lls  coated with spec ific  antibody o f 
the relevant class. This is  illu s tra te d  in  Figure 3. Immune 
complexes or aggregated immunoglobulins carrying e ithe r fluorescent
53
FIG 3 Rosette assay fo r detecting FcRs on ce ll populations
Test Population
Incubation @4° for 1hr
»v
Indicator RBC coated with antl-RBC
Rosettes enumerated and 
expressed as a percentage of 
total cell population
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or radioactive tags have also been used. This methodology has been 
exce llen tly  reviewed by Andersson e t al (1981). Monoclonal 
antibodies have also been used to  demonstrate FcR (reviewed Anderson 
and Looney, 1986).
The re la tive  d is tr ib u tio n  o f FcRs on d iffe re n t lymphoid 
populations varies from report to  report (reviewed D ick le r, 1976; 
Unkeless e t a l , 1981). This is  probably due to  the varying 
techniques used and the Fc receptors exh ib iting  d iffe re n t binding 
a f f in it ie s  fo r d iffe re n t classes or subclasses o f immunoglobulin. 
For example, in  man, IgG-j and IgG3  subclasses are more strongly bound 
than IgG2  and IgG^. FcRs also vary in  th e ir  a b i l i ty  to  bind 
aggregated or monomeric Ig (see next section).
Despite such d if f ic u lt ie s ,  estimates o f the d is tr ib u tio n  o f FcR 
on various ce ll populations do e x is t. A large percentage (80 -  95%) 
o f B ce lls  in  peripheral blood bear FcR (reviewed by Fornusek and 
Vetvicka, 1984), w h ils t a ll active k i l le r  (K) c e lls , some nu ll ce lls  
and a smaller percentage { z i  30%) o f T ce lls  are FcR+. This 
d is tr ib u tio n  changes with a lte ra tion  o f the a c t iv ity  o f the 
lymphocyte. For example, w h ils t immature B ce lls  are FcR+ (Moller, 
1974), antibody forming ce lls  lose th e ir  Fc receptors (Basten e t a l , 
1972). With T c e lls , activa tion  is  found to  increase the percentage 
o f FcR+ c e lls . However, thoracic duct activated T lymphocytes do not 
bear FcR (Kramer e t a l , 1975).
5. Characterisation of FcR
Fc receptors are a group o f glycoproteins which vary in 
molecular weight and Ig subclass s p e c if ic ity . Three main receptors 
have been described in  man fo r  IgG. These are FcRI, FcRII and FcRIII 
(or FcRlo ) (see Table 3). These receptors vary in th e ir  a b i l i ty  to
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bind IgG. Thus FcRI is  o f a high enough a f f in i ty  to  bind monomeric 
IgG, w h ils t aggregated or complexed immunoglobulin is  required fo r 
detecting FcR 11 and FcR-j0 . Cells may express one or more receptor 
type. Thus macrophages may express a ll three FcRs w h ils t B c e lls  and 
p la te le ts  may express only one, eg FcRII. The same receptor type may 
appear on d iffe re n t populations. Further heterogeneity is  observed 
when enzyme s e n s it iv ity  is  examined: FcRI is  found to  be tryps in  
sensitive  and FcRII tryps in  re s is tan t. Colombatti e t al (1981) 
demonstrated tha t Fc^, R on T and B c e lls  were protease sensitive 
w h ils t those on accessory ce lls  and PMN were not. Physical 
properties o f these receptors are summarised in  Table 3.
6. Functions of FcR* cells
FcR+ ce lls  are involved in  antibody-mediated ce ll c y to to x ic ity  
(ADCC), Type 1 hypersensitiv ity  reactions involving mast ce lls  and 
FcR fo r IgE, placental transport o f maternal IgG, phagocytosis, 
transport o f b i l ia r y  IgA by a specialised Fc receptor called 
secretory piece and, o f course, immunoregulation.
FcR expression in  RA has been reported to  be increased in 
comparison to  tha t observed in  normal healthy controls by some 
authors (Sharpin and Wilson, 1977; Wooley and Panayi, 1978; Bach et 
a l , 1970; Hall e t a l , 1980). This is  found to  be more pronounced in 
patients with systemic disease (Carter e t a l , 1984). Other authors, 
however, have observed no change (Burmester e t a l, 1978; Horwitz and 
Duul-Nielsen, 1977).
S im ila rly , assessment o f FcR function in  RA has produced 
co n flic tin g  data. FcR+ function in  the RA jo in t  as measured by ADCC 
a c t iv ity  has been reported to  be impaired compared to  corresponding
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TABLE 3 Characteristics of human IgG Fc receptors*
C haracteristic FcRI FcR 11 FcR1oa
Molecule 72 kDa 40 kDa 50-70 kDa
A ff in ity  fo r Ka=108 -109 M‘ 1 monomer binding undetectable monomer binding undetectable
IgG monomer
S ites/Cell 1-4x104
Cells monocytes monocytes, neutrophils, neutroph i 1 s, eosinophils,
(HL60, U937) eosinophils, p la te le ts ,
B ce lls  (U937, HL60, K562, 
Daudi, Raji)
macrophages, NK, K, LGL, T
S p e c ific ity , IgG^=IgG3 >IgG4; IgG1 =IgG3 >IgG2  and IgG4 IgG}=IgG3
human IgG2  no
a 1 o = low a f f in i ty
* derived from Anderson and Looney (1986)
PBMNCs (Carriga ll and Panayi, 1978; Abrahamson e t a l, 1977; Diaz-
Oouanen e t a l , 1976). This is  believed to  be due to  the blocking of
FcRs by immune complexes (Diaz-Oouanen e t a l , 1976). The other 
p o s s ib ility  is  the loss o f FcR from the ce ll surface fo llow ing 
attachment o f immune complexes, as suggested by Moretta e t al (1978). 
These explanations may also su ffice  fo r depressed phagocytic a c t iv ity  
observed in RA peripheral blood and in SF (Turner e t a l , 1973; A ttia  
e t a l , 1982). Other workers, however, have reported increased 
(Oessop et a l , 1973) or normal (Kavai e t a l, 1979) phagocytic
a c t iv ity .  I t  is  probable th a t these d iffe re n t observations re su lt 
from varia tions in  patient groups, disease a c t iv ity  and the 
techniques used. As fa r FcR function is  concerned, one should
ascertain tha t FcR-mediated phagocytosis is  being measured, since 
C3b-mediated phagocytic a c t iv ity  also occurs. This is  called immune 
adherence and is  reported to  be defective in  RA (Hurst e t a l , 1983).
Although the ro le  o f FcR in  immunoregulation has already been 
discussed, T ce lls  with receptors fo r IgM and IgG deserve a special 
mention. These ce lls  were o r ig in a lly  thought to  correspond to  helper 
and suppressor ce lls  respective ly. This, however, was found not to 
be true since:
i )  Tjj ce lls  could produce suppression and T*y ce lls  were observed
to  provide help fo r the immune response;
i i )  the same ce ll could express both FcjjR and Fc^yR and
i i )  on incubation at 37°C Tjj ce lls  could switch to  Fc^R expression.
Pichler and Broder (1981) suggest tha t these receptors are markers
fo r activa tion  lik e  the class I I  MHC antigens. Thus FcjjR expression 
on T ce lls  represents the resting s ta te , w h ils t Fc^R the activated 
counterpart.
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A product o f activated T-y ce lls  is  reported to  be important in 
feedback suppression. I t  is  found th a t when these c e lls  are 
incubated with immune complexes, they release soluble factors called 
immunoglobulin binding factors (IBF) (Fridman and Golstein, 1974). 
These bind to  the Fc portion o f the IgG molecule and are able to 
in se rt themselves in to  the ce ll membranes o f B lymphocytes (Fridman 
e t a l , 1981). IBF have been shown to  pa rtic ipa te  in  suppression o f 
antibody synthesis in  v it ro  (G isler and Fridman, 1975). Thus while a 
T ce ll product -  TRF - can in te rrup t antibody feedback suppression, 
IBF can enhance i t .
I t  is  clear from the above tha t in  order to  examine immuno- 
modulation o f the immune response by antibody, one needs s t r ic t ly  
defined conditions and reagents. For th is  reason i t  was decided tha t 
antibody-mediated feedback suppression in RA should be carried out 
using a defined FcR-bearing population. The present work is  
concerned mainly with feedback suppression mediated by MNC carrying a 
receptor fo r the Facb fragment o f IgG. These ce lls  were f i r s t  
described in  our laboratory using a modified rosette assay. Work 
carried out by previous workers is  reviewed in  Section 3, together 
with the aims o f the present study.
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SECTION 3 FacbR+ CELLS IN RA; AIMS OF THE PROJECT
Recently, a subpopulation o f MNCs has been described which 
carries receptors fo r the Facb fragment o f IgG (Hall e t a l , 1980). 
Facb is  essentia lly  the IgG molecule minus the CH3  region, as shown 
in  Figure 4. I t  is  enzymatically produced through the use of 
plasmin.
Indications fo r an unusual FcR came from e a rlie r studies 
examining leucocyte migration in h ib itio n  in  patients with RA (H a ll, 
1978). I t  was found tha t Facb was a much more e ffe c tive  in h ib ito r  in 
the migration in h ib it io n  te s t than native IgG, suggesting an 
increased re a c tiv ity  o f RA ce lls  to  antigenic determinants in the CH2  
region. An abnormal c e llu la r  response to  IgG had already been 
demonstrated by previous workers (Froland and Gaarder, 1971; Brostoff 
e t a l , 1973; Weisbart e t a l , 1975).
Using a modified rosette assay, where Facb instead o f the whole 
IgG molecule was used to  coat ind icator RBC, Hall e t al (1980) found 
th a t patients with RA had s ig n if ic a n tly  higher numbers o f FacbR+ 
c e lls  compared to  normal healthy contro ls. Furthermore, patients
with 0A or ankylosing spondylitis  did not d if fe r  from contro ls, 
although the mean percentage value o f FacbR+ ce lls  in  the la t te r  was 
intermediate between those obtained fo r  normal ind iv idua ls and 
patients with RA. These resu lts  suggested th a t the increase in 
FacbR+ ce lls  was not due to  old age and mechanical wear and tear but 
to  the rheumatoid disease process. However, no corre la tion  was found
between disease a c t iv ity ,  disease duration and levels o f IgG and IgM
RhF and the numbers o f FacbR+ ce lls  in these patients. These f in d ­
ings, however, were in  agreement with other authors who had also
reported increased numbers o f FcR+ ce lls  in  RA (Wooley and Panayi,
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FIG 4 I l lu s tra t in g  the Facb region o f the IgG molecule
The constant (CH1-3; CL) and variable (VH and VL) domains are shown, as are in te r-  and in tra-cha in  disulphide 
bonds ( - s - s - ) . ------------ denotes the point o f cleavage by plasmin.







1978; Bach e t a l , 1970; Sharpin and Wilson, 1977),
Preliminary experiments showed th a t these receptors were not 
expressed on mature monocytes since incubation with carbonyl iron did 
not a ffe c t the numbers o f FacbR+ c e lls  present in  the peripheral 
blood.
Thus fu rthe r studies were undertaken to  define the phenotypic, 
morphological and functional characteris tics  o f FacbR+ c e lls .
1. Phenotypic analysis
Monoclonal antibodies and a va rie ty  o f rosetting and lymphocyte 
frac tiona tion  techniques were used to  investigate the surface
phenotype o f FacbR+ c e lls .
Winrow e t al (1985) showed tha t FacbR+ ce lls  did not belong to  
the T ce ll population. They did not form E rosettes with AET treated 
sheep RBC, nor did they express CD3, a T ce ll spec ific  marker. Human 
T ce lls  are known to e xh ib it a receptor fo r  the he lix  pomatia le c tin  
fo llow ing neuraminidase treatment. FacbR+ ce lls  were found to 
express no such receptors.
Neither did these c e lls  carry any B ce ll markers. There was no
slg as indicated by d ire c t immunofluorescence, FACS analysis and
a n t i- l ig h t  chain rosette formation. Nor was there any evidence o f C3 
receptors.
Thus, FacbR+ ce lls  appeared to  be s im ila r to  the 'th ird
population1, ' L ' or 'n u l l '  ce lls  described by various workers 
(Froland e t a l, 1974; Horwitz and Ouul-Nielsen, 1977; Lobo, 1981).
However, FacbR+ ce lls  were found to  bind to  the monocyte
monoclonal antibody OKMI and to  a lesser extent OKIal, which defined
HLA-DR antigens. Further analysis showed th a t these ce lls  were able
to  bind to  the monoclonal reagent 7.2 but not to  17.5. The former
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detects an HLA-DR framework antigen present on both lymphocytes and 
monocytes, w h ils t the la t te r  reacts only w ith an antigen expressed by 
lymphocytes carrying certa in  HLA-DR haplotypes.
FacbR+ ce lls  therefore have a myelo-monocytic lineage, but are 
not mature monocytes since they have been shown not to  phagocytose 
carbonyl iron (Hall e t a l , 1980). These ce lls  are thus d iffe re n t 
from L ce lls  which are believed to  be lymphocytes. This would 
explain why L ce lls  were not found in  increased numbers in  RA 
peripheral blood (Horwitz and Ouul-Nielson, 1977) w h ils t FacbR+ ce lls  
were (Hall e t a l , 1980).
2. Morphology of FacbR* cells
Expression o f both monocytic characte ris tics  and class I I  MHC 
antigens suggested tha t FacbR+ ce lls  may be associated with accessory 
ce ll function. Electron microscope studies showed th a t these ce lls  
did indeed share morphological s im ila r it ie s  with other accessory 
c e lls  such as dendritic  and Langerhans c e lls . They possessed a 
deeply cleaved nucleus and the cytoplasm contained numerous 
ribosomes. Mitochondria were also present, being more numerous in 
ce lls  from RA patients. The la t te r  also contained polysomes and 
well developed Golgi apparatus. Cytoplasmic f i b r i l l a r  structures 
reminiscent o f myeloid ce lls  were also present (Eales, PhD thesis,
1982).
FacbR+ ce lls  were smaller than monocytes (10.9 ;jm) but RA FacbR+ 
( 8 . 2  ;jm) were s ig n if ic a n tly  larger than those obtained from healthy 
controls (5.1 ^m). This was due to  the presence o f a greater amount 
o f cytoplasm in the former, as indicated by a smaller ce llinucleus 
diameter compared to  healthy contro ls. Comparison o f ce ll densities 
showed tha t FacbR+ ce lls  from patients with active disease were less
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dense compared to  those obtained from normal healthy controls and 
patients with inactive  disease (Eales, PhD thes is , 1982).
3. Functional characteristics of FacbR* cells
The s im ila r ity  o f FacbR+ ce lls  to  L ce lls  led to  the examination 
o f various functions a ttribu ted  to  the la t te r ,  namely natural k i l le r  
and antibody mediated c e llu la r  c y to to x ic ity  (Kay and Horwitz, 1980; 
Ozer e t a l , 1979; Horwitz and G arrett, 1977) and immunoregulatory 
e ffects  on lymphocyte a c t iv ity  (Horwitz and Garrett, 1977; Carvalho 
and Horwitz, 1980; Caraux e t a l , 1982; Lobo, 1981; Tilden e t a l ,
1983). Functional analysis was carried out by Eales et al (1984 and 
1985).
i ) FacbR* ce lls  and NK and ADCC a c t iv ity
NK and ADCC a c tiv it ie s  were examined using K562 erythro- 
leukaemic lin e  ce lls  and IgG-coated Chang ce lls  respective ly. 
Release o f ^ C r from lysed ce lls  was used as an ind ica to r o f 
c y to to x ic ity . Removal o f FacbR+ ce lls  from RA and normal PBMNC 
preparations did not a lte r  the NK a c t iv ity  measured at two 
lymphocyte:target ce ll ra tio s . Nor was ADCC affected. However, 
depletion o f a ll FcR+ ce lls  using EA rosettes abrogated a ll ADCC 
a c t iv ity .
i i ) FacbR* ce lls  and lymphocyte p ro life ra tio n
Various authors have reported tha t L ce lls  promote T ce ll 
p ro life ra tio n  (Horwitz and G arrett, 1977; Carvaux e t a l , 1982). 
Eales et al (1985) examined the ro le  o f FacbR+ c e lls  in  lympho­
cyte p ro life ra tio n  in  response to ConA, PHA and PWM stim ula tion. 
Depletion o f FacbR+ ce lls  was not found to  produce a s ig n ifica n t 
e ffe c t on lymphocyte p ro life ra tio n  as assessed by 3 H-thymidine 
incorporation. Nor did addition o f Facb fragment to  PBMNC
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cultures a lte r  the p ro life ra tiv e  response.
Thus, FacbR+ ce lls  are not important in  T ce ll p ro l ife r ­
a tive  responses, data which corre late w ith observations in  mice 
showing tha t FacbR+ ce lls  did not pa rtic ipa te  in  DTH reactions 
(Eales e t a l , 1984).
i i i ) FacbR+ ce lls  and immunoglobulin synthesis
L ce lls  have been reported to  have both enhancing and 
suppressing e ffects  on antibody production (Lobo, 1981). The 
ro le  o f FacbR+ ce lls  in  modulating the immunoglobulin synthesis 
was thus examined. In i t ia l  experiments were carried out in 
mice, where the primary and secondary PFC responses to  sheep RBC 
in  the spleen were investigated. I t  was found th a t while the 
primary response to  SRBC produced only d ire c t PFCs, the 
secondary response resulted not only in  an in d ire c t and d ire c t 
PFC response but also produced a marked increase in  the number 
o f FacbR+ ce lls  which peaked on Day 3 o f the response. A 
s im ila r response was obtained when a cross-reacting antigen, 
goat RBC, was used, but no secondary response was observed with 
a non-cross-reacting antigen (chicken RBC).
These resu lts  suggested tha t th is  increase in FacbR+ ce lls  
was in  some way connected with a secondary response. These data 
corre late with previous work (Eales e t a l , 1982) where an 
increase in FacbR+ ce lls  was observed in the c ircu la tio n  o f 
Mantoux te s t pos itive  subjects but not in Mantoux te s t negative 
ind iv idua ls a fte r challenge with tubercu lin . So the r ise  in 
FacbR+ ce lls  was re lated e ithe r to  the generation o f memory 
ce lls  or to  the synthesis o f IgG.
Studies with 1ipopolysaccharide showed th a t a s im ila r 
increase in  FacbR+ ce lls  was produced during the primary and
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secondary responses to  th is  antigen. LPS is  a T-independent 
antigen and thus does not generate memory c e lls . This therefore 
lead to  the conclusion tha t the increase in  FacbR+ c e lls  was 
re lated in  some way to  IgG synthesis.
Modulation o f Fc^yR on L ce lls  by immune complexes has been 
shown to  suppress the antibody response (Lobo, 1981). 
Experiments were set up to  investigate the e ffe c t o f using 
d iffe re n t fragments o f IgG as an antigen-specific response.
Mice sensitised with c a lf  RBC (cRBC) were challenged with 
cRBC alone, cRBC plus anti-cRBC IgG, cRBC plus anti-cRBC Facb or 
cRBC plus anti-cRBC F(ab1 ) 2  fragment. These experiments showed 
tha t Facb was able to  suppress the PFC response to  the same 
extent as the whole IgG molecule whereas the F(ab1 ) 2  fragment 
had no e ffe c t a t a l l .  This suppression was highly spec ific  and
could not be reproduced with a cross-reacting antigen such as 
SRBC. Thus FacbR+ ce lls  were involved in  negative feedback 
suppression.
So the increase in the numbers o f FacbR+ ce lls  seen in  mice 
during the secondary response and in  patients with RA may well 
re f le c t an attempt by the immune system to  l im it  the production 
o f IgG. But in  view o f the B ce ll hyperactiv ity  and auto­
antibody production ju s t how receptive are the RA ce lls  to  th is  
suppression?
4. FacbR* cells and negative feedback suppression in normal healthy 
controls and RA patients
Eales et al (1985) examined Facb suppression o f IgG production
in  v it ro  using PBMNC from normal healthy contro ls and patients with
RA. A dose-dependent suppression o f the IgG response was produced in
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both control subjects and patients. However, the la t te r  were found 
to  be s ig n if ic a n tly  less suppressed compared to  the normal healthy 
co n tro ls .
This suppression could be due e ith e r to  the activa tion  o f a 
suppressor mechanism or to  blocking o f accessory ce ll function.
Depletion o f FacbR+ ce lls  resulted in  a dramatic f a l l  in  IgG
synthesis. This was not altered in  any way by addition o f Facb
fragment. Furthermore, the lack o f an IgG response was not due to  a 
loss o f monocytes, since these were s t i l l  present, shown by non­
spec ific  esterase sta in ing .
Removal o f suppressor function would have resulted in  an
enhanced IgG response so the results  above corre la te with a blocking 
o f accessory function by Facb fragment. These data are c le a rly  in  
agreement w ith the phenotypic characte ris tics  o f the FacbR+ c e ll .  
Furthermore, these resu lts  support Hoffman's postulate (1980) tha t 
antibody-mediated feedback suppression occurs through interference 
with T and B ce ll co-operation.
Aims of the project
In a chronic disease such as RA i t  is  usually not c lear whether 
defects in  immunoregulation are secondary to  the disease process or 
actua lly  serve to  in i t ia te  i t  (or at least allow i t s  establishment). 
One way to  answer th is  is  to  examine patients with early disease. 
However, diagnosis o f RA at th is  stage is  notoriously d i f f ic u l t .  The 
a v a ila b il ity  o f a technique which c le a rly  d iffe re n tia te s  patients 
with RA from others w ith non-RA arthropathies would be o f immense 
benefit to  both the c lin ic ia n  and the pa tien t. Early accurate 
diagnosis would mean early treatment, which might reduce the r is k  o f 
severe, d isabling disease.
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The aims o f the present investiga tion  were tw o fo ld :- f i r s t ,  to 
examine Facb-mediated negative feedback suppression o f antibody 
synthesis in  patients with early RA; second, to  evaluate the 
potentia l o f the assay system as a tool fo r  determining disease 
s p e c if ic ity .
Patients with early seropositive, seronegative or palindromic RA 
were investigated and compared to  ind iv idua ls with established 
disease. A very small number o f F e lty 's  patients were also 
investigated. Control groups included normal healthy contro ls as 







A ll chemicals except where 
otherwise stated
A ll reagents fo r media and 
tissue culture p lastics
A ll anti sera and reagents fo r 
the ELISA technique except 
where otherwise stated
A ll enzymes:
Pepsin (from hog stomach 1:60,000 
2  x c rys ta llised  and lyophilised) 
Plasmin (from human plasma, 
lyophilised)
7-IFN
F lexib le , polyvinyl chloride 
f la t  bottom plates, M29
Suppliers
B ritish  Drug Houses Ltd 
Poole, Dorset
GIBCO Biocult Ltd 
Paisley, Scotland
Sigma Chemical Co 
Poole, Dorset
Sigma Chemical Co 
Poole, Dorset
Biogen Research Corp, 
Cambridge, Mass. USA
Dynatech Laboratories Ltd, 
B illin g h u rs t, Sussex
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Rigid polystyrene M129A plates
Rigid polystyrene M129B plates
Rigid polystyrene Nunc Immunoplate 6IBC0 B iocult Ltd 
Paisley, Scotland
Pokeweed mitogen (lyoph ilised ; crude GIBCO B iocult Ltd
preparation from phvlolacca americana) Paisley, Scotland
Concanavalin A (lyoph ilised  from 
Oack bean Canavalia ensiform is)
Pharmacia (GB) Ltd 
M ilton Keynes, UK
DEAE Sephadex A50 Pharmacia (GB) Ltd 
M ilton Keynes, UK
Ficol 1 paque (density 1.077 
+ /- 0 . 0 0 1  g/m l)
Pharmacia (BGB) Ltd 
M ilton Keynes, UK
Protein A Sepharose 4B Pharmacia (GB) Ltd 
M ilton Keynes, UK
Sephadex G100 (frac tiona tion  range 
4,000 -  150,000 dal tons)
Pharmacia (GB) Ltd 
M ilton Keynes, UK
Agarose (Type 1 low EEO) Sigma Chemical Co 
Poole, Dorset
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Bovine serum albumin (<1% immunoglobulin) Sigma Chemical Co
Poole, Dorset
Casein Sigma Chemical Co 
Poole, Dorset
Calf RBC in Alsevers solution Tissue Culture Services 
Slough, Berks
'Tago' a f f in i ty  p u rified  anti human 
IgM a lka line  phosphatase conjugate
Tissue Culture Services 
Slough, Berks
Heparin sodium (mucous) 'monopurin1 
1 1 0 0  units/ml
Weddell Pharmaceutical Ltd 
Wrexham, UK
Phytohaemagglutinin (p u rifie d  from 
Phaeseolus supp. lyoph ilised)
Wellcome Foundation Ltd 
Dartford, Kent





Ami con s tir re d  ce lls  and D iaflo 
f i l t r a t io n  membranes
Supplier
Ami con Ltd 
Stonehouse, 61 os
Rotary turntab le Baird and Tatlock 
PO Box 1, Romford, Essex
Dynatech automatic microELISA 
reader Mk 580
Dynatech Instruments 
C a lifo rn ia , USA
Laborlux 12 microscope E Leitz Ltd 
Luton, UK
LKB 6520 recorder LKB Instruments Ltd 
South Croydon, Surrey
LKB Bromma 7000 U ltrorac frac tion  
co l1 ector
LKB Instruments Ltd 
South Croydon, Surrey
LKB Bromma 8300 Uvicord I I  detector u n it LKB Instruments Ltd
South Croydon, Surrey
LKB 12000 Varioperpex p e r is ta lt ic  pump LKB Instruments Ltd
South Croydon, Surrey
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Power pack and electrophoresis tank Shandon Southern 





ROUTINE BUFFERS AND MEDIA
A. CELL CULTURE
i )  Calcium and magnesium-free salt solution (CMFSS)
s Z l
Sodium chloride 8 . 0 0
Potassium chloride 0.40
Glucose 1.60
Potassium dihydrogen phosphate 0.06
Disodium hydrogen phosphate 0.048
The above were dissolved in  t r ip le  d is t i l le d  water, the pH adjusted 
to  7.3 with 1M NaOH and the volume made up to  1 l i t r e .  The solution 
was then f i l t e r  s te r ilis e d  and stored at 4°C u n til use.
i i )  Cell culture medium RPMI 1640 (+10% FCS)
RPMI 1640 (x 10 strength) 100 ml
Heat inactivated foeu il c a lf  serum 100 ml
P e n ic illin  and streptomycin solution 20 ml
(5000 units/m l)
200 mM L-Glutamine 20 ml
7.5% sodium bicarbonate solution 27 ml
The above reagents were d ilu ted  to  1 l i t r e  with s te r i le  t r ip le -  
d is t i l le d  water and the pH adjusted to  7.3 using s te r i le  3M NaOH. 
The medium was f i l t e r  s te r ilis e d  and stored at 4°C u n til required.
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i i i )  Cell counting flu id
Glacial acetic acid 3 ml
Methylene blue 
D is t il le d  water
0 . 1  g
97 ml
The above constituents were mixed and stored at room temperature.
B. COLUMN CHROMATOGRAPHY
i )  ^0/150 art phosphate buffer, pH 7.4
Solutions A and B were mixed with s t ir r in g  to  give a buffe r o f pH 
7.4. This was d ilu ted  10-fold in d is t i l le d  water. To each l i t r e  o f 
d ilu te  solution was added 8.77g sodium ch loride.
i i )  0.1M acetate buffer, pH 4.5
Stock solutions containing 0.82g sodium acetate in  100 ml d is t i l le d  
water (so lution A) and 1.15 ml g lac ia l acetic acid in  200 ml 
d is t i l le d  water (so lu tion B) were prepared. Solution B was then 
added to  solution A u n til the pH was 4.5. This buffer was then used 
to  prepare a 6 M urea so lution fo r use in  the preparation o f Facb.
i i i )  0.01M phosphate buffer, pH 6.5








Solutions A and B were mixed to  give a buffer o f pH 6.5
75
C. ELISA





The above were dissolved in  1 l i t r e  o f d is t i l le d  water, the pH 
checked and the solution s tirre d  a t 4°C.
i i )  Phosphate buffered saline (PBS), pH 7.4
all
Sodium chloride 8.0
Potassium dihydrogen chloride 0.2
Disodium hydrogen phosphate dodecahydrate 2.9
Potassium chloride 0.2
Sodium azide 0.2
The above were dissolved in 1 l i t r e  of d is t i l le d  water and stored at 
room temperature u n til use.
i i i )  PBS-Tween (PBST)
To 1 l i t r e  o f PBS was added 0.5 ml Tween 20 (polyoxyethylene sorbitan 
monolaurate). The solution was stored at room temperature u n til 
required.
iv ) PBS-1% BSA
1g o f bovine serum albumin (BSA) was dissolved in  100 ml o f PBS. 
This solution was prepared fresh and d ilu ted  1 in  2 with PBS to  give
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PBS-0.5% BSA which was then used fo r d ilu tin g  te s t samples fo r IgG 
and IgM ELISA.
v) Diethanol amine buffer, pH 9.6
Diethanol amine 




0 . 1 0  g
0 . 2 0  g
97 ml
The above were mixed and the pH adjusted to  9.6 with 1M hydrochloric 
acid. The fin a l volume was made up to  1 l i t r e  and the solution 
stored in  an amber b o ttle  a t room temperature.
D. imUNOELECTROPHORESIS
i )  Barbitone buffer, pH 8.4 -  8.6
The above were dissolved in  1.5 l i t r e s  o f water, heated to  aid
d isso lu tion . The buffer cooled, 0.4 g o f sodium azide was added and
the volume made up to  2 l i t r e s  and stored at 4°C u n til required.
i i )  IX Agarose in barbitone buffer
1g o f agarose (Type 1; low EEO) was placed in  a conical flask 
containing 90 ml o f barbitone bu ffe r. The mixture was boiled u n til 
the agarose lumps dissolved completely. The solution was then made





in to  glass b o ttle s . The gel was allowed to  cool and stored at 4°C 
u n til required.
i i i )  Coomassie blue
Coomassie blue 
Glacial acetic acid 
D is t il le d  water
Destainer
This is  the same as the above solution but minus the Coomassie blue.
E. MODIFIED LOWRY METHOD FOR PROTEIN ESTIMATION
Stock solutions
i ) Copper ta rtra te
50 mg o f CuSO^  was dissolved in  10 ml o f 1% w/v sodium potassium 
ta r tra te . This solution was then added to  100 ml o f 10% w/v sodium 
carbonate in 0.5M NaOH.
i i ) Folin and Ciocalteau phenol reagent
This is  available commercially and was d ilu ted  1 in  10 in d is t i l le d  
water immediately p r io r to  use.
i i i ) Standard protein
20 mg o f high grade p u rity  BSA were dissolved in  100 ml o f d is t i l le d





1. PREPARATION OF HUNAN IgG AND ITS FRAGMENTS
a) Preparation of IgG
Two sources o f human IgG were used: one, a pool o f normal human 
serum and the other, the serum o f an IgG1 class myeloma pa tien t. Ion 
exchange chromatography using DEAE-Sephadex A50 was employed fo r  both 
p u rifica tio n s .
i ) P u rifica tion  o f normal human IgG
A pool o f normal serum was d ilu ted  x 10 in  PBS and 
saturated ammonium sulphate so lution added dropwise u n til 50% 
saturation was achieved. The serum-ammonium sulphate mixture 
was le f t  s t ir r in g  fo r one hour a t room temperature to  e q u ili­
brate before the immunoglobulin-rich p rec ip ita te  was harvested 
by centrifugation a t 1000g fo r  15 minutes. This was then 
dissolved in 0.01M phosphate bu ffe r, pH 6.5 and dialysed f i r s t  
against d is t i l le d  water and then against several changes o f 
0.01M phosphate buffe r a t 4°C u n til the pH and the conductivity 
matched tha t o f the bu ffe r. The dialysate was centrifuged to 
remove any p rec ip ita te  formed during d ia lys is  and mixed with 
DEAE-Sephadex A50 equ ilib rated with 0.01M phosphate bu ffe r, pH 
6.5, fo r batch preparation o f IgG.
The gel was le f t  mixing fo r  one hour and then washed with 
several a liquots o f 0.01M phosphate buffer on a Buchner funnel, 
u n t il the O.D2go o f the eluant, which was collected in to  a flask 
by suction, f e l l  to  near zero. The contents o f the flask were 
concentrated by vacuum d ia lys is  using the Ami con s tir re d  ce ll 
u l t r a f i l t r a t io n  system. The protein content was then assessed by 
a modified Lowry assay. The IgG was shown to be pure by 
immunoelectrophoresis (IEP) (see Figure 1).
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FIG 1 Iwmjnoelectrophoresis o f pu rified  normal human IflG
A single immunoprecipitin arc (a) was obtained when IgG pu rified  from 
a normal human serum pool was analysed by IEP. (b) shows the
p re c ip itin  lines obtained when normal human serum was examined, (c) 
and (d) are the same as (a) and (b) respective ly, but at 1 : 2  
d ilu t io n .
•iwSttfcr  i >>. »,- v- . ■ —  -
■ r: W '> -- ■■■?*>*■ ■
i=Anti-Human IgG anti-serum 
ii=Anti Whole Human Serum antiserum
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The p u rifie d  normal human IgG was aliquoted and stored at - 
20°C u n til required. This preparation was used in  the 
rheumatoid fac to r assay,
i i ) P u rifica tion  o f human myeloma IgG^
30 ml o f myeloma serum were extensively dialysed against
0.01M phosphate bu ffe r, pH 6.5, centrifuged and applied to  a 2.5 
x 30 cm column o f DEAE-Sephadex A50 which had been previously 
equ ilib rated w ith 0.01M phosphate bu ffe r, pH 6.5. 10 ml
frac tions were co llected. A single peak was obtained and th is  
was concentrated by u lt r a f i l t r a t io n  over an Ami con D ia flo  XM50 
membrane (exclusion l im it  50,000). Protein content and pu rity  
were assessed as above. Results o f the IEP appear in Figure 2. 
The preparation was f i l te r - s te r i l is e d  using a 0.22 urn f i l t e r ,  
aliquoted and stored a t -90°C u n til use.
P urified myeloma IgG-j was used in  experiments employing 
heat aggregated IgG (Hagg) and also fo r preparation o f the IgG 
fragment F(ab' )2•
b) Preparation of F(abf )2
This was prepared from pu rified  IgG  ^ using the method described 
by Nisonoff e t al (1961).
IgG-j was dialysed against 0.01M acetate bu ffe r, pH 4.5, fo r 4 
hours at 4°C. A so lu tion o f pepsin was prepared (1 mg/ml in  0.01M 
acetate buffe r) and added to  the IgG-j dialysate to  give a fin a l 
concentration o f 1:100. The solution was incubated at 37°C fo r 22 
hours. The enzymic reaction was stopped by the addition o f so lid  
T ris  (hydroxymethyl) methyl amine to  produce a pH o f 8 . The digest 
was then applied to  a 1.5 x 100 cm Sephadex G-100 column equilib rated
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FIG 2 Immunoelectrophoresis o f p u rifie d  human myeloma IgG^
Purity o f the isolated IgG-j is  indicated by the single 
immunoprecipitin arc (a) produced when the immunoglobulin was 
analysed by IEP. (b) shows the p re c ip itin  lines obtained w ith normal 
human serum.
A n ti human IgG
Antihuman IgG
A n ti whole human 
serum
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with 10/150 mM phosphate bu ffe r, pH 7.4. Undigested IgG and F(ab) 1 2  
both appear in  the f i r s t  peak, which was concentrated and applied to 
a protein A-Sepharose 4B column. The F(ab) 1 2  was eluted o f f  in  the 
f i r s t  peak using 10/150 mM phosphate buffe r and the undigested IgG 
eluted in  the second peak using 1M acetic acid. The F(ab) ’ 2  was 
concentrated and assayed fo r protein content as above. The 
preparation was f i l te r - s te r i l is e d ,  aliquoted and then stored a t -90°C 
u n til use.
2. HEAT AGGREGATED HUMAN IgG
Heat aggregated IgG (Hagg) was produced by incubating a 1 ml 
volume o f p u rified  IgG-j (concentration 11.5 mg/ml) a t 63°C fo r h a lf 
an hour. This was prepared fresh fo r each experiment, ju s t p r io r to 
use.
3. PREPARATION OF Facb FRAGMENT FROM RABBIT IgG
Facb fragment was prepared from a rabb it a n t i-c a lf  RBC serum (a 
g i f t  from Dr Hunneyball, Boots, Nottingham) using a m odification o f 
the method described by Stewart e t al (1973).
The hyperimmune ra bb it serum was applied to  a 1 x 15 cm column
o f Protein A-Sepharose 4B equ ilib rated with 10/150 mM phosphate 
bu ffe r, pH 7.4. Unbound material appeared in  the f i r s t  peak (Figure 
3, peak (a)) and IgG was eluted in  the second peak (Figure 3, peak 
(b)) using 1M acetic acid. The immunoglobulin fra c tio n  was 
concentrated by u l t r a f i l t r a t io n  and incubated fo r  one hour at 37°C.
The pH o f the concentrate was then adjusted to  pH 7 using 1M NaOH and
the plasmin added (3 units/100 mg IgG). The mixture was incubated 
fo r 4 hours at 37°C w ith periodic mixing. A fter th is  period the 
digest was applied to  a 1.5 x 100 cm Sephadex G-100 column,
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equ ilib ra ted with 6 M urea in  0.1M acetate bu ffe r, pH 4.5. Using a 
flow ra te  o f 8  m l/h r, 4 ml fractions were co llected. Two peaks were 
obtained; undigested IgG and Facb appearing in  the f i r s t  peak (Figure
3, peak (c )) , which was concentrated and dialysed against two changes 
o f 10/150 mM phosphate buffe r fo r 4 hours a t 4°C. Peak (d) (Figure 
3) contained the digested CH3 domain and other smaller peptides. The 
IgG-Facb containing d ia lysate was then applied to  Protein A-Sepharose 
4B to  e ffe c t separation o f the Facb from undigested IgG. Facb is  
unable to  bind to  Protein A and thus appears in  the f i r s t  peak 
(Figure 3, peak (e )) . Peak ( f )  (Figure 3) contains the undigested 
IgG. The Facb preparation was concentrated, the protein content 
determined immediately, and the solution was aliquoted and stored at 
-90°C u n til required.
A ll procedures were carried out a t 4°C unless otherwise stated.
4. CELL CULTURE
a) Preparation of peripheral blood mononuclear cells
Peripheral blood mononuclear c e lls  (PBMNCs) were isolated from 
heparinised (10 IU/ml blood) venous blood by density centrifugation  
as described by Boyum (1968). The blood was d ilu ted  1 in  2 with 
CMFSS and approximately 7 ml layered onto 3 ml o f Ficoll-paque in  a 
s te r i le ,  polystyrene centrifuge tube. This was then centrifuged at 
400 g fo r 30 minutes a t 18°C. The mononuclear ce ll (MNC) layer which 
appeared as a th in  white band a t the plasma-Ficoll in te rface was 
harvested, washed three times in  CMFSS and once in  the RPMI 1640 
(+ 10% FCS) cu lture  medium,, before being counted and adjusted to 
e ith e r 1 x 106/ml or 1.11 x 106/ml as required. A ll ce ll experiments 
were carried out in  s te r i le ,  large w e ll, f l a t  bottom cu ltu re  plates 
a t a fin a l concentration o f 1 x lo fym l. The plates were incubated at
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pjg 3  Preparation o f Facb fragment from rabb it a n ti-c a lf  RBC IgG
The e lu tion  p ro files  o f the chromatographic stages used in Facb 
preparation show:- (1) pu rifica tio n  of rabb it anti-cRBC IgG using 
protain A-Sepharose 4B - peak (a) contains unbound m aterial, peak (b) 
the rabb it IgG. (2) separation of Facb (peak (c )) and pFc (peak
(d)) on G100 Sephadex, following plasmin digestion. (3) removal of 
undigested IgG (peak ( f ) )  from Facb (peak (e)) using a protein A- 
Sepharose 4B column.
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37°C in  a humidified atmosphere containing 5% carbon dioxide.
Concentrations o f reagents and conditions o f cu lture  described 
below were determined in  a series o f prelim inary experiments, results  
o f which appear in  Chapter 3.
b) Facb cultures
0.9 ml volumes o f washed PBMNC adjusted to  1.11 x 10^/ml were 
aliquoted in to  cu lture  plates and s te r i le  Facb, d ilu ted  in  medium, 
was added in 1 0 0  pi volumes to  give f in a l concentrations o f 0 . 2 , 2  
and 2 0  pg/m l. 1 0 0  y\ o f medium was added to  cultures not containing
Facb. Pokeweed mitogen (PWM) was used to stimulate antibody 
synthesis. This was d ilu ted  in  CMFSS and added in 20 jjI volumes to 
give f in a l reciprocal d ilu tio n s  o f 50, 200 and 1000. CMFSS was added 
to control cu ltu res. The ce lls  were cultured fo r  14 days and then 
the cu ltu re  supernatants harvested by cen trifuga tion . These were 
stored at -20°C before being assayed fo r  IgG and rheumatoid fac to r 
(RhF), and in  some cases, IgM.
c) Hagg cultures
PBMNCs adjusted to  1 x 106/ml were set up in  1 ml volume 
cultures + /-  5 pg/ml Hagg and + /- 1/200 f in a l d ilu tio n  o f PWM. Cells 
were cultured fo r  5 days, harvested, washed three times in  medium to 
remove the Hagg (which in te rfe res w ith the ELISA) and then readjusted 
to 1 x 10^/ml before cu ltu ring  fo r  a fu rthe r 5 days. The 
supernatants were harvested by centrifuga tion  and stored a t -20°C 
before assaying fo r IgG and RhF.
d) Gamna-interferon ( 7-IFN) cultures
The e ffe c t o f 7-IFN  on Facb- and Hagg-mediated suppression o f
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antibody synthesis was investigated in  4 normal ind iv idua ls . Facb 
and Hagg cultures were set up as usual and cultured + /-  a fin a l 
concentration o f 10 un its Y-IFN/ml. Supernatants were assayed fo r 
IgG by ELISA.
e) 2-mercaptoethanol (2-ME) treated cultures
The e ffe c t o f preincubating PBMNCs with the th io l-reducing agent 
2-ME was examined. PBMNCs were isolated from fresh blood, washed as 
usual and incubated with 5 x 10_5M fin a l concentration o f 2-ME fo r 1 
hour at 37°C. The c e lls  were then washed three times to  remove the 
2-ME and Facb and Hagg cultures set up as usual. The percentages o f 
Facb rosetting  c e lls  were also determined before and a fte r 2-ME 
treatment.
5. Facb ROSETTE CELL ASSAY
The Facb rosette ce ll assay was carried out as described by Hall 
e t al (1980). Essentia lly , the assay consists o f three steps as 
fo l 1 ows:-
a) Sensitisation of c a lf RBC
Calf RBC were washed three times in  CMFSS and a 2% v/v ce ll 
suspension prepared. This was mixed with an equal volume of 
optim ally d ilu ted  Facb and incubated a t 37°C fo r h a lf an hour. The 
sensitised ce lls  (s-cRBC) were centrifuged and washed three times in 
CMFSS and a 1% v/v ce ll suspension prepared. This was kept on ice 
u n til required.
b) Incubation of PBMNC with sensitised c a lf RBC
PBMNCs were isolated as described above, washed three times in 
CMFSS and adjusted to  2 x 106 /m l. 200 jjI o f th is  ce ll suspension
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were mixed with an equal volume o f 1% s-cRBC in  an LP3 tube (Luckham 
Ltd, Sussex) and centrifuged at 400 g fo r  3 minutes at 4°C. The 
pelleted ce lls  were incubated on ice immediately fo r 1 hour. 
Unsensitised cRBC were used as controls fo r non-specific rose tting .
c) Enumeration of Facb rosettes
Afte r incubation a small amount o f crysta l v io le t was introduced 
in to  each tube and the ce lls  resuspended on a ro ta ting  turntable 
inclined at an angle o f 45° and operated a t 20 rpm fo r  1 minute. The 
ce lls  were then counted in  a Neubauer improved haemocytometer. Any 
lymphocyte surrounded by 3 or more RBC was scored as a rosette . The 
resu lts  were expressed as a percentage o f the to ta l number o f 
lymphocytes counted. A minimum o f 200 lymphocytes were counted each 
time.
6. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
a) IgG and IgM ELISA
Fla t bottom, polystyrene (Nunc immunoplate 1) m ic ro titre  plates 
were coated with an optimal d ilu tio n  o f goat anti-human polyvalent 
immunoglobulin in  carbonate bu ffe r, pH 9.6 fo r  18 hours at 4°C. The 
plates were washed in PBST and any available s ites on the p la s tic  
blocked using 100 jug/wel1 o f PBS-1% BSA and incubating at 37°C fo r 1 
hour. The blocking solution was removed by washing the plates in 
PBST, and IgG (or IgM) standard and te s t supernatants su itab ly  
d ilu ted  in  PBS-0.5% BSA were then added to  the appropriate wells and 
incubated fo r 1 hour at 37°C. This was followed by another wash in 
PBST. A 1/1000 d ilu t io n  o f goat anti-human IgG (or IgM) a lka line  
phosphatase conjugate in  PBST was added in  100 ; il volumes/well and 
the plates then re-incubated at 37°C fo r  1 hour. Unbound conjugate
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was removed by washing the plates in  PBST. The substrate, d- 
nitrophenyl phosphate, was d ilu ted  in diethanol amine bu ffe r, pH 9.8, 
to a concentration o f 1 mg/ml and added in  1 0 0  jjI volumes/well and 
the plate incubated a t room temperature u n til a predetermined IgG/IgM 
standard gave an absorbance value o f approximately 1 at a wavelength 
o f 405 nm. The plates were then read using the microELISA automatic 
plate reader. A standard curve o f absorbance (E4 0 5 ) against IgG/IgM 
concentration in ng/ml was constructed and immunoglobulin content o f 
te s t samples determined using only the lin ea r part o f the curve. 
These values were then su itab ly corrected fo r d ilu t io n .
IgG and IgM standards
A normal serum pool (negative fo r  RhF a c tiv ity )  was used as a 
source o f IgG and IgM standards. The concentrations o f these 
immunoglobulins were determined by nephelometry (by Mr K Case, 
Immunology Department, Royal United Hospital, Bath). The serum pool 
was aliquoted and stored a t -90°C u n til required.
b) IgM rheumatoid factor ELISA
The conditions fo r the IgM RhF assay were essentia lly  the same 
as those described above fo r the immunoglobulin' ELISAs, with the 
fo llow ing exceptions
i )  Purified normal human IgG, at a concentration o f 1 ;jg/ml in  
carbonate bu ffe r, pH 9.6 was used to  coat f le x ib le , polyvinyl 
chloride m ic ro titre  plates.
i i )  A ll te s t samples were tested neat and the RhF standard was 
d ilu ted  in  medium.




IgM RhF had in i t ia l l y  been p u rifie d  from a strongly seropositive 
rheumatoid serum by a f f in i ty  chromatography using p u rifie d  human IgG 
linked to  Sepharose 4B. This preparation was used to  define some of 
the optimal conditions fo r the RhF ELISA. However, the a c t iv ity  o f 
th is  material fe l l  rap id ly  on storage and a second standard had to  be 
selected.
A rheumatoid serum containing high t i t r e  RhF was used. This 
serum was repeatedly absorbed with Hagg and tested fo r RhF a c t iv ity  
using the Rheuma-Wel1 cotest (a la tex agglutination te s t) u n til no 
agglutination was observed. A normal serum was simultaneously 
absorbed with Hagg to  determine the amount o f IgM which was non- 
sp e c ifica lly  removed during the absorption procedure.
The pre- and post-absorption sera were tested fo r RhF and IgM 
concentration by ELISA. The decrease in IgM concentration a fte r 
absorption represented the amount o f IgM RhF present in  the serum. 
This figure  was corrected fo r non-specific loss o f IgM during 
absorption.
7. IFflUNOELECTROPHORESIS
10 ml o f 1% w/v agarose (Type 1, low EEO) in a barbitone bu ffe r, 
pH 8 . 6 , were heated in  a water bath u n til molten and then ca re fu lly  
poured onto a 8  x 8  cm glass plate resting on a le ve llin g  tab le . 
Once the gel was set, a pattern o f wells and troughs was cut and only 
the gel from the wells was removed. 5 ^il o f te s t samples were placed 
in to  the appropriate w ells. Normal human serum to  which a small 
amount o f bromophenol blue (BPB) had been added was always run as a 
co n tro l. The electrophoresis tank was f i l le d  with barbitone buffer 
and the gel connected to  the buffer by means o f paper wicks placed on
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e ithe r side o f the p la te . The samples were electrophoresed under a 
constant voltage o f 100V and the run stopped when the BPB had nearly 
reached the edge o f the p la te . Agarose was then removed from the 
troughs previously cut in to  the gel and the trough f i l le d  with 25jj1 
o f the appropriate anti serum. The plate was le f t  overnight in  a 
humid atmosphere a t room temperature before being washed in  three 
changes o f 1M NaCl, once in d is t i l le d  water and f in a l ly  dried. The 
plate was then stained with Coomassie blue and d iffe re n tia tio n  
obtained w ith destainer. Plates were f in a l ly  dried in  a ir  and read.
8. MODIFIED LOWRY METHOD FOR PROTEIN ESTIMATION
Test samples and protein standard (200 jjg/ml BSA solution) were 
appropriately d ilu ted  in  1 ml volumes and then 1 ml o f copper 
ta r tra te  added. The samples were mixed and allowed to  stand fo r 10 
minutes, a fte r which 3 ml o f d ilu ted  Folin and Ciocalteau's phenol 
reagent were added to  each sample as quickly as possible. The 
samples were incubated at 50°C fo r  10 minutes, cooled and the 
absorbance measured a t 650 nm. A standard curve o f absorbance 
against protein concentrate was constructed and unknown values read 
o f f  th is  and corrected fo r  d ilu t io n .
9. PATIENT AND CONTROL GROUPS
Patients w ith early rheumatoid disease were drawn from the Early 
Synovitis C lin ic  at the Royal National Hospital fo r Rheumatic 
Diseases. These subjects were c la ss ifie d  in to  early RA positive  
(mean age 55 years), early RA negative (mean age 54 years) and early 
palindromic RA (mean age 34 years) groups by Dr A D Woolf (Senior 
Registrar) and a t each v is i t  patients were assessed fo r disease 
a c t iv ity .
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A ll other patient groups were obtained from the c lin ic s  and 
wards a t the hosp ita l. The average ages o f the established RA, OA 
and F e lty 's  groups used in the Facb study were 56, 70 and 6 8  years 
respective ly, and those o f established RA, AS, OA and F e lty 's  
subjects used fo r  the Hagg study were 62, 46, 6 8  and 74 years 
respective ly.
At the time of investigation patients were e ithe r receiving no 
medication or only NSAIDs. Where second lin e  therapy had been 
previously employed, only those patients with a wash-out period o f 
not less than 8  weeks were used.
Normal healthy controls mean age 31 ( fo r  the Facb study) and 28 
( fo r  the Hagg study) were derived from laboratory and hospital 
personnel. Old normal subjects (mean age 69 years) were obtained 
from St M artin 's Hospital, Odd Down, Bath, by courtesy o f Dr R Oones.
10. STATISTICAL ANALYSIS
A ll data were analysed using the Mann Whitney U-test unless 
otherwise indicated. Correlations were conducted using Spearman's 




The resu lts  presented in th is  chapter concern experiments 
carried out to  determine optimal operating conditions fo r : -
1. The ELISA technique
2. Antibody synthesis in  v i t r o ,
SECTION 1 ELISA
The p rinc ip les  o f enzyme-linked immunosorbent assays used to 
measure IgG and IgM and IgM RhF in cu lture  supernatants are depicted 
in  Figures 1 and 2. These assays had o r ig in a lly  been established in
G uilford microELISA cuvettes and then transferred to  m ic ro titre
p la tes. Here optimal conditions were re-established using the IgM
assay. Data from these experiments are presented below.
One o f the f i r s t  considerations was choice o f so lid  support (ie  
type o f p la te) since although p la s tic  nonspecifica lly  adsorbs protein 
(Catt and Tredegar, 1967), d iffe re n t p las tics  do so to  varying 
degrees. Four types o f plates were examined (see Table 1) and o f 
these the Dynatech 129B ELISA plates were found to  be the best fo r 
both high prote in adsorption and low in te r -  and in tra -  plate 
va ria tio n . However, these plates are s te r i le  and therefore more
expensive. Polyvinyl (PVC) plates were thus selected as the next
best choice. Later IgG and IgM were carried out in  Nunc immunol 
plates (Tissue Culture Services) but use o f PVC plates was continued 
fo r  RhF ELISAs as these plates exhibited a high adsorption o f
p u rifie d  human IgG.
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KEY TO FIG 1
Y
X
KEY TO FIG 2
I
= Goat anti human polyvalent immunoglobulin
= IgG/IgM containing culture supernatants/standards
= A ff in ity  purified  anti human IgG/IgM alkaline 
phosphatase conjugate
= d-nitrophenyl phosphate (native and degraded)
o o
= Pure human IgG
^  = IgM RhF containing culture supernatants/standards
= A ff in ity  purified  anti human IgM alka line 
phosphatase conjugate
o o Q
o •  #o = d-nitrophenyl phosphate (native and degraded)
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FIG 1 I llu s tra tin g  the double antibody ELISA used fo r  quantifying 
IgG and IgH in  cu lture  supernatants
♦Excess binding sites on the so lid  phase were blocked using PBS-1% 
BSA before proceeding to step 2.
x
4
OSS '° < %
T 
1
1. Antibody adsorbed to  plate
Wash
2. Test solution containing antigen added
Wash
3. Add enzyme labelled specific  antibody
Wash
4. Add enzyme substrate
Amount hydrolysed =  amount antigen present 
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FIG 2 I llu s tra tin g  the ind irec t ELISA used fo r quantifying IgH
RhF in cu ltu re  supernatants
♦Excess binding sites on the solid phase were blocked using PBS-1% 
BSA before proceeding to  step 2.
i








3. Add enzyme labelled anti globulin which 
attaches to antibody
Wash
o ° * o  
o •  _ •  •
%
4. Add substrate
Amount hydrolysed =• amount antibody present
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TABLE 1 Showing the four types of plate tested fo r degree o f prptein adsorption and In te r- and in tra -p la te
variation when one concentration of IgM was incubated in a ll the wells o f a ll the plates tested.
Four m ic ro titre  plates o f each o f the types below were coated with goat anti human polyvalent immunoglobulins 
anti serum and incubated with a given d ilu tio n  o f the IgM standard. The degree o f adsorption (as indicated by 
absorbance values a t 405 nm) and in te r-  and in tra -p la te  v a r ia b il i ty  o f th is  were determined fo r  each type o f 
p la te  examined.
Plate tested Average
absorption
Average c o e ffic ie n t o f 
va ria tion  w ith in  plates
Comparison o f absorb- 
ancies between plates 
o f the same type
Dynatech M129A 0.340 15.95% p > 0.05
Dynatech M129B 1.147 7.30% p > 0.05
Dynatech polyvinyl f le x ib le 0.894 6.64% p > 0.05
Nunc tissue cu ltu re  plates 0.826 6.60% p > 0.05
In the IgG and IgM assays goat anti human polyvalent 
immunoglobulin anti serum was used to  coat the so lid  phase. D ilutions 
ranging from 1/100 to  1/3200 were examined. The standard curves 
obtained are shown in  Figure 3. No s ig n ifica n t differences were 
found between these and a d ilu tio n  o f 1/400 was selected fo r future 
use.
In the IgM RhF assay ELISA plates were coated w ith 1-10 pg/ml 
pure human IgG. Tenfold d ilu tion s  o f a f f in i ty  pu rified  RhF were used 
to construct standard curves. These are shown in  Figure 4. A
concentration o f 1 jjg/ml was selected fo r  use in  subsequent RhF 
assays.
Human IgG used in  these assays was prepared from a pool o f
normal human serum by ion exchange chromatography on DEAE-Sephadex as 
described in  Chapter 2.
For both assays, excess binding s ites  on plates were then
blocked using PBS-1% BSA, shown to  be optimal in  prelim inary
experiments (data not shown).
Various solutions were tested fo r d ilu tin g  the te s t 
samples/standards. S im ilar standard curves were obtained when PBS- 
Tween, medium and PBS-0.5% BSA were used as shown in Figure 5. With 
PBS the higher absorbances may be a re su lt o f some non-specific
in te ra c tio n , since the background was also found to  be s lig h t ly  
higher w ith th is  d ilu e n t.
Since some supernatants had to be tested neat or at low
d ilu t io n s , i t  was decided th a t a protein-containing so lu tion such as 
PBS-0.5% BSA should be the d iluen t o f choice, although PBS-Tween was 
equally as good and would have been cheaper. This would allow suc­
cessive d ilu tio n s  o f the sample (cu lture  supernatant containing 1 0 %
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FIG 3 The e ffec t o f varying the d ilu tions  o f coating antibody on 
the IgM standard curve
M ic ro titre  plates were coated with 1/100 (o  o ) , 1/200 (□ ----- □),
1/400 ( • — • ) ,  1/800 (a— A ), 1/1600 (■— ■) and 1/3200 (a — a ) fin a l 
d ilu tions  of goat polyvalent anti human immunoglobulin anti serum. An 
IgM standard curve was then constructed fo r each d ilu tio n  used. Each 
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FIG 4 The e ffe c t o f varying coating concentrations o f pure human 
IgG on the IgM RhF standard curve
M ic ro titre  plates were coated with 1 ( • — • ) ,  2.5 (□— □ ), 5 (o— o) 
and 10 (a— a ) jjg/ml IgG. A ff in ity  pu rified  IgM RhF was used as a 
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FIG 5 The e ffec t o f d iffe re n t diluants on the IgH standard curve
The serum standard was dilu ted in PBS (o  o ) ,  PBS-T (a  a ) ,  PBS-
























foeta l c a lf  serum) without producing an overall disturbance in the 
prote in content o f the system, which might otherwise a ffe c t the way 
the antigen interacted with the various immunological reagents used 
in  the ELISA.
Antigen and conjugate incubating times and temperatures were 
also assessed. The resu lts  are shown in  Figure 6 . I t  was found tha t 
the background absorbance values were increased when antigen or 
conjugate incubation times were lengthened from 1 to  4 hours. These 
changes were more prominent with increases in  time o f conjugate 
incubation. S im ila rly , i t  was found tha t increasing the times of 
antigen incubation produced an increase in the slope o f the standard 
curve. This was fu rthe r elevated by prolonging incubation with 
conjugate. Although th is  enhanced slope meant a more sensitive 
assay, i t  also lim ited  the range over which the lin e a r curve was 
usable. I t  was thus decided tha t the assay should have a 1 hour 
antigen incubation at 37°C, followed by incubation fo r  1 hour with 
conjugate a t the same temperature. This would re su lt in  a low 
background and a curve which was lin ea r over a fa i r  range o f standard 
antigen concentrations.
Figure 7 shows the e ffe c t o f using d iffe re n t d ilu tio n s  of 
conjugate on the IgM standard curve. The manufacturers had 
recommended a f in a l d ilu tio n  o f 1/3000 fo r use in  ELISAs. However, 
i t  was found th a t a 1 / 1 0 0 0  d ilu tio n  produced a much be tte r standard 
curve than the higher d ilu tio n s . Thus th is  d ilu tio n  was used in 
subsequent assays. IgG conjugate was also used at a 1/1000 d ilu tio n , 
as recommended by the suppliers o f th is  p a rticu la r reagent.
Figure 8  shows degradation o f the substrate (measured by the 
increase in  absorbance at 405 nm) d-nitrophenyl phosphate, by a n ti-  
human IgG a lka line  phosphatase conjugate. Plates had to  be incubated
1 0 2
FIG 6  The e ffe c t o f varying antigen and conjugate incubation times and temperature on the IgH standard curve
IgM standards were incubated fo r 1 hr (•-----• ) ,  2 hrs (a  a ) 0r  4 hrs (■------■) at 37°C, followed by incubation
with anti-IgM a lka line  phosphatase conjugate fo r 1 hr, 2 hrs or 4 hrs at 37°C or fo r 24 hrs at 4°C. Absorbance 
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FIG 7 The e ffe c t o f d iffe re n t anti-IgH alka line phosphatase 
conjugate d ilu tio ns  on the IgM standard curve
The conjugate was tested at fin a l d ilu tions  of 1/1000 (•— •) , 1/2000
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FIG 8  Degradation o f substrate w ith time as measured by an 
increase in absorbance a t 405 nm
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usually fo r  nearly an hour a t 37°C to  produce a usable standard 
curve. During th is  time the enzyme-substrate reaction was found to 
be lin e a r. An hour's substrate incubation a t 37°C had o r ig in a lly  
been selected as optimal. However, the rea lisa tion  tha t d iffe re n t 
batches o f conjugate had d iffe re n t potencies and therefore d iffe re n t 
rates o f reaction and did not always need incubation a t 37°C led to 
the decision th a t reaction should be terminated when a predetermined 
concentration o f the standard reached an absorbance value o f 1 at 
room temperature.
Summarising from the above:-
1. A 1/400 d ilu t io n  o f goat anti-human polyvalent immunoglobulins
anti serum was used fo r  coating the so lid  phase. For IgM RhF 
plates were to  be coated with 1 jjg/ml pure human IgG.
2. Plates were then blocked fo r  an hour a t 37°C with PBS-1% BSA.
3. Test cu ltu re  supernatants and standards were d ilu ted  in  PBS-0.5% 
BSA and the samples incubated fo r  1 hour at 37°C. Samples being 
examined fo r  IgM RhF were tested neat and the standards d ilu ted  
in  medium.
4. A lkaline phosphatase conjugates were used at a f in a l d ilu tio n  o f
1/1000 and the plates incubated fo r 1 hour a t 37°C.
5. Enzyme-substrate reaction was incubated at room temperature
u n til a given standard concentration reached an absorbance o f 1 . 
The plates were then read immediately using the ELISA microplate 
reader a t 405 nm.
Reproducibility of IgM and IgG standard curves
R eproducib ility  o f IgM and IgG standard curves was examined. 
This is  shown in  Figures 9 and 10. Each curve is  a composite o f f iv e
standard curves. The bar indicates one standard deviation.
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FIG 9 Reproducibility o f the IgM standard curve
Each point is  a mean of 5 determinations and the bar represents one 
standard deviation.
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FIG 10 Reproducibility o f the IgG standard curve






















Sensitivity of IgM and IgG assays
Very low concentrations o f IgM and IgG were set up in 
quadruplicate and the absorbances compared (one ta i l  t - te s t)  with the 
resu lts  obtained when no IgM or IgG was present. S e n s itiv ity  was 
defined as the lowest concentration o f IgM or IgG which gave an 
absorbance value s ig n ific a n tly  d iffe re n t (p < 0.05) from the 
background. For IgG th is  was usually found to  be 4 ng/ml and fo r IgM 
8  ng/ml.
Specificity of IgM and IgG assays
This was ensured by using a f f in i ty  p u rifie d  anti-human IgM or 
IgG a lka line  phosphatase conjugate. Figure 11 shows tha t anti IgM 
conjugate did not bind to  pure human IgG coated plates but tha t a 
normal IgM standard curve was produced in goat polyvalent anti human 
immunoglobulins coated plates. When standard curves were set up 
using pooled normal human serum and pure human IgG, para lle lism  was 
observed as shown in Figure 12, ind ica ting  tha t the same antigen was 
being detected.
IgM RhF standard
A very high t i t r e  rheumatoid serum was used as a standard in 
the IgM RhF ELISA. The percentage o f IgM with RhF a c t iv ity  was 
determined in a manner s im ila r to  tha t described by Faith e t al 
(1982). A 1/10 d ilu tio n  o f the RA serum was adsorbed with heat 
aggregated IgG and a fte r each absorption, RhF a c tiv ity  was measured 
using the Rheuma-Wellcotest la tex te s t. A fte r 3 absorptions RhF 
a c t iv ity  was no longer detectable. The IgM concentrations o f the 
s ta rtin g  material and the adsorbed samples were then measured by the 
ELISA system.
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FIG 11 S p ec ific ity  o f the IgH ELISA
IgM standards were incubated in  goat polyvalent anti human 
immunoglobulin anti serum ( • — • )  and pure normal human IgG (O— O) 
coated m ic ro titre  plates. A normal IgM curve produced with the 
former but no re a c tiv ity  was observed with the la t te r .  Mean values 




























FIG 12 S p e c ific ity  o f the IgG ELISA
Parallelism between IgG curves obtained when purified  human IgG 
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A normal serum w ith the same IgM concentration (as measured by 
nephelometry) as the RA serum was also treated s im ila rly  as a control 
fo r  nonspecific adsorption o f IgM. This serum showed no RhF a c t iv ity  
as determined by the la tex te s t.
Table 2 shows the percentage o f IgM removed at each adsorption 
o f the 2 sera. Much o f the RhF was removed during the f i r s t  
absorption. The second and th ird  phases removed any remaining RhF. 
The resu lts  show th a t 73.3% o f IgM in th is  p a rticu la r serum had RhF 
a c t iv ity .  S im ilar values have been obtained by Panayi and co-workers 
(personal communication), especially in  patients w ith systemic 
rheumatoid disease.
Thus high t i t r e  RA sera where percentage IgM with RhF a c t iv ity  
had been quantified  as above were used as standards in  the RhF ELISA.
The effect of Facb on IgG, IgM and IgH RhF assays
Since cu ltu re  supernatants would contain Facb, i t  was important 
to  show tha t th is  ligand did not in te rfe re  with the immunoglobulin 
and RhF assays.
Figures 13, 14 and 15 show th a t Facb had no s ig n ifica n t e ffe c t 
on IgG, IgM and IgM RhF curves respectively when i t  was added to  the 
relevant standards a t f in a l concentrations o f 2  and 2 0  ;jg /m l.
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TABLE 2 Showing the percentage of IgM removed at each absorption of the RA and normal sera.
No o f times 
absorbed
% o f IqM absorbed by Haqq % o f IgM absorbed by Hagg in 
RA serum a fte r correction fo r 
non-specific absorption o f IgM
RA serum Normal serum
1 71.1 8.3 62.8
2 77.7 9.1 6 8 . 6
3 8 6 . 0 12.7 73.3
FIG 13 The e ffe c t o f Facb on the IgG ELISA
This was examined by d ilu tin g  the IgG standard in  PBS-0.5% BSA
containing 0 ( • ------ • ) ,  2 (□ -------□) or 20 ( a ------ a ) jjg/ml fin a l









FIG 14 The e ffec t o f Facb on the IgM ELISA
This was examined by d ilu tin g  the IgM standard in PBS-0.5% BSA
c o n t a i n i n g  0 ( • ------- • ) ,  0 . 2  (a — -a ) ,  2 (□— □) or 20 ( o  o) j jg /m l





















FIG 15 The e ffe c t o f Facb on the IgM RhF ELISA
This was examined by d ilu tin g  the IgM RhF standard in PBS-0.5% BSA
containing 0 ( • ----- • ) ,  2 (□ ---------□) or 20 ( a ----a ) jjg/ml fin a l
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SECTION 2 ANTIBODY SYNTHESIS IN VITRO
Generation o f immunoglobulin in  v it ro  was achieved by 
stim ulating isolated and washed PBMNC with pokeweed mitogen. This is  
a crude extract obtained from the Phytolacca americana root and is  
known to  stimulate both T and B ce lls  (Ling and Kay, 1975).
A. PWM dose response curves
Using a ce ll concentration o f 1 x 10^/ml shown by prelim inary 
data to  be optimal (Table 3), 1 ml cultures were set up with doubling 
d ilu tio n s  o f PWM. PBMNC from 7 healthy controls and 11 patients with 
RA were used. Culture supernatants were harvested on Day 7 and 
assessed fo r IgG and IgM content by ELISA. These resu lts  are shown 
in  Figures 16 and 17. Peak responses were observed a t f in a l 
d ilu tio n s  o f 1/40 in normal controls and 1/80 - 1/160 in RA patients. 
PWM d ilu tions  approaching 1/1000 and over returned immunoglobulin 
production to  background leve ls .
IgG production in  RA and normal subjects was not d iss im ila r, 
although the patients generated s lig h t ly  higher levels o f IgG 
compared to  contro ls. But with spontaneous IgG production a marked 
difference (p < 0.05) was observed between RA patients and healthy 
controls with the former generating nearly three times as much IgG as 
the la t te r .  With IgM a s im ila rly  s tr ik in g  difference was observed, 
but with PWM-stimulated c e lls . Here, rheumatoid patients produced 
much less IgM than healthy subjects with levels o f s ignificance 
reaching a p value o f < 0.01 at peak response. This is  in  agreement 
w ith the findings reported by Olsen e t al (1982). Spontaneous IgM 
production, however, was found to  be s im ila r in  the two groups.
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TABLE 3 E ffect o f increasing ce ll concentration on IgM synthesis (ng/ml) by normal
PBMNC measured at Day 7.
PWM dose
Cell concentration x 10^/ml
0.5 1 . 0 2 . 0 3.0
PO 17 61 87 1 2 2
P50 231 1385 1697 1165
P100 385 2315 1800 2178
n = 4
FIG 16 PWM dose response curves in  normal healthy controls
PBMNCs from normal healthy controls were incubated with doubling d ilu tio n s  o f PWM fo r 7 days. Levels o f IgG
( • ----- • )  and IgM (□— □) produced were measured using the ELISAs. Spontaneous IgG (---------•) and IgM (-------- •-)
generation was also assessed. Median values are shown and the corresponding in te rq u a rtile  ranges are omitted 
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FIG 17 PWM dose response curves 1n RA patients
PBMNCs from RA subjects were stimulated with doubling d ilu tions  o f PWM. Levels o f IgG ( • — •) and IgM (□— □)
were measured in day 7 cultures using the ELISAs. Spontaneous IgG (-------- ) and IgM (--------- ) were also examined.
Results are expressed as median values and the corresponding in te rq u a rtile  ranges are omitted fo r purposes of 
c la r ity .
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In view o f these data, fin a l PWM d ilu tio n s  o f 1/50, 1/100 and 
1/200 were selected fo r subsequent use in  Facb experiments. However, 
batch-to-batch varia tion  in  the PWM preparations used led to  peak 
responses occurring at d ilu tio n s  as high as 1/1000. Thus a revised 
selection o f PWM doses led to  the use o f the mitogen at f in a l 
d ilu tio n s  o f 1/50, 1/200 and 1/1000 in the aforementioned
experiments.
B. Antibody production over 21 days
Using a 1/50 d ilu tio n  o f PWM, antibody production o f a 21 day 
period was examined. Figures 18 and 19 show Ig production in  one 
index case. IgG and IgM were measured. For the f i r s t  5 days there 
was very l i t t l e  immunoglobulin production. However, between Day 5
and Day 10 there was an exponential increase in  Ig concentration and
th is  was followed by a much slower r ise  in  Ig levels from Day 10 to 
Day 21.
A normal subject was used here and again levels o f IgM were 
greater than IgG. This was also true o f another normal individual 
examined at the same time (data not shown). Background Ig levels 
were found to  increase but only very slowly, the increase becoming 
more marked a fte r Day 4.
The data above thus indicated a period o f a t least 10 days to











FIG 18 PWM-stimulated ( • — • )  and spontaneous ( o  o) IgG pro­
duction in  one normal individual over a period o f 2 1  days












FIG 19 PWM-stimulated (» — •) and spontaneous ( o ------o) IgM pro­
duction in  one normal individual over a period o f 2 1  days
Each point is  a mean value o f two determinations.
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FIG 1 Numbers o f c ircu la tin g  FacbR* ce lls  1n normal, RA and
F e lty 's  patients
Median values o f percentage Facb rosette forming ce lls  are indicated 
by the horizontal bars.





























The resu lts  presented in  th is  chapter concern immunomodulation 
o f antibody production by Facb. This is  a fragment produced by 
enzymic digestion o f the IgG molecule whereby the CH3 domain is  re­
moved. Prelim inary studies in th is  laboratory have shown tha t PBMNCs 
from patients w ith established RA are s ig n if ic a n tly  less responsive 
to  the suppressive e ffects  o f Facb compared to  normal healthy 
contro ls , despite the observation th a t the percentage o f FacbR+ ce lls  
(Figure 1) in  these patients is  s ig n if ic a n tly  higher than in 
contro ls . The greatest numbers are observed in  subjects with F e lty 's  
syndrome, which can be regarded as representative o f advanced 
disease.
The present study was undertaken to  assess Facb-mediated feed­
back suppression in  patients with early RA to determine whether a 
s im ila r defect existed in these subjects and to  evaluate whether th is  
had any disease s p e c if ic ity .
SECTION 1
1. I n i t ia l  experiments
I t  has already been established by previous workers th a t Facb 
is  best used a t f in a l concentrations o f 0 . 2 , 2  and 2 0  ^g/m l to 
produce suppression o f the IgG response. However, i t  was not known 
what e ffects  d iffe re n t incubation periods had on the emergence o f 
Facb suppression. Nor was i t  c lear whether Facb had to  be present at 
the beginning o f the cu ltu re  period in  order to  be suppressive.
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Therefore in i t ia l  experiments were set up using normal PBMNCs 
stimulated with reciprocal d ilu tio n s  o f 50 (P50), 200 (P200) and 1000 
(P1000) o f PWM as determined in  Chapter 3, and Facb concentrations o f 
0.2, 2 and 20 ;jg /m l. Results obtained here and in  a ll subsequent 
experiments are expressed as a percentage o f the PWM response where 
no Facb was present. The la t te r  is  sometimes referred to  as the 
'base line 1 response in  the te x t.
a) Time o f incubation
Figure 2 shows Facb suppression o f IgG synthesis in  PBMNC 
cultures harvested on Days 7, 10 and 14. I t  was found tha t, 
although not s ig n if ic a n tly  d iffe re n t, the best levels o f 
suppression were observed on Day 14. I t  was therefore decided 
th a t subsequent Facb cultures should be incubated fo r  a period 
o f 14 days. This would have the added advantage tha t 
measurable quantities o f RhF may accumulate in  the ce ll cu lture 
supernatants.
b) Time o f Facb additiu..
Using 14-day Facb cultures, the e ffects  o f adding the 
ligand on Day 0, 1, 4 and 7 were examined. Figure 3 shows tha t 
Facb was only suppressive i f  i t  was present at the beginning of 
the cu ltu re .
Patient studies were then commenced using 14-day PBMNC 
cultures where Facb was added at Day 0 in f in a l concentrations 
o f 0.2, 2 and 20 jjg/ml to  cultures stimulated with P50, P200 
and P1000 d ilu tio n s  o f PWM.
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FIG 2 Facb-mediated suppression o f the IgG response at P1000 on 
Days 7, 10 and 14
PBMNCs from normal subjects were stimulated with PWM and Facb 
fragment added at fin a l concentrations of 0.2, 2 and 20 ^g /m l. 
Suppression o f the IgG response was assessed and the results 
expressed as a percentage of the stimulated response where no Facb 
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FIG 3 The e ffe c t o f adding Facb a t d iffe re n t times during culture
on feedback suppression o f IgG production a t P1000
Normal PBMNCs were stimulated with PWM and Facb added at fin a l 
concentrations of 2 and 20 jug/ml to cultures on days 0, 1, 4 and 7. 
Suppression of IgG response is  expressed as a percentage of the Facb 
response where no ligand was present.
2.0 *jg /m l Facb  
|  20  p g /m l Facb
No Facb 0 1 4  7
Time of addition of Facb in days
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2. Facb suppression o f PWM-driven IgG synthesis
The fo llow ing series o f graphs il lu s tra te s  the e ffe c t o f Facb 
fragment on PWM-induced IgG production in normal healthy contro ls, 
patients with early and established RA, subjects with OA and a smaH 
number o f F e lty 's  patients. Only those ind iv idua ls producing 
>300 ng/ml IgG were considered. The absolute values o f IgG levels 
generated in  response to  PWM in each group appear in  Table 1 and 
la te r  in  Figures 12 - 15.
Figure 4 shows Facb suppression o f IgG synthesis in  normal 
healthy contro ls . I t  was found that as the concentration o f mitogen 
was reduced the degree o f suppression became greater. Thus at P50, 
the highest stim ulating dose o f PWM, the suppressive e ffects  o f Facb 
were ne g lig ib le . At P200, suppression was observed at ligand 
concentrations o f 2 and 20 ug/ml Facb and a t P1000 a ll doses o f the
fragment were found to be suppressive. Here the IgG synthesis was
reduced to  76%, 77% and 49% o f the P1000 response. The values 
obtained a t 0.2 and 20 ug/ml Facb were found to  d if fe r  s ig n if ic a n tly  
(p < 0.01). Comparing the results obtained here with those seen at 
the two higher doses o f PWM revealed s ig n ifica n t difference's a t 2 and
20 ug/ml Facb at P50 (p < 0.01) and a t 20 ug/ml Facb at P200
(p < 0.01). At a ll permutations of PWM dose and Facb concentrations, 
the responses were found to  be highly variable.
S im ilar responses were obtained in patients with early RA 
positive  and palindromic disease (see Figures 5 and 7). True sup­
pression was only observed a t P1000. In the former group these 
results  were h igh ly s ig n if ic a n tly  d iffe re n t from those seen at the 
two higher doses o f PWM. In the la t te r ,  levels o f s ignificance were 
reached a t a ll concentrations o f Facb tested when compared to the
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TABLE 1 The effects of Facb fragment on PWM-stimulated IgG production in test groups
Median levels o f IgG production (ng/ml + /- in te rq u a rtile  range) in  response to  three doses o f PWM are shown, 
together w ith the e ffec ts  o f increasing concentrations o f Facb on th is  production. Only those ind iv idua ls 
generating > 300 ng/ml IgG are shown.





0 0 . 2 2 2 0 0 0 . 2 2 2 0 0 0 . 2 2 2 0
Normals 585 585 591 545 1800 1908 1474 1282 2520 1908 1933 1237
n = 1 1 + /- 1227 268 170 388 3220 634 329 369 2927 6 6 8 899 327
Early RA pos itive 623 662 644 669 1204 1 1 1 1 1 2 2 1 1163 900 692 577 506
n = 14 + /- 1009 232 195 318 3242 345 525 562 2204 161 141 273
Early RA negative 631 555 567 604 843 723 654 708 782 769 722 573
n = 8 + /- 647 151 380 620 455 2 0 166 370 547 195 225 163
Early palindromic RA 939 1048 957 8 6 8 1960 2183 1915 1909 3550 2840 2183 2 1 0 2
n = 8 + /- 3470 356 124 432 7800 548 387 762 6700 633 159 395
Established RA 2180 2158 2280 2396 2680 2243 2417 2372 1146 974 1053 970
n = 2 0 + /- 4212 458 702 604 4000 603 834 1036 3143 232 453 644
OA 3400 3587 3483 4406 2270 2052 2259 2912 1324 1223 1484 1786
n = 8 + /- 3908 545 505 3032 9066 417 727 3938 4821 334 1023 3853
F e lty 's 622 614 601 465 1086 1144 1194 959
n = 6 + /- 1597 77 295 58 876 326 315 376 — —
FIG 4 Facb-mediated suppression o f PWM-stimulated IgG response in  
normal healthy con tro ls
Facb was added at f in a l concentrations of 0.2, 2 and 20 jjg/ml to 
PBMNC cultures stimulated with 3 doses of PWM. Suppression of the 
IgG response was assessed and the results expressed as a percentage 
of the stimulated response where no Facb was present. Median values 
and in te rqu a rtile  ranges (T) are depicted.
* p < 0.01 when compared with equivalent Facb concentrations at 
P1000
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FIG 5 Facb-mediated suppression o f PWM-stimulated IgG response in 
early RA positive patients
Facb was added at fin a l concentrations of 0.2, 2 and 20 pg/ml to 
PBMNC cultures stimulated with 3 doses of PWM. Suppression of the 
IgG response was assessed and the results expressed as a percentage 
o f the stimulated response where no Facb was present. Median values 
and in te rq u a rtile  ranges (T) are depicted.
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FIG 6  Facb-mediated suppression o f PMM-stimulated IgG response In 
early RA negative patients
Facb was added at fin a l concentrations of 0.2, 2 and 20 jjg/ml to 
PBMNC cultures stimulated with 3 doses of PWM. Suppression of the 
IgG response was assessed and the results expressed as a percentage 
of the stimulated response where no Facb was present. Median values 
and in te rqua rtile  ranges (T) are depicted.
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response a t P200 and a t 2 and 20 jig/ml fo r P50. The palindromic RA 
group contained both seropositive and seronegative patients. 
However, these were not treated as separate groups because o f the 
small number o f patients involved in  each subset.
Patients w ith early RA negative disease were found to  behave 
somewhat d if fe re n tly  (Figure 6 ) . Here a degree o f suppression was 
observed a t a ll doses o f PWM but unlike the other two early RA 
groups, suppression did not become greater with increasing d ilu tio n  
o f PWM. Indeed, s ta t is t ic a l analysis showed th a t there were no 
s ig n if ic a n t differences e ithe r w ith in  a group o f responses at a given 
PWM dose or between d iffe re n t PWM doses at a given concentration of 
Facb fragment. I t  is  probable th a t any s ig n ifica n t differences which 
might ac tua lly  e x is t in  th is  group were not evident because o f ( i)  
the small number o f patients investigated and ( i i )  the v a r ia b il ity  o f 
the response.
Figure 8  i l lu s tra te s  the e ffe c t o f Facb on the IgG response in 
patients w ith established RA. There was no suppression at P50. 
Reducing the PWM dose to  P200 produced a degree o f suppression which 
d iffe red  s ig n if ic a n tly  a t 0.2 and 20 jig/ml from tha t observed at P50. 
Decreasing the PWM dose fu rthe r to  P1000, however, did not re su lt in 
a greater degree o f suppression. Thus lik e  the early RA negative 
group suppression was not g reatly  affected by lowering the 
concentration o f PWM. This group contained both seropositive and 
seronegative patients w ith a disease duration o f 2 -  22 years. Pre­
lim inary data analysis had shown tha t in  contrast to  early disease, 
Facb suppression o f IgG production did not d if fe r  s ig n if ic a n tly  in 
patients w ith established seropositive and seronegative RA.
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FIG 7 Facb-mediated suppression o f PWM-stimulated IgG response in
patients with early palindromic RA
Facb was added at f in a l concentrations of 0.2, 2 and 20 pg/ml to 
PBMNC cultures stimulated with 3 doses of PWM. Suppression of the 
IgG response was assessed and the results expressed as a percentage 
of the stimulated response where no Facb was present. Median values 
and in te rqu a rtile  ranges (T) are depicted.
* p < 0.05 when compared with equivalent concentrations at P1000
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FIG 8 Facb-mediated suppression o f PWM-stimulated IgG response in
patients with established RA
Facb was added at fin a l concentrations of 0.2, 2 and 20 jjg/ml to 
PBMNC cultures stimulated with 3 doses of PWM. Suppression of the 
IgG response was assessed and the results  expressed as a percentage 
of the stimulated response where no Facb was present, Median values 
and in te rq u a rtile  ranges (T) are depicted.
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Patients with OA (Figure 9) were also investigated. These 
patients were c lea rly  d iffe re n t from any o f those previously 
described. There was no suppression o f antibody synthesis at any o f 
the PWM doses examined. The overall p icture  instead was tha t o f 
enhancement with increasing ligand concentration. However, no 
s ta t is t ic a l differences existed between d iffe re n t Facb concentrations 
at a given PWM dose nor between a given Facb concentration a t 
d iffe re n t PWM doses. This group also had the highest levels o f 
v a r ia b il i ty  o f a ll the te s t groups examined, with the greatest 
va ria tion  occurring a t an Facb concentration o f 20 pg/ml.
In Figure 10 are shown the resu lts  obtained with a small number 
o f F e lty 's  patients. The graph shows an incomplete p icture o f sup­
pression produced by Facb in  th is  group, since data were available 
fo r  only two patients at P1000 and therefore have not been shown. At 
P50 there was no suppression a t 0.2 and 2 pg/ml Facb. However, a t 20 
pg/ml Facb the IgG response was reduced to 75% o f the baseline le ve l. 
This, however, was not s ig n if ic a n tly  d iffe re n t from the values noted 
at the two lower concentrations o f Facb. At P200 although the PWM 
concentration was reduced, very l i t t l e  suppression was produced. 
This group was found to  have the lowest degrees o f response 
v a r ia b il i ty ,  possibly because the patients constituted a well-defined 
group. However, the number o f patients investigated was small and 
the number o f ind iv idua ls responding to  PWM even smaller. Therefore 
the data presented above can a t best only be used to  draw ten ta tive  
conclusions.
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FIG 9 The e ffects o f Facb fragment on PWM-stimulated IgG response 
in OA patients
Facb was added at f in a l concentrations o f 0.2, 2 and 20 )jg/ml to 
PBMNC cultures stimulated with 3 doses of PWM. Suppression of the 
IgG response was assessed and the results expressed as a percentage 
of the stimulated response where no Facb was present. Median values 
and in te rq u a rtile  ranges (T) are depicted.
No s ig n ifica n t differences were observed between responses obtained 
at the PWM doses tested.
200-1 n=8 □  0 fjg/ml Facb 
■] 0.2 >jg/ml Facb 
jj^ l 2.0 pg/ml Facb 
I  20 yg/m l Facb
345
P50 P200 P 1 0 0 0
Reciprocal dilution of PWM
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FIG 10 Facb-mediated suppression o f PWM-stimulated IgG response In
Facb was added at f in a l concentrations of 0.2, 2 and 20 pg/ml to 
PBMNC cultures stimulated with PWM. Suppression o f the IgG response 
was assessed and resu lts  expressed as a percentage of the stimulated 
response where no Facb was present. Median values are shown and 
in te rq u a rtile  ranges (T) included where possible.
No s ig n ifica n t differences were observed between responses obtained 
at the 2 PWM doses.
F e lty fs patients
I I o Jjg/ml Facb 
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In summary
i )  Facb suppression o f IgG production was dependent on the dose o f 
PWM used. Thus, there was v ir tu a l ly  no suppression o f antibody 
response at P50, but with decreasing PWM concentration, 
increasing Facb suppression was seen, with the greatest being 
seen at P1000. This is  illu s tra te d  in  Figure 11. Whilst th is  
was true  o f normals, early RA positive  and palindromic 
subjects, suppression in the early RA negative and RA groups 
was not found to  be s ig n ific a n t, even at the lowest PWM dose. 
In early seronegative disease s im ila r levels o f suppression 
were observed a t a ll three concentrations o f mitogen, w h ils t in 
established RA responses to  Facb d iffe red  only at P50 and not 
between P200 and P1000. A lte ra tion  o f PWM dose had no e ffe c t 
on Facb modulation o f IgG response in  OA patients. At a ll 
three concentrations o f mitogen, antibody synthesis was found 
to  be enhanced in  the presence o f the ligand.
i i )  At a ll doses o f PWM and Facb the e ffe c t o f the ligand on IgG 
production was highly variab le. Greatest va ria tion  was most 
frequently seen at P50 with 20 jjg/ml Facb and o f a ll the te s t 
groups examined, patients with OA exhibited the greatest 
v a r ia b i l i ty  o f response. This v a r ia b il ity  may also explain 
why, where suppression occurred i t  was not always in  a tru ly  
dose-dependent manner.
3. Comparison of Facb suppression of IgG responses between test 
groups
The levels o f suppression produced by Facb in  the various 
groups were compared using the Mann-Whitney U -test. Although a ll 
doses o f PWM were examined, only responses observed at P1000 were
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FIG 11 Variation In Facb-mediated suppression o f the IgG response with PWM dose In control and patient groups
Only results obtained with 20 jjg/ml fin a l concentration o f Facb at P50 ( fg j ), P200 ( □  ) and P1000 ( g j  ) 
are depicted. These are expressed as percentage of the stimulated response where no Facb was present. Median 
values are shown fo r each group. In te rqua rtile  ranges are omitted fo r purposes o f c la r ity .  In most groups 
suppression was greatest a t P1000.
i40 -» Normal Early RA positive Early RA nogatlv Early PaHndromIc RA OA
thought to  be o f any relevance since suppression was found to  occur 
best a t th is  dose. The resu lts  o f the comparisons a t P1000 are shown 
in  Table 1 A.
Patients with early RA positive  and palindromic disease were 
not found to  d if fe r  from normal healthy contro ls . However, responses 
seen in  subjects with early RA negative and established disease were 
observed to  reach levels o f significance a t 20 jjg/ml Facb and those 
in  OA patients were s ig n if ic a n tly  d iffe re n t from controls at a ll the 
Facb concentrations examined. No differences o f any b io log ica l 
s ign ificance were found when comparing the degrees o f suppression 
between the early RA groups. However, when these patients were 
compared w ith subjects with established RA, s ig n ifica n t differences 
were seen between the la t te r  and patients with early RA positive  and 
palindromic disease at 2 and 20 jug/ml Facb. In contrast, early RA 
negative subjects were not found to  be d iffe re n t from patients with 
established RA a t any Facb concentrations, nor were they d iffe re n t 
from OA patien ts. RA and OA patients were not found to  d if fe r  from 
each other.
F e lty 's  patients only exhibited some degree o f suppression and 
th is  was at P50 with 20 >ig/ml Facb. Comparing th is  with responses 
observed in  other groups i t  was found tha t these patients were highly 
s ig n if ic a n tly  d iffe re n t from early RA pos itive , OA and RA patients, 
but not from normal contro ls, palindromics and early RA negative 
patients.
In summary, a t P1000 where the best suppression occurred, early 
seronegative patients behaved lik e  RA and OA patients with regard to 
Facb suppression o f IgG response, w h ils t those with early 
seropositive and palindromic RA were akin to  normal healthy contro ls. 
However, early seropositive and seronegative patients themselves did
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TABLE 1A Comparison of Facb suppression of IgG response at P1000 in 
health and disease
C lin ica l group Levels o f s ig n i­
ficance and Facb 
dose in jjg /m l
Normal controls : Early RA positive NS
: Early palindromic NS
: Early RA negative 2 0 **
: RA 2 0 * **
: 0A 0 . 2 *
2 ★
2 0 **
Early RA positive : seronegative : palindromic NS
Early RA negative : RA NS
Early palindromic RA~
I :  RA 2 *
Early RA positive J 2 0 *
RA : 0A NS
* p < 0.05
** p < 0 . 0 1  
***  p < 0 . 0 0 1
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not d if fe r  from each other. RA and OA patients were in d is t in ­
guishable, in  sp ite  o f the s lig h t ly  d iffe re n t e ffects  produced in 
each by the ligand. No conclusion could be drawn on F e lty 's  patients 
because o f in s u ff ic ie n t data.
4. Facb suppression and PWM response
From Figures 4 -  10 i t  is  clear tha t where there is  suppression 
th is  occurs best at P1000. One explanation fo r th is  is  th a t a t P50 
the IgG response is  too powerful to  be overcome and therefore 
suppression by Facb is  minimal. However, when the stim ulating dose 
is  reduced to  P1000, the IgG response is  perhaps not so great and 
thus more easily  suppressed. Figures 12 -  15 show the PWM dose 
response curves obtained with the te s t groups examined. I t  can be 
seen tha t in  normal controls and in  palindromics, fa r from the 
response fa ll in g  at P1000, i t  was much higher than a t P50. With the 
early seropositive and seronegative patients, although the overall 
IgG response was lower than in  the former two groups, levels at P1000 
in  the early patients were not lower than those observed a t P50. I t  
should, however, be noted tha t in  the seronegative group IgG 
synthesis a t the three doses o f PWM was s im ila r. Higher levels o f 
antibody production were obtained with patients with established RA. 
Although IgG production was lower at P1000 than at P200, the levels 
o f Facb suppression seen a t these two doses were s im ila r. Data 
obtained with OA patients also serve to  emphasise the point th a t 
lower levels o f IgG production do not necessarily mean greater Facb 
suppression. Here Facb was found to have no e ffe c t even a t P1000, 
where immunoglobulin production was observed to  be the lowest.
In the l ig h t  o f the above data another explanation was
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FIG 12 The IgG response at 3 doses o f PWM in normal healthy 
controls
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FIG 13 The IgG response at 3 doses o f PWM in early RA
Early RA positive, negative and palindromic patients are represented
by ( a  a ) ,  (O O) and (■— ■) respectively. Median values are
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FIG 14 The IgG response at 3 doses o f PWM In established RA 
patients
Median values are shown. f  represent in te rq u a rtile  ranges.
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FIG 15 The IgG response at 3 doses o f PWM in OA patients
Median values are shown. t  represent in te rqua rtile  ranges
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considered - th a t w ith maximum stim ula tion , as fo r example in  normal 
contro ls a t P1000, the FacbR+ population is  expanded and more FacbR+ 
c e lls  are available fo r  recruitment in to  negative feedback suppres­
sion. However, other factors must be involved since patients with 
established RA were found to  possess higher levels o f FacbR+ ce lls  
compared to  normal subjects but Facb-mediated suppression was 
impaired.
Another explanation o f the better Facb suppression o f IgG seen 
a t P1000 is  th a t PWM at higher concentrations might block the FacbRs 
on the PBMNC. This was investigated and the resu lts  are presented in 
the next section.
5. Effect of PWM on Facb rosettes
Facb rosette  assays were performed in  the presence o f PWM at 
f in a l d ilu tio n s  o f 50, 200 and 1000. Controls assays contained an 
appropriate amount o f CMFSS. Both normal healthy controls and RA 
patients were examined. Results o f these experiments appear in 
Figure 16. I t  can be seen th a t the addition o f PWM a t a 1/50 
d ilu tio n  markedly reduced the number o f Facb rosettes; a p value o f 
< 0.05 compared to  control assays was obtained fo r  both RA and normal 
subjects. When the PWM was added at reciprocal d ilu tio n s  o f 200 and 
1000, percentages o f Facb rosettes were found to  return to  near 
normal levels in  both groups. In te re s ting ly , in  one normal healthy 
subject Facb rosettes were not found to  be suppressed by PWM. This
ind iv idua l was also found not to  respond to PWM in v i t r o . This,
together with the data above, seems to  suggest tha t Facb receptors 
and those fo r  mitogen may be closely associated on the ce ll surface.
Since the presence o f PWM or the response to  i t  can a lte r  the
suppressive e ffec ts  o f Facb, i t  is  possible tha t even at low doses,
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FIG 16 The e ffec t o f PWM on Facb rosettes
PWM at f in a l reciprocal d ilu tions of 50, 200 and 1000 was added to 
PBMNCs from RA ( [ ” ] ) and normal subjects ( □  ), which were then 
assessed fo r percentage of FacbR+ ce lls  in the rosette assay. Median 
values and in te rqu a rtile  ranges (T) are shown.
* p < 0.05 when compared to rosette numbers observed in the 
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PWM might change the k ine tics o f th is  suppression. Therefore, 
suppression o f spontaneous IgG synthesis by Facb was examined. 
Results o f th is  are presented in  the next section. Only those 
ind ividuals producing more than 100 ng/ml o f IgG in the resting state 
were examined.
6. Facb suppression of spontaneous IgG production
Figures 1 7 - 2 3  show the e ffects o f Facb fragment on spontaneous 
IgG production in the various te s t groups. The absolute values o f IgG 
generated spontaneously in  each group appear in Table 2.
In normal healthy controls Facb was found to be suppressive at 
a ll concentrations, reducing the spontaneous IgG level to  8 6 %, 72% 
and 65% of the o rig ina l response with 0.2, 2 and 20 ug/ml o f ligand 
respectively. Although these values were not s ig n ific a n tly  d iffe re n t 
from each other, i t  can be seen from Figure 17 tha t the suppression 
was dose-related. As with the PWM-driven response, the e ffects  o f 
the ligand on spontaneous antibody generation were variab le. In a ll 
the other groups examined, levels o f suppression were e ithe r lower, 
as fo r example with early RA patients, or p ra c tica lly  n i l ,  as with 
patients with established RA, OA and F e lty 's  syndrome. Again in a ll 
groups v a r ia b ility  o f response was noted but not to  the extent seen 
with PWM-stimulated cultures. Furthermore, as before, OA patients 
exhibited the highest levels o f va ria tion .
The degrees to  which Facb suppressed spontaneous production o f 
IgG in the various te s t groups were compared. These resu lts  appear 
in Table 2A. The data here d if fe r  from those found at P1000 (see 
Table 1A) in the fo llow ing respects. F irs t ly ,  patients with early 
RA negative disease were found not to  d if fe r  from normal healthy 
controls but did so s ig n ific a n tly  (p < 0.05) from subjects with 
established RA. However, no differences were seen when compared with
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TABLE 2 The effect of Facb fragment on spontaneous IgG production 
in test groups
Median levels o f spontaneous IgG production (ng/ml + /- in te rq u a rtile  
range) observed in  the various te s t groups are depicted. The e ffects 
o f increasing Facb concentrations on th is  synthesis are also shown. 
Only those ind iv idua ls  generating ^  100 ng/ml o f IgG spontaneously 
were selected fo r  analysis.
Facb in  jig/ml
Test groups and numbers 0 0 . 2 2 2 0
Normals 163 140 118 105
n = 1 1 + /- 8 6 + /- 76 + /- 57 + /- 26
Early RA positive 2 1 1 205 192 186
n = 16 + /- 179 + /- 25 + /- 44 + /-  45
Early RA negative 143 125 123 1 2 1
n = 7 + /- 58 + /- 33 + /- 18 ■ + /- 7
Early palindromic RA 137 1 2 1 127 1 2 2
n = 7 + /- 125 + /- 28 + /- 8 + /- 29
Established RA 183 179 187 2 0 2
n = 16 + /- 162 + /- 33 + /- 40 + /- 78
OA 310 297 291 307
n = 9 + /- 480 + /- 63 + /- 175 + /- 193
Fe lty 's 272 277 254 283
n = 9 + /- 234 + /- 30 + /- 98 + /- 92
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FIG 17 The e ffec t o f Facb on spontaneous IgG production in  normal
healthy controls
Results are expressed as a percentage of the unstimulated IgG 
response where no Facb was present. Median values and in te rq u a rtile  
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FIG 18 The e ffec t o f Facb on spontaneous IgG production in  early 
RA positive patients
Results are expressed as a percentage o f the unstimulated IgG 
response where no Facb was present. Median values and in te rq ua rtile  
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FIG 19 The e ffe c t o f Facb on spontaneous IgG production in  early 
RA negative patients
Results are expressed as a percentage of the unstimulated IgG 
response where no Facb was present. Median values and in te rqu a rtile  
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FIG 20 The e ffe c t o f Facb on spontaneous IgG production in  early 
palindromic RA patients
Results are expressed as a percentage of the unstimulated IgG 
response where no Facb was present. Median values and in te rq u a rtile  
ranges (T) are shown.
Concentration of Facb in jjg/ml
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FIG 21 The e ffec t o f Facb on spontaneous IgG production in
established RA patients
Results are expressed as a percentage o f the unstimulated IgG 
response where no Facb was present. Median values and in te rq u a rtile  
ranges (T) are shown.
Concentration of Facb in ,Mg/ml
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FIG 22 The e ffe c t o f Facb on spontaneous IgG production in  OA
patients
Results are expressed as a percentage of the unstimulated IgG 
response where no Facb was present. Median values and in te rq u a rtile  
ranges (T) are shown.
180-1 n=9
160 -
Concentration of Facb in jjg/ml
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FIG 23 The e ffe c t o f Facb on spontaneous IgG production 1n F e lty 's
pati ents
Results are expressed as a percentage of the unstimulated IgG 
response where no Facb was present. Median values and in te rq u a rtile  
ranges (T) are shown.
Concentration of Facb injjg/ml
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TABLE 2A Comparison o f Facb suppression o f spontaneous IgG production 
in health and disease
C lin ica l group Levels of s ig n i­
ficance and Facb 
dose in jjg/ml
Normal controls : Early RA negative NS
: Early palindromic NS
: Early RA positive 20 **
: RA 2 **
20 **
: Fe lty 's 2 *
20 **
: OA 2 *
20 **
Early RA positive : palindromic : negative NS






negative : Fe lty 's NS
palindromic
RA : Felty 's :0A NS
* p < 0.05
** p < 0.01
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F e lty 's  patien ts. Secondly, early RA pos itive  patients d iffe red  from 
normal subjects, although th is  was only a t the highest concentration 
o f Facb.
Comparing the data shown in  Figures 1 7 - 2 3  with those obtained 
a t P1000 in  these groups produced very few resu lts  o f s ta t is t ic a l 
s ign ificance. This is  surprising in  view o f the obviously greater 
suppression seen in  stimulated cu ltu res, especially in  early RA. 
However, th is  can be explained by the large v a r ia b il ity  o f response, 
p a rtic u la r ly  in  the PWM-driven system. Comparison o f these two sets 
o f data suggests the fo llow ing
i )  In normal subjects PBMNC are able to  respond to the suppressive 
e ffects  o f Facb in  both the stimulated and resting state.
i i )  PBMNC from early RA patients in  unstimulated cultures are less 
responsive to  FcR-mediated feedback suppression than contro ls. 
However, as seen in  Section 1(2), ce lls  from these patients 
possess the a b i l i ty  to  be triggered by mitogen to suppressive 
a c t iv ity ,  as fo r example in  early RA positive  and palindromic 
disease. This capacity fo r some reason appears to  be impaired 
in  early RA negative patients.
i i i )  Unstimulated PBMNC from RA subjects are not suppressed by Facb 
fragment. Furthermore, the a b il i ty  to  be induced to suppressor 
function is  diminished or absent. S im ila rly , patients with OA 
are not suppressed in  the resting s ta te . Modulation o f FcR 
ce lls  by ligand in  the presence o f PWM in  these patients serves 
to  enhance the immunoglobulin response.
F e lty 's  patients could not be compared in  th is  manner because o f 
a lack o f data a t P1000.
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SECTION 2 FACB SUPPRESSION OF IgG RESPONSE AND DISEASE PARAMETERS
Associations between various disease parameters and Facb 
suppression o f IgG synthesis were examined in  early RA patien ts. A ll 
comparisons were made at the P1000 response. These are discussed 
below.
1. Facb suppression and disease activ ity
Patients with early RA were assessed fo r disease a c t iv ity  and 
the resu lts  expressed as a figure  ranging from 0  ( l i t t l e  or no
a c t iv ity )  to  5 (severe synovitis and very active disease). Figure 24
shows the various parameters used to  a rrive  a t a grading o f the 
disease. This is  based on the R itchie A rticu la r Index.
The re la tionsh ip  between Facb suppression o f IgG production at 
P1000 and disease a c t iv ity  was examined using only early RA positive  
patien ts. Early RA negative and palindromic subjects were not
examined because in  the former very l i t t l e  Facb suppression was 
observed (see Section 1 (2 )). In the la t te r ,  disease a c t iv ity  ranged 
only from 0 - 1 .
Figure 25 shows how Facb suppression in  early RA positive
subjects varied w ith increasing disease a c t iv ity  a t 0 . 2 , 2  and 
20 pg/ml Facb. As disease a c t iv ity  increased suppression became more 
apparent a t a ll Facb doses. The best corre la tion  is  seen at
0.2 jjg/ml with an r s value o f 0.56 (p < 0.05). At 20 ;jg/ml Facb 
levels o f significance are approached with an r s value o f 0.455. At 
2 jug/ml Facb r s has a value o f only -0.179, which is  not s ig n ific a n t.
The greater degree o f Facb suppression with increasing disease 
a c t iv ity  seems puzzling a t f i r s t  s igh t. However, analysis o f the 
number o f FacbR+ ce lls  a t d iffe re n t disease a c t iv it ie s  provides one
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FIG 24 Clinical parameters used to assess disease activ ity  in early
RA patients
Disease a c t iv ity  was scored on a scale from 0 - 5  depending on active 
jo in ts  (painfu l and/or swollen), morning s tiffness  and plasma 
v isco s ity . Details o f assessment are given below. Joints counted as 
used in R itchie Index.
Score C rite ria
0 Plasma v iscos ity  normal; no active jo in ts
1 ^ 2  active jo in ts
2 < 4 active jo in ts
3 ^ 8  active jo in ts
4 ^ 1 2  active jo in ts
5 > 16 active jo in ts
Early morning s tiffn e ss  > 2 hours or plasma v iscosity  > 1.90 
increased the score by 1
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FIG 25 Correlation o f Facb-roediated suppression at P1000 1n early 
RA positive  patients and disease a c t iv ity
Disease a c t iv ity  was scored as ranging from 0 (inactive  disease) to 5 
(severe aggressive synov itis ). Suppression o f the IgG response is  
expressed as a percentage of the P1000 response where no Facb was 
present, 
a p < 0.05
b p approaching significance at the 5% level












possible explanation. Figure 26 shows the increase in the percentage 
o f FacbR+ ce lls  as disease becomes more active in  early RA patients. 
I t  is  possible tha t the increase in  the number o f FacbR+ ce lls  at 
high disease index might allow better suppression o f the 
immunoglobulin response in  these patients.
2. Facb suppression and disease duration
Association between Facb suppression o f IgG synthesis and 
increasing disease duration was investigated. Responses noted in  
early seropositive RA patients at P1000 were compared with those seen 
in  subjects with established disease o f ( i )  2 -  5 years and ( i i )  5 -  
2 2  years duration.
These data are il lu s tra te d  in  Figure 27. Although the degrees o f 
suppression seen in patients with established disease are lower than 
those obtained with early RA positive  subjects, no s ta t is t ic a l d i f ­
ferences were found. This is  probably due to  the large v a r ia b il ity  
o f response. C learly, the findings here d if fe r  s ta t is t ic a lly  from 
those noted when the established RA patient group is  not subdivided 
according to  the period o f disease duration (see Section 1 (2 )).
3. Facb suppression and laboratory measurements of serum and blood
components
Measurements o f haemoglobin, p la te le ts , CRP and plasma v iscos ity  
are frequently used by c lin ic ia n s  as ind icators o f disease a c t iv ity .  
Relationships between these c lin ic a l parameters and Facb suppression 
o f IgG response a t P1000 were investigated. Other parameters 
examined included serum immunoglobulins (G, A and M), IgM RhF, 
a lka line  phosphatase and serum th io ls .  A ll doses o f Facb were 
















FIG 26 Correlation o f the FacbR+ ce ll numbers with disease
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FIG 27 The varia tion  in Facb-mediated feedback suppression o f the 
IgG response with disease duration
Suppression of the P1000 response by 0.2 ( O  ), 2 ( | | |  ) and 20
( H  ) pg/ml of Facb was assessed. Results are expressed as a
percentage of the stimulated response where no Facb was present.
Median values and in te rq u a rtile  ranges (T) are shown.
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None o f the above variables was found to be re lated to  the 
degree o f Facb suppression o f antibody production in  patients with 
early RA (data not shown).
4. Facb suppression and age of onset
Facb suppression o f IgG response was examined in  re la tion  to  the 
age o f onset o f disease. No s ig n ifica n t differences were found 
between levels o f Facb suppression seen in ind iv idua ls with an early 
age o f onset and those whose disease began in  th e ir  s ix t ie s . These 
resu lts  are shown in Figure 28.
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FIG 28 The varia tion o f Facb-mediated feedback suppression o f IgG
synthesis with age o f onset
P1000-stimulated PBMNC from early and established RA patients were 
incubated with 0.2 ( 0  ), 2 ( |§| ) and 20 ( B  ) jjg/ml f in a l
concentrations of Facb. Suppression of the IgG response was assessed 
and expressed as a percentage of the stimulated response where no 
Facb was present. Median values are depicted. In te rquartile  ranges 
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SECTION 3 FACB SUPPRESSION OF RHEUMATOID FACTOR
The above resu lts  have a ll concerned Facb suppression o f the IgG 
response. The question now arose as to  whether these e ffects  were 
lim ite d  to  only th is  immunoglobulin or whether suppression extended 
to  other types o f antibody, in  p a rticu la r RhF. C learly, th is  was 
important since i f  the addition o f the ligand were found to  produce 
suppression o f RhF in  normals but not in  patients with rheumatoid 
disease then th is  would provide a t least one explanation fo r  the 
presence o f th is  autoantibody in RA. Thus the production o f RhF and 
i t s  suppression by Facb was investigated.
1. Rheumatoid factor synthesis in controls and disease groups
Figures 29 to  36 show spontaneous and PWM-induced RhF production
in  the various te s t groups. I t  was found tha t both young and old
normal, healthy controls produced no RhF spontaneously. The la t te r  
were ind iv idua ls over 60 years o f age who had been examined 
separately to determine whether RhF production was re lated in  part to 
the process o f aging, since the average age o f the RA patients was 
higher than tha t o f normal healthy controls obtained from the 
laboratory personnel. C learly, age does not appear to  a ffec t 
spontaneous RhF production. 0A patients were also not observed to 
generate RhF in  the resting sta te . In patients with early 
seronegative or palindromic RA, very small numbers o f subjects 
generated RhF spontaneously. This, however, was a t low levels and 
since these were below the s e n s it iv ity  o f the assay, the values had 
to  be considered as background. In early RA pos itive , established 
RA and F e lty 's  patients numbers o f ind iv idua ls producing autoantibody 








FIG 29 Spontaneous and PVIM-stimulated IgH RhF production in  normal
healthy controls
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FIG 30 Spontaneous and PWM-stimulated IgH RhF production 1n early
RA pos itive  patients
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FIG 31 Spontaneous and PWM-stimulated IgH RhF production In early
RA negative patients
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FIG 32 Spontaneous and PWM-stimulated IgM RhF production in early 
palindromic RA patients
Horizontal bars represent median values
70 n=8
60 RhF + •  
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FIG 33 Spontaneous and PWM-stimulated IgM RhF production in
established RA patients


















FIG 34 Spontaneous and PWM-stimulated IgH RhF production in  OA 
patients
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FIG 35 Spontaneous and PWM-stimulated IgH RhF production in
Fe lty 's  patients
Horizontal bars represent median values
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FIG 36 Spontaneous and PMM-stimulated IgH RhF production in  old
normal con tro ls
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production o f each o f these groups were zero. Using 5 ng/ml as the 
lowest detectable level o f RhF in  the ELISA, i t  was found tha t 22.2%, 
7.4% and 18% o f a ll the patients tested in  early RA pos itive , RA and 
F e lty 's  groups respective ly, generated RhF spontaneously. 
Considering only these patients, median levels o f RhF production in 
the absence o f mitogen were 8  ng/ml in  early RA pos itive , 6  ng/ml in  
RA and 106 ng/ml in  F e lty 's  patients. Thus, although in  the former 
two groups s im ila r levels o f RhF were generated, the proportion o f 
patients who were spontaneous generators o f RhF was higher in  the 
early RA group. In F e lty 's  syndrome, although most patients did not 
produce the autoantibody spontaneously, the subjects who did had much 
higher levels o f generation than in early RA positive  and established 
RA groups.
With PWM the numbers o f ind iv idua ls synthesising RhF, as well as 
the levels o f autoantibody production, were increased in  most groups, 
except in  F e lty 's  patients where ind iv idua ls with high levels o f 
spontaneous RhF production were found to  be a l i t t l e  suppressed. 
Overall median values o f the autoantibody in  the te s t groups were 
quite low. At peak responses these values were 6  ng/ml in  both
normal healthy contro ls and patients with early seropositive disease. 
In early RA negative and palindromic patients these values were < 5 
ng/ml and 5 ng/ml respective ly. A median peak value o f 11.5 ng/ml
was noted in  RA subjects and o f 7 ng/ml in  0A patients. In both old
normal contro ls and F e lty 's  patients median values fo r a ll doses o f 
PWM were zero. This fu rthe r emphasises tha t old age is  not a
contributory fac to r fo r  RhF production. Using only the responses 
obtained a t P200, the re la tiv e  proportions o f subjects producing RhF 
in each o f the te s t groups was determined. Values o f > 5 ng/ml were 
regarded as a pos itive  response. These data appear in Table 3. The
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TABLE 3 IgH RhF production a t P200
C lin ica l
group
n Range in 
ng/ml
Overall median 
RhF in  ng/ml
% o f subjects 
producing RhF
Young normal 34 0 - 2 1 6 50
Old normal 9 0 - 1 0 0 1 1 . 1
Early RA 
positive
27 0-48 6 56
Early RA 
negati ve
1 0 0-62 2 40
Palindromic 8 0-69 4 37.5
RA 27 0-30 7.5 63
OA 9 0-25 2.5 33
Fe lty 's 1 1 0-94 0 33
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percentages o f ind iv idua ls  generating autoantibody were much improved 
in  the presence o f PWM, with the highest value (63%) occurring in 
patients w ith established RA. S im ilar values were obtained in  normal 
(50%) and early RA positive  (56%) subjects, w h ils t those in  early RA 
negative (40%) and palindromic (37.5%) patients were s lig h t ly  lower. 
In OA, F e lty 's  and old normal groups these values were 33%, 33% and
1 1 . 1 % respective ly .
Using data from only early RA positive  and established RA 
patien ts, i t  was found tha t levels o f RhF produced in  v it ro  did not 
corre la te  w ith concentrations o f IgM and IgM RhF observed in the 
corresponding sera.
2. Facb suppression o f RhF synthesis
Subjects who were found to  generate RhF in  v it ro  were fu rthe r 
investigated fo r  e ffec ts  o f Facb on th is  synthesis. Not a ll o f the 
subjects o r ig in a lly  found to  synthesise RhF generated i t  on 
subsequent te s tin g , so the patients numbers were smaller than a n t ic i­
pated. Also, not a ll doses o f PWM gave rise  to  RhF synthesis, 
leading to  unmatched numbers o f patients a t each dose.
The fo llow ing graphs (Figures 37 - 42) show the e ffects o f Facb 
on PWM-induced RhF synthesis. I t  was o r ig in a lly  decided to  use only 
those ind iv idua ls  generating > 10 ng/ml o f RhF. However, i t  was 
discovered th a t some subjects who produced < 10 ng/ml without Facb 
produced more RhF with the ligand present.
Thus, in  a ll the groups tested, though the response was v a r i­
able, increasing concentrations o f Facb fragment tended to  enhance 
the production o f RhF. However, suppression was also observed and
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FIG 37 The e ffec t o f Facb on PhM-stimulated IgH RhF production In 
normal healthy controls

























FIG 38 The e ffe c t o f Facb on PWM-stimulated IgH RhF production 1n 
early RA positive  patients
Median values of RhF and in te rq u a rtile  ranges (T) are shown.
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FIG 39 The e ffe c t o f Facb on PWM-stimulated IgH RhF production in
early RA negative patients
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FIG 40 The e ffe c t o f Facb on PWM-stimulated IgM RhF production in  
early  palindromic RA patients
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FIG 41 The e ffe c t o f Facb on PWM-stimulated IgH RhF production in 
established RA patients
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FIG 42 The e ffe c t o f Facb on PMM-stimutated IgH RhF production in 
OA patients
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4here the lower concentrations o f the ligand were more e ffe c tive  than 
20 jjg /m l. At the la t te r  concentration RhF production was found to  be 
unaffected or enhanced but ra re ly  suppressed.
The data were fu rthe r analysed by selecting out those 
ind iv idua ls  with > 10 ng/ml RhF and converting responses seen at 0.2, 
2 and 20 ^ig/ml Facb to  a percentage o f the response where no Facb was 
present. This is  presented in Figures 43 -  45. Also illu s tra te d  in 
these graphs are the corresponding IgG responses, since the question 
arose whether e ffects  o f Facb on RhF were part o f a generalised 
e ffe c t on immunoglobulin production. I t  should be noted th a t these 
data were available fo r  only a very small number o f patients and tha t 
the same ind iv idua ls were not present a t a ll PWM doses. Thus, 
resu lts  o f each PWM dose should be examined w ith in  tha t dose rather 
than comparing responses between the other doses examined. Although 
only data on early RA pos itive , palindromic and RA subjects are 
shown, the other groups were also examined.
From these graphs i t  can be seen tha t unlike IgG response, the 
dose o f PWM used did not appear to  a ffe c t Facb modulation o f the 
autoantibody production. The response was highly variable and as 
seen e a r lie r  suppression was often be tte r a t 0.2 and 2 ;jg/ml Facb 
than a t 2 0  ;jg/ml o f the ligand, as il lu s tra te d  by patients with 
palindromic RA (see Figure 44). The highest concentration o f Facb 
was found in  some cases to  markedly enhance the autoantibody 
production. However, the most in te res ting  observation here was tha t 
RhF production was not always suppressed in  pa ra lle l or to  the same 
extent as the IgG response; sometimes quite  the reverse was 
observed. For example, a t P200 in early  RA positive  patients (Figure 
43) the IgG production was reduced w h ils t tha t o f RhF was enhanced by 
increasing the concentration o f Facb. C learly, th is  indicates tha t
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Facb modulates IgG and IgM RhF responses d if fe re n tly , e ithe r because 
i t  operates a t d iffe re n t leve ls fo r the two immunoglobulins or 
because d iffe re n t k ine tics  are operational in  each case.
Figures 43 -  45 should be regarded as purely i l lu s t r a t iv e .  The 
responses were h igh ly variable and the numbers o f patients so small 
as not to  allow accurate assessment o f the extent to  which RhF is  
suppressed by Facb.
In some o f the above patients Facb suppression o f the to ta l IgM 
response was also examined. Figure 46 shows the e ffects  o f Facb on 
IgM RhF, IgM and IgG responses in  early RA pos itive , negative, 
palindromic and established RA patients. I t  is  clear tha t w h ils t the 
e ffects  o f Facb on RhF do not shadow those observed with IgM, there 
is  nonetheless a greater s im ila r ity  between these responses than 
between those o f IgG and RhF. The graphs also i l lu s t ra te  the 
d ifference in  the e ffe c t o f Facb on IgG and IgM responses: the former 
was suppressed w h ils t the la t te r  tended to  be enhanced.
The extent to  which IgG is  seen to  be suppressed in these data 
does not m irror tha t which has been presented in  the e a r lie r  part o f 
th is  chapter. However, i t  should be remembered tha t only a very 
small number o f ind iv idua ls are depicted and the response to Facb is  
highly variab le .
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FIG 43 The e ffec t o f Facb on IgM RhF and corresponding IgG
production a t 3 doses o f PWM In patients with early RA 
positive disease
Results are expressed as a percentage o f the stimulated response 
where no Facb was present. Median values and in te rqua rtile  ranges 
(T) are shown where appropriate.
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FIG 44 The e ffe c t o f Facb on IgH RhF and corresponding IgG 
production a t 3 doses o f PWM in  patients w ith early 
palindromic RA
Results are expressed as a percentage o f the stimulated response 
where no Facb was present. Median values and in te rq u a rtile  ranges 
(T) are shown where appropriate.
n=3 n~5 n=4
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FI6  45 The e ffe c t o f Facb on IgM RhF and corresponding IgG 
production at 3 doses of PWM in  patients with established 
RA
Results are expressed as a percentage o f the stimulated response 
where no Facb was present. Median values and in te rq ua rtile  ranges 
(T) are shown where appropriate.
n=7 n=4 n=3
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FIG 46 The e ffe c t o f Facb on IgG ( ^  ) , IgH ( I I ) and IgH RhF ( BB1 ) production a t P10Q0 in  early and 
established RA patients








































SECTION 4 MECHANISMS OF Facb SUPPRESSION
Impaired Fc-mediated suppression o f in  v it ro  IgG production by 
RA PBMNC compared to normal healthy controls has been observed with 
Facb fragment. I t  is  possible tha t th is  might re su lt from in e f­
fe c tive  binding o f the ligand e ithe r because o f a low number o f 
receptors or because o f low association constants o f Fc binding. The 
former, however, is  un like ly  because, as Figure 1 shows, RA patients 
have s ig n if ic a n tly  higher numbers o f Facb rosetting  ce lls  compared to 
healthy con tro ls . Furthermore, enhanced binding o f labelled 
aggregated IgG by RA PBMNC has been reported by other workers (Wooley 
and Panayi, 1978). At present no information is  available on 
association constants in  health and rheumatoid disease regarding Facb 
receptors.
Another explanation fo r impaired feedback suppression comes from 
the observation th a t free SH groups are important in  many immune 
responses (H a ll, 1986). In view o f the decreased levels o f SH 
expression in  RA (Lorber and Chang, 1968) and the observation th a t 
FcR function is  dependent on SH groups (Abrahamson et a l , 1971), the 
p o s s ib ility  existed tha t Facb-mediated suppression o f IgG response 
may be modulated by th io l reagents. Thus the e ffe c t o f pretreating 
PBMNCs with 2ME p r io r to  incubation w ith Facb fragment was 
investigated in  RA and normal subjects. Results were available fo r 
only a very small number o f ind iv idua ls in  each group. I t  was found 
tha t although 2ME did not have a marked e ffe c t on Facb suppression o f 
antibody synthesis, levels o f suppression were s lig h t ly  greater in 
PBMNC cultures pretreated with the th io l compared to  those which had 
not been incubated with 2ME (data not shown). These experiments need 
to  be repeated using a la rger number o f subjects.
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The e ffe c t o f 2ME on Facb rosettes was also examined. I t  was 
found tha t there was an increase in the number o f rosettes fo llow ing 
2ME treatment, in  agreement with previous findings in  th is  laboratory 
(Eales, PhD thes is , 1982). These data are shown in Figure 47.
The e ffec ts  o f 7-IFN on Facb-mediated suppression o f the IgG 
response were also examined. This molecule, amongst i t s  various 
actions, is  able to  induce the expression o f FcRs (Taylor- 
Papadimitriou and Rozengurt, 1985). Thus the e ffects  o f increased 
numbers o f FcR+ ce lls  on negative feedback suppression were 
investigated using PBMNC from both normal and RA subjects. Cultures 
were set up as usual in  the absence or presence o f 10 units o f 7-IFN, 
a concentration found by prelim inary experiments to  s ig n if ic a n tly  
enhance Facb expression in  normal, healthy contro ls. S im ilar data 
(see Figure 48) were obtained here but levels o f s ignificance were 
not reached, probably because o f the small number o f ind iv idua ls 
tested. Figures 49(a) and (b) show the e ffe c t 7-IFN had on Facb 
suppression o f antibody response in  a very small number o f normal 
subjects. The data presented here d if fe r  from those described 
e a r lie r  because greater suppression was observed a t the two higher 
doses o f PWM than a t P1000. However, in  the presence o f 7-IFN there 
was p ra c tic a lly  no suppression o f IgG at P50 and P200 and at P1000 
s lig h t ly  greater suppression was observed at 0.2 and 2 jug/ml Facb. 
S im ila rly , in  RA patients (Figures 50(a) and (b)) any suppression 
observed in Facb cultures (eg at P200) alone was negated in the 
presence o f 7-IFN.
Looking a t the corresponding PWM-induced IgG synthesis in  
normals in Figure 51, i t  can be seen tha t although the e ffects o f 
7-IFN were variable on IgG response, th is  was not s ig n if ic a n tly  
a ltered by adding 7-IFN to  the cu ltu res. RA patients were s im ila r ly
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FIG 47 The e ffe c t o f 2ME on Facb rosettes
PBMNC from normal and RA subjects were incubated with 2ME at a fin a l 
concentration of 5 x 10"5M for 1 hour at 37°C. Cells were washed and 
then assayed fo r FacbR expression in the rosette assay. Results are 
expressed as median values of percentage Facb rosetting ce lls .
| | Normals (n = 3)













FIG 48 The e ffe c t o f 7-IFN on Facb rosettes
PBMNC from normal subjects were incubated in the presence ( ) or
absence ( ^  ) of 10 units/ml 7-IFN fo r 18 hrs at 37°C. Percentage 
of FacbR+ ce lls  were then determined. Median values and 
in te rq u a rtile  ranges (T) are shown.
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PXQ 4 9  The e ffe c t o f 7-IFN on Facb-mediated feedback suppression
of PWM-stimulated IgG response in  normal healthy controls
PBMNC were stimulated with 3 doses of PWM and Facb added at fina l 
concentrations of 0.2 ( □  ), 2 ( H  ) and 20 ( Q  ) pg/ml. The 
cultures were incubated in the presence or absence of 10 units of 
7-IFN. Results are expressed as a percentage of the stimulated 
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FIG 50 The effect of 7-IFN on Facb-mediated feedback suppression 
of PWM-stimulated IgG response In patients with established 
RA
PBMNC were stimulated with 3 doses o f PWM and Facb added a t f in a l 
concentrations o f 0.2 ( 0  ) , 2 ( | | |  ) and 20 ( Q  ) jjg /m l. The 
cultures were incubated in  the presence or absence o f 1 0  un its  o f 
7-IFN. Results are expressed as a percentage o f the stimulated 
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investigated (data not shown) but o f the f iv e  patients examined only 
two ind iv idua ls responded to  PWM and then not a t a ll doses. However, 
there was no evidence o f an e ffe c t on IgG production.
Thus from the above i t  would appear tha t 7-IFN does not act 
d ire c tly  on the immunoglobulin producing c e lls  themselves but is  able 
to  reduce or negate the suppression produced by Facb. This could be 
e ithe r by rendering the Ig synthesising ce lls  re frac to ry  to  the 
suppressive e ffec ts  o f FacbR+ c e lls  or by acting on the la t te r  and 
preventing suppressor a c t iv ity .
Like the 2ME experiments, the numbers o f ind iv idua ls shown are 
very small. The above experiments need to  be repeated to  confirm the 
prelim inary find ings reported here.
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FIG 51 The e ffe c t o f 7-IFN on IgG synthesis in  normal subjects
PBMNC were incubated fo r 14 days in the presence or absence o f 10 
units o f 7-IFN. Levels of IgG were measured by ELISA. Median 
values o f IgG are depicted in the figu re .
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The resu lts  presented in  th is  chapter concern modulation o f 
antibody synthesis by heat aggregated IgG. A p u rifie d  myeloma 
protein o f the IgG-| subclass was employed to  produce Hagg. This was 
isolated from human serum using ion-exchange chromatography as 
described in  Chapter 2, and was always used fresh ly  aggregated at 
63°C fo r  30 minutes fo r  each experiment.
This ligand had not previously been used in th is  laboratory to 
investigate negative feedback suppression o f immunoglobulin syn­
thes is . Thus in i t ia l  experiments involved se tting  up an assay fo r 
ju s t th is  purpose. Since Hagg would in te rfe re  with IgG and RhF 
ELISAs, a two-step cu ltu re  system had to  be employed. PBMNC were 
f i r s t  reacted with Hagg and PWM fo r a period o f 5 days and then 
washed in fresh medium (to  remove ligand) and recultured to  generate 
supernatants which were then assessed fo r  antibody production by the 
ELISA system. Results o f the prelim inary experiments which deter­
mined the operating conditions o f th is  assay appear below in 
Section 1.
SECTION 1
1. Suppression o f IgG synthesis by Hagg
Heat aggregated IgG<| was added to PWM-stimulated (P200) cultures 
o f normal PBMNC at f in a l concentrations o f 0.05, 0.5 and 
5 jjg /m l. Figure 1 shows tha t suppression was found to  occur 
best when Hagg was present at a concentration o f 5 ;jg /m l. The 
IgG response was reduced by 50% at th is  concentration, giving 
p values o f < 0.05 and < 0.01 when compared with suppression
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FIG 1 Pose-dependent suppression o f PWM stimulated IgG response 
by Hagg
Normal PBMNC were stimulated with P200 and incubated with 3 dosesof 
Hagg fo r 5 days. Cells were washed and then re-incubated in fresh 
medium fo r a fu rther 5 days. Suppression of the IgG response was 
assessed and results expressed as a percentage of the stimulated IgG 
response where no Hagg was present. Horizontal bars represent median 
values,
* p < 0.05 when compared with suppression at 5 jjg/ml Hagg 
* *  p < 0.01 when compared with suppression at 5 pg/ml Hagg
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observed a t 0.5 and 0.05 ^ug/ml Hagg respective ly. Responses 
seen at these 2  la t te r  concentrations did not d if fe r  from each 
other (p > 0.05). In 2 subjects i t  was found tha t the 2 lower 
doses o f Hagg produced enhancement instead o f suppression. 
These subjects were also found to  e xh ib it less suppression at 
5 /jg/ml Hagg.
Figure 2 shows data obtained when equivalent concentrations 
o f aggregated F(ab ' ) 2  and BSA were added to  normal PBMNC and 
cultured as fo r Hagg. F(ab ' ) 2  was found not to  suppress the 
antibody response, w h ils t BSA exhibited some a c t iv ity .  This 
almost ce rta in ly  was due to  the presence o f small amounts o f IgG 
in BSA preparation. Casein was then tested as an a lte rna tive  
protein (data not shown). This was found not to  suppress the 
IgG response at the two higher concentrations, 5 and 0.5 jig/m l.
These experiments thus show tha t Hagg suppression o f the 
IgG response seen in Figure 1 was due to  the presence o f Fc and 
not ju s t to  an excess o f protein present in  an aggregated form.
2. Time of incubation o. Hagg cultures
PWM-stimulated PBMNC from normal subjects were set up with 0.05, 
0.5 and 5 ;jg/ml Hagg and the cultures incubated fo r a to ta l o f 
10 or 14 days. Figure 3 shows th a t in  one index case Hagg 
suppression o f the IgG response was bette r a t Day 10 than at Day 
14. In another individual where only Day 14 cultures were set 
up, no suppression was observed (data not shown).
3. Time of addition of Hagg
Using a f in a l concentration o f 5 jjg/ml Hagg in P200-stimulated 
normal PBMNC cu ltures, i t  was found tha t suppression o f IgG
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FIG 2 The e ffe c t o f heat aggregated F ta b '^ t  BSA and IgGj on PWH 
stimulated IgG response in  one index case
Purified F(ab1 )2 fragment ( Q  ) and BSA ( ^  ) were heat
aggregated at 63°C fo r h a lf an hour and added to P200 stimulated 
normal PBMNC cultures at a fin a l concentration o f 5 >jg/ml. The 
e ffects o f Hagg ( ^  ) were simultaneously investigated. Suppression 
o f the IgG response is  expressed as a percentage of the PWM 
stimulated response where no Hagg was present.
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FIG 3 Hagg suppression o f PWM-stimulated IgG response on days 10 
and 14 in one index case
P200 stimulated normal PBMNCs were incubated with 3 doses o f Hagg fo r 
5 days, then washed and recultured in fresh medium fo r a to ta l of 10 
( £2 ) or 14 ( £3 ) days. Suppression of the IgG response was 
assessed and expressed as a percentage o f the stimulated IgG response 
where no Hagg was present.
0 Hagg
Concentration of Hagg in>ig/ml
205
production only occurred when the ligand was present at the
beginning o f the cu ltu re . Adding Hagg on Day 1 and Day 3 was
in e ffe c tive . These data are shown in  Figure 4.
From the above i t  was decided tha t subsequent Hagg
experiments should be conducted using PWM at a d ilu tio n  o f 1/200 
and tha t Hagg should be added a t a f in a l concentration of
5 jjg/ml a t the beginning o f the cu ltu re  period, which was to  
la s t a to ta l o f 1 0  days.
Using these conditions Hagg suppression o f IgG synthesis in 
various te s t groups was examined. These resu lts  appear in 
Section 2.
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FIG 4 The e ffec t o f varying time o f Hagg addition on feedback
suppression o f PWH-stiaulated IgG response
Normal PBMNC were stimulated with P200 and a fin a l concentration of 
5 /jg/ml o f Hagg added on days 0, 1 and 3. Cells were washed on day 5 
and recultured in fresh medium fo r a fu rther 5 days. The degree of 
suppression was assessed and results expressed as a percentage of the 
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SECTION 2
1. Suppression o f IgG production by Hagg in  health and disease
The e ffe c t o f Hagg on both spontaneous and PWM-stimulated IgG 
responses was examined in  young and old normal healthy controls and 
in  patients w ith RA, AS, OA and F e lty 's  syndrome.
Hagg was found to  have no s ig n ific a n t e ffe c t on spontaneous IgG 
synthesis. Table 1 shows tha t the median values o f IgG production 
were e ithe r to ta l ly  unaffected or s lig h t ly  reduced. Only with RA 
patients were leve ls o f IgG s lig h t ly  raised compared to  cultures
where no Hagg was present. I t  should be noted, however, tha t w ith in  
each group the ind iv idua l responses were variab le. This explains why
in  groups such as old normals (ON) and F e lty 's  patients the response
range increased, although with Hagg the median values were found to 
be reduced.
The e ffects  o f Hagg on PWM-induced IgG production in  various 
te s t groups are il lu s tra te d  in Figures 5 - 1 0 .  Only ind iv idua ls pro­
ducing > 300 ng/ml IgG have been considered.
Figure 5 shows Hagg suppression o f IgG synthesis in  normal
healthy contro ls . The PWM response was quite variable but both high 
and low responders, w ith the exception o f one ind iv idua l, exhibited a 
suppressed antibody response upon addition o f Hagg. A median value 
o f 1568 ng/ml f e l l  s ig n if ic a n tly  to 780 ng/ml (p < 0.05).
A degree o f suppression was also observed in most o f the 
subjects in  the various te s t groups, with the exception o f one or two 
ind iv idua ls who exhib ited an enhanced or unaltered IgG response. 
With RA patients the median value fe l l  from 2844 ng/ml to  1747 ng/ml 
IgG. With AS IgG was reduced from 1813 ng/ml to  955 ng/ml and in  OA 
from 1073 to  598 ng/ml. In old controls the median values appear to 
ind icate a lack o f suppression. This, however, is  misleading, since
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TABLE 1 Showing the range and Median values o f spontaneous IgG production in  the absence and presence 
o f Hagg in  normal healthy controls and patients with RA, AS, OA and F e lty 's  syndrome









Normals 2 0 0  - 1 2 0 15 0 - 5 5 15
RA 15 0 - 5 4 14 0 - 6 1 2 0
AS 1 0 0 - 8 2 32.5 5 - 7 5 29
OA 14 0 - 6 2 23 0 - 5 3 18.5
ON 1 0 3 - 7 3 16 0 -  103 13.5
Fe lty 's 4 5 -  117 27 9 - 155 23
FIG 5 Hagg suppression o f PWM-stimulated IgG synthesis in  normal 
healthy controls
P200 stimulated PBMNC were incubated in the presence or absence o f 
5 >jg/ml fin a l concentration of Hagg fo r 5 days. Cells were then 
washed and recultured in fresh medium fo r a fu rther 5 days. IgG 
content was assessed by ELISA. Median levels are indicated by the 
horizontal bars.










FIG 6  Hagg suppression o f PWM-stimulated Ig6  synthesis in 
patients w ith established RA
P200 stimulated PBMNC were incubated in the presence or absence of 
5 >jg/ml fina l concentration of Hagg fo r 5 days. Cells were then 
washed and recultured in fresh medium for a fu rther 5 days. IgG 














FIG 7 Hagg suppression o f PWM-stimulated IgG synthesis in  AS
patients
P200 stimulated PBMNC were incubated in the presence or absence of 
5 jjg/ml fina l concentration of Hagg fo r 5 days. Cells were then 
washed and recultured in fresh medium fo r a fu rther 5 days. IgG 














NTOR= 1.449x 103ng/ml MTOR=0.534x ICPng/mi
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FIG 8  Hagg suppression o f PMM-stimulated Ig6  synthesis in  OA
patients
P200 stimulated PBMNC were incubated in the presence or absence of 
5 jug/ml fin a l concentration of Hagg fo r 5 days. Cells were then 
washed and recultured in fresh medium fo r a further 5 days. IgG 











FIG 9 Hagg suppression o f PWM-stimulated IgG synthesis in  old 
normal subjects
P200 stimulated PBMNC were incubated in the presence or absence of 
5 jug/ml fina l concentration of Hagg fo r 5 days. Cells were then 
washed and recultured in fresh medium fo r a further 5 days. IgG 










FIG 10 Hagg suppression o f PWM-stimulated IgG synthesis in  F e lty 's  
patients
P200 stimulated PBMNC were incubated in the presence or absence of 
5 pg/ml fin a l concentration of Hagg fo r 5 days. Cells were then 
washed and recultured in  fresh medium fo r a fu rthe r 5 days. IgG 




most subjects were found to  be well suppressed when individual 
responses were examined. None o f the above data was found to  reach 
levels o f s ta t is t ic a l significance when P200 +/ -  Hagg resu lts  were 
compared w ith in  each group using the Mann-Whitney U-test. Fe lty 's  
patients were not included in th is  analysis because o f the very low 
number o f patients availab le. In th is  group only 2 subjects 
responded to PWM adequately, w h ils t the th ird  was a low responder and 
the fourth  did not respond at a l l .  However, a ll three responding 
subjects exhibited marked suppression with the median value fa ll in g  
from 1170 ng/ml to  340 ng/ml. A larger number o f patients would need 
to  be tested in  order to  evaluate the e ffects  o f Hagg on IgG 
synthesis in  th is  subgroup o f RA.
I t  can be seen from the above tha t RA patients generated much 
more IgG than normal subjects. This, however, did not reach 
s ta t is t ic a l s ign ificance. Immunoglobulin levels in  patients with AS 
were only s lig h t ly  raised above normals, w h ils t those in 0A, old 
normals and F e lty 's  subjects were s lig h t ly  lower. The 0A group was 
found to  contain a large number o f non-responders. Only 7 o f the 14 
ind iv idua ls tested responded to  PWM. Possibly another dose o f 
mitogen might have yielded a better re s u lt.
Because o f the d iffe re n t levels o f IgG production, i t  was not 
possible to  d ire c tly  compare the extent to  which Hagg suppressed the 
antibody response in each o f the above groups. The P200 + 5 jjg/ml 
Hagg resu lts  were thus converted to  percentages o f the antibody 
response where no ligand was present. These data are shown in  Figure
11. Responses in  normal subjects fe l l  to  a median o f 53% o f the P200 
response when Hagg was added to  the cu ltu res. This value was 76% in 
patients with RA, 53% in  AS subjects, 34% in  the 0A group, 59% in  old
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FIG 11 Comparison o f Hagg-mediated suppression o f the PWM- 
stimulated IgG response in  normal and patient groups
Suppression is  expressed as a percentage of the P200 response where 
no Hagg was present. Median values and in te rq u a rtile  ranges (T) are 
shown.it d < 0.02 when compared to the suppression observed in normal 
healthy controls
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normals and 30% in  F e lty ’ s patients. Comparing these resu lts  using 
the Mann-Whitney U -test, i t  was found th a t only the RA group showed 
s ig n if ic a n tly  less suppression compared to  normal healthy controls 
(p = 0.016). No differences were found between control subjects and 
any o f the other groups examined, nor were these groups, including 
old normals, d iffe re n t from RA patien ts. This is  probably explained 
by the greater v a r ia b i l i ty  seen in response to  Hagg in  these groups. 
This, a t least in  the 0A group, may be a ttribu ted  p a rtly  to  age, 
since the in te rq u a rtile  range in old normals was found to be larger 
than tha t observed in  the young contro ls . ( I t  should be noted tha t 
the term 'normal con tro ls ' in  the above te x t re fers to  the young 
healthy subjects and not to  the group comprising the old normals.)
F e lty 's  patients were not included in  the above s ta t is t ic a l 
analysis because o f the very small numbers o f patients involved. 
However, these patients were well suppressed, although they form a 
subgroup of RA. A la rger number o f these patients needs to  be 
investigated in order to  confirm these data.
2. The effect of Hagg on IgM RhF production
The e ffe c t o f Hagg on spontaneous and PWM-induced IgM RhF pro­
duction was also examined. These data appear in Figures 12 - 17.
Addition o f Hagg completely abolished low levels o f spontaneous 
RhF synthesis. In one RA patient and one F e lty 's  subject, who 
produced 35 and 14 ng/ml o f RhF respective ly, Hagg was found to 
markedly suppress the autoantibody response. This dropped to  30% o f 
the o rig ina l level in  the RA patien t and to  21% in  the F e lty 's  
subject. Only in  one person, an old normal, was Hagg found to  e l ic i t  
RhF production and then only to  very low leve ls (< 5 ng/ml).
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FIG 12 The e ffe c t o f Hagg on spontaneous and PWM-stimulated IgM 
RhF production in  normal healthy controls
Hagg was added at a fin a l concentration o f 5 pg/ml to PBMNC cultures 
in the absence or presence of PWM (P200). Median values are 
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FIG 13 The e ffe c t o f Hagg on spontaneous and PWM-stlmulated IgH
RhF production in  established RA patients
Hagg was added at a fin a l concentration of 5 jjg/ml to PBMNC cultures 
in the absence or presence of PWM (P200). Median values are 
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FIG 14 The e ffe c t o f Hagg on spontaneous and PUM-sti imitated IgM
RhF production in OA patients
Hagg was added at a fin a l concentration of 5 pg/ml to PBMNC cultures 
in the absence or presence of PWM (P200). Median values are 
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FIG 15 The e ffe c t o f Hagg on spontaneous and PWM-stimulated IgH
RhF production In A5 patients
Hagg was added at a fin a l concentration of 5 ^ig/ml to PBMNC cultures 
in the absence or presence of PWM (P200). Median values are 
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FIG 16 The e ffe c t o f Hagg on spontaneous and PWM-stimulated IgH
RhF production In Fe lty 's  patients
Hagg was added at a fina l concentration of 5 jjg/ml to PBMNC cultures 
in the absence or presence of PWM (P200). Median values are 
represented by the horizontal bars.
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FIG 17 The e ffec t o f Hagg on spontaneous and PWM-stimulated IgH
RhF production in  old normal subjects
Hagg was added at a fin a l concentration of 5 jjg/ml to PBMNC cultures 
in the absence or presence of PWM (P200). Median values are 
















Stimulation o f PBMNCs led to  an increase in  the number o f 
ind iv idua ls generating autoantibody in  most groups. However, the 
median levels o f RhF were not always enhanced above those observed 
w ith spontaneous production. The addition o f Hagg produced variable 
responses. In normal and AS subjects the median values were s lig h t ly  
reduced; in  old normals there was no change and in OA and RA subjects 
there was enhancement. This, however, was only o f note in  the la t te r  
group where a tw o-fo ld  increase (3.5 to  6  ng/ml) in  RhF synthesis was 
observed. In F e lty 's  patients, on the other hand, PWM-induced RhF 
production was completely suppressed in  both low and high generators 
o f autoantibody.
Thus is  would appear from the above data tha t Hagg is  able to  
suppress spontaneous RhF production, but when PBMNC are polyclonally 
stimulated with mitogen, a variable e ffe c t is  produced, which in  RA 
subjects tends towards enhancement.
Part o f th is  v a r ia b il ity  might re s u lt from effects on to ta l IgM 
synthesis in  normals. Supernatants from 6  normal, 6  RA and 6  OA 
PBMNC ce ll cultures were examined fo r the e ffe c t o f Hagg on IgM 
production. Figure 18 shows tha t IgM is  not as well suppressed as 
the corresponding IgG response (a t least in  normals and RA) and tha t 
the e ffe c t o f the ligand is  highly variable but even with IgM the RA 
subjects are less suppressed compared to  contro ls . C learly, more 
subjects needed to  be examined, since o f the 18 people tested, 6  were 
non-responders fo r  IgM. Certainly fo r  RA subjects, IgM production is  
reported to be reduced compared to  controls (Olsen e t a l , 1982). 
This was also indicated in  Chapter 3.
Percentage suppression o f RhF by Hagg could not be su itab ly  com­
pared between patien t groups shown in  Figures 1 2 - 1 7  because o f the 
low levels o f RhF generated. However, using only those ind iv iduals
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FI6  18 The e ffe c t o f Hagg on PWM-stimulated IgM and IgG responses 
in normal, RA and OA subjects
Suppression of the IgM and IgG synthesis by 5 pg/ml Hagg is  expressed 
as a percentage o f the P200 stimulated response where no ligand was





























producing > 10 ng/ml RhF, percentage Hagg suppression o f the
autoantibody was compared with the corresponding e ffects  o f Hagg on 
IgG production a t P200.
Figure 19a shows th a t in  some cases IgG was suppressed much more 
than RhF w h ils t in  others (Figure 19b) the s itua tion  was reversed. 
Furthermore, i t  was found tha t Hagg may have opposing e ffects  on IgG 
and RhF generation (Figure 19c). Thus, lik e  Facb in Chapter 4, Hagg 
may modulate polyclonal IgG and spec ific  RhF responses d iffe re n tly  in  
the same person and between ind iv idua ls .
3. Comparison of Hagg and Facb suppression of IgG response
Data presented in  Chapter 4 and here suggest tha t Hagg is  a 
be tte r suppressor o f IgG synthesis than Facb. This is  i l lu s tra te d  in 
Figure 20 which depicts suppression o f antibody response in  normal 
PBMNC by Facb a t concentrations o f 0.2, 2 and 20 jug/ml and by Hagg at 
0.05, 0.5 and 5 jjg /m l. S ta t is t ic a lly  s ig n ifica n t difference between 
the two ligands is  reached only when Hagg is  used a t 5 jjg /m l.
One obvious explanation fo r differences observed in  Facb- and 
Hagg-mediated suppression .s tha t the former is  not able to  bind to  
the relevant Fc receptors as strongly as the la t te r .  Thus in h ib it io n  
experiments were carried out using PBMNC from RA patients, which gave 
a higher level o f FacbR+ ce lls  then normal subjects. PBMNC were
incubated with d iffe re n t concentrations o f Hagg and Facb (the ranges 
included those concentrations normally employed in  cu lture) fo r h a lf 
an hour on ice before being set up in  an Facb rosette assay as usual. 
The resu lts  o f these experiments appear in  Figures 21 and 22. 
Preincubating PBMNCs w ith increasing concentrations o f Facb, w h ils t 
giving r ise  to  varia tions in  the percentage o f rosettes, did not
a ffe c t the level o f Facb rosettes observed (p > 0.05), even when the
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FIG 19 Modulation o f PWM-stimulated IgG and IgM RhF responses by 
Hagg
The e ffects  o f Hagg on IgG ( £3 ) and corresponding IgM RhF ( | | ) 
production are depicted. Results are expressed as a percentage of 
the P200 response where no Hagg was present. Median values are 
shown. In (a) IgG is  better suppressed than RhF. In (b) IgM RhF is  
suppressed better than the corresponding IgG response. In (c) IgM 
















































FIG 20 Comparison o f Hagg and Facb suppression o f IgG response at
P200 in normal healthy controls
Suppression is  expressed as a percentage o f the stimulated response 
where no ligand was present. Facb and Hagg data are represented by 
(■— ■) and ( • — •) respectively, where each point in the former is  a 
median value of 16 observations and in the la t te r  o f 19 
determinations.
** p < 0.01 when the degree of suppression is  compared with tha t
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FIG 21 The e ffe c t o f Facb on percentage o f Facb rosettlng c e lls
RA PBMNC were pre-incubated with increasing concentrations of Facb 
fo r 30 mins on ice and examined by the rosette assay fo r FacbR 
expression. Each point is  a mean of 4 determinations and the (T) 



















concentration increased to  80 jjg /m l. With Hagg the percentage o f 
Facb rosettes fe l l  dramatically (p < 0.05) from 6.5% to  1.4% and 2.7% 
at concentrations o f 2 2  and 1 1  ^jg/ml respectively, ind ica ting  tha t 
Hagg is  c le a rly  be tte r than Facb fo r in h ib it in g  rosette formation. 
This perhaps is  not surprising since i t  should by the very nature of 
i t s  m ulti valency be able to  do so. Although Hagg would appear to  be 
a much more e ffe c tive  ligand than Facb, i t  should be remembered tha t 
Hagg is  also able to  re c ru it other FcR+ ce lls  apart from those 
bearing the Facb receptor in to  the process o f negative feedback 
suppression.
Table 2 shows the suppression o f IgG production in  normal 
healthy contro ls and RA patients at P200 with Facb and Hagg. I t  can 
be seen th a t even w ith a superior ligand, FcR-mediated feedback sup­
pression is  not improved in RA subjects. Comparing resu lts  obtained 
with Facb with those observed in  Hagg cultures reveals no s ta t is t ic a l 
d ifferences. In normal ind iv idua ls , however, suppression is  s ig n if i ­
cantly improved upon using Hagg. The Table also includes median 
values o f IgG which shows tha t w ith in  a te s t group Facb and Hagg 
cultures a t P200 had comparable levels o f IgG production. So d i f ­
ferences in  suppression or the lack o f them were not due to  
differences in  lymphocyte stim ula tion.
Comparison o f Facb and Hagg e ffects  on RhF production is  not 
re a lly  possible because o f the very small number o f patients 
producing s u ff ic ie n t autoantibody to  be analysed in th is  way.
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FIG 22 The e ffect o f Hagg on percentage Facb rosettlng ce lls
RA PBMNC were pre-incubated with increasing concentrations of Hagg 
fo r 30 mins on ice and examined by the rosette assay fo r FacbR 
expression. Each point is  a mean of 4 determinations and the (T) 
represents one standard deviation.
* p < 0.05 when compared to the percentage o f FacbR* ce lls  
















TABLE 2 Comparing suppression produced by Facb and Hagg in  normal healthy controls and RA patients a t P200
Asterixes refer to p values obtained when results of Facb and Hagg were compared using the 
Mann-Hhitney U-test. * *  p < 0.01; *  p = 0.02
Test groups
F A C B H A G G
n IgG in Results expressed as % 
ng/ml median value o f the 
P200 response alone
n IgG in Results expressed as % 
ng/ml median value o f the 
P200 response alone
Normals 16 1800 P200.2 = 106% **
P2002 = 82% ** 
P200.20 = 71% *
19 1600 P200 + Hagg = 53%
RA 22 2680 P200.2 = 84%
P2002 = 90% 
P20020 = 89%
i -  _____ ___________
12 2800 P200 + 5 ng/ml Hagg = 76%
CHAPTER 6  
DISCUSSION
Mechanisms con tro lling  antibody synthesis in  RA are defective. 
This is  c lear not only from the observations tha t hypergamma- 
globulinaemia and autoantibody formation are common findings in RA, 
but also from the jo in t  pathology where numerous plasma ce lls  are 
ac tive ly  synthesising immunoglobulin (Munthe and Natvig, 1972). Such 
observations have led to  intensive investigations o f the pathways 
which regulate antibody synthesis in  th is  disease. Many o f the in 
v it ro  studies have centred on T ce ll function and these have revealed 
th a t suppressor ce ll a c t iv ity  in  RA is  impaired, especially in  the 
jo in t  (Chattopadhyay e t a l , 1979 a,b; Abdou e t a l , 1981; Romain et 
a l , 1982; Sakane e t a l , 1982). Currently, th is  is  believed to  be due 
to  a lack o f suppressor inducer ce lls  in  the CD4+ population (Emery 
e t a l , 1987; Salmon e t a l , 1987). However, another mechanism exists 
which is  also important in  co n tro lling  the antibody response and th is  
is  Fc-mediated negative feedback suppression. Here the immuno­
g lobulin  is  able to suppress i ts  own synthesis by in te raction  with 
the Fc receptor on the responding c e ll .  Exactly how th is  suppression 
occurs is  not c lear, but two schools o f thought e x is t; f i r s t ,  tha t 
antibody in te rfe res with T-B ce ll co-operation (Hoffman e t a l , 1980) 
and second, tha t i t  switches o f f  B c e lls  from immunoglobulin 
synthesis and d iverts them to  memory ce ll production (Kolsch e t a l, 
1980), a process which can be reversed by T ce ll fac to rs . Recently, 
a subpopulation o f FcR+ ce lls  has been described which bears 
receptors fo r  the CH2 region o f rabb it IgG (Hall e t a l , 1980). These 
ce lls  are referred to  as FacbR+ c e lls  and have been found to
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partic ipa te  in  negative feedback suppression (Eales e t a l , 1984). 
E a rlie r work in  th is  laboratory has shown tha t in  patients with 
established RA, Facb-mediated feedback suppression o f IgG response is  
impaired in comparison to  tha t observed in  normal healthy controls 
(Eales e t a l , 1985).
On the basis o f these data the question arose as to  whether th is  
defect was also present in  early RA and furthermore, did i t  express 
any disease sp e c ific ity?  This would not only provide information 
concerning the early  aetiopathogenetic events in  RA, but more 
importantly may be o f potentia l use to  the c lin ic ia n . Rheumatoid 
disease in  i t s  early  stages is  d i f f ic u l t  to  d istingu ish from other 
forms o f p o ly a r th r it is  seen in the Early Synovitis C lin ic . C learly, 
a parameter which could indicate w ith some degree o f accuracy the 
existence o f RA would be o f enormous benefit in  terms o f early 
treatment and management o f the pa tien t.
The present study was thus undertaken to  investigate Facb- 
mediated negative feedback suppression in patients with early RA.
The subjects used in  the investigation were a ll drawn from the 
Early Synovitis C lin ic , where they were c la ss ifie d  in to  early RA 
pos itive , early RA negative or early palindromic RA subgroups. The 
la s t group had o r ig in a lly  been subdivided in to  RhF pos itive  and RhF 
negative sets, but in  the f in a l analysis no d is tin c tio n  was made 
between them because o f the small number o f patients in  each subset. 
Control groups consisted o f normal healthy ind iv idua ls , patients with 
established RA as pos itive  controls and OA subjects as controls fo r 
chronic a r th r i t is .  F e lty 's  patients were also tested, being repre­
sentative o f advanced disease.
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Antibody production was induced by PWM at doses selected as 
optimal during prelim inary experiments, which were carried out using 
PBMNC from normal and established RA subjects. In these early 
experiments, i t  was found tha t w h ils t PWM-driven IgG response in  the 
two groups was s im ila r, both in  terms o f the levels o f immunoglobulin 
produced and k in e tics , nearly three times as much IgG was generated 
spontaneously by PBMNC from RA patients compared to  contro ls . This 
is  in  agreement with data obtained by other authors who have reported 
high leve ls o f spontaneous Ig secretion by B ce lls  (Al-Balaghi e t a l , 
1982). However, when Facb and Hagg cultures were examined, i t  was 
found th a t spontaneous IgG production by RA PBMNC was s im ila r to  tha t 
observed in  normal cu ltures; furthermore, the k ine tics  o f the IgG 
response to  PWM were d iffe re n t. At P200 higher levels o f 
immunoglobulin were generated by established RA subjects compared to 
normal healthy contro ls, w h ils t a t P1000 the s itua tion  was reversed. 
I t  is  thus possible to  obtain d iffe re n t immunoglobulin responses on 
d iffe re n t occasions even though the operating conditions remain the 
same throughout. I t  is  therefore not surprising th a t c o n flic tin g  
data e x is t in  the lite ra tu re  regarding PBMNC responses to  mitogens in 
v i t r o . Part o f th is  v a r ia b il ity  may arise from the PWM preparation 
i t s e l f ,  which a t best is  ju s t a crude extract o f the parent roo t. 
Another explanation is  tha t o f patient se lection. Most investigators 
tre a t RA patients as a whole and do not c la ss ify  them in to  subsets of 
early and established disease - as has been done in  the present study 
- or else group the patients according to  treatment, eg NSAIDs or 
immunosuppressant therapy.
Although the resu lts  were not s ig n ifica n t in  the present report, 
i t  was found th a t established RA patients generally produced more IgG 
than contro ls, w h ils t in  patients with early palindromic RA levels o f
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Ig production were s im ila r to  normal controls and in  patients with 
early  seropositive and seronegative disease, these were s lig h tly  
less. Other authors have reported e ithe r s ig n if ic a n tly  depressed 
(Segond e t a l , 1979; Poikonen e t a l , 1982; Pardo e t a l , 1984) or 
normal (Bell e t a l , 1981; Patel e t a l , 1983) in  v it ro  antibody 
responses in  RA. Thus, RA patients need to  be much more c learly  
defined in  investiga tive  studies.
Examination o f the e ffe c t o f Facb on IgG in  the various te s t 
groups revealed th a t suppression o f antibody response was dependent 
on the dose o f PWM used. In groups where suppression was observed, 
ie  in  normal healthy contro ls, early RA positive  and palindromic 
patien ts, i t  was found th a t suppression became apparent as the PWM 
concentration was reduced. Thus suppression was best observed at the 
PWM dose P1000. This raised the question o f whether IgG synthesis 
was lower at th is  dose compared to  other doses tested and therefore 
was easier to  suppress.
Examination o f the immunoglobulin production at the three PWM 
doses showed, fo r instance,that in  normal and palindromic subjects, 
IgG synthesis on the contrary was maximal a t P1000. Therefore, 
maximum stim ulation appeared to  generate maximum suppression. These 
data are in  agreement with those presented by Weigle and Berman 
(1979) who reported th a t the greatest degree o f suppression produced 
by Fc fragment in  Fab immunised mice was obtained in  those 
ind iv idua ls in  whom the antibody response was good. With low 
responders on the other hand, poor suppression was observed. 
Analysis o f disease a c t iv ity  in  early RA positive  patients also 
showed tha t as a c t iv ity  increased Facb suppression became greater. 
Furthermore, there was a d ire c t co rre la tion  between the number o f 
FacbR+ ce lls  and disease a c t iv ity .  These data suggest tha t when the
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immune system is  highly activated, the FacbR+ population is  expanded 
and more o f these ce lls  are recruited in to  the process o f negative 
feedback suppression.
However, other factors must be involved. F irs t ly ,  in  patients 
w ith established RA, numbers o f FacbR+ ce lls  were s ig n if ic a n tly  
higher compared to normal healthy contro ls, but Facb-mediated 
feedback suppression in  these subjects was impaired, Secondly, in 
early RA positive  subjects the IgG responses at P200 and P1000 were 
not very d iffe re n t, yet no suppression was observed at the former 
dose. Experiments with both humans (Goulding e t a l , 1986) and 
animals (Eales et a l , 1984) have shown tha t secondary responses or 
immunisation regimes lead to  an increase in  the number o f FacbR+ 
c e lls . S im ila rly , there have been numerous reports o f increased FcR 
expression upon ce ll stim ulation (Van Boxel and Rosenstreich, 1974; 
Kramer e t a l , 1975; Eales e t a l , 1984; Goulding e t a l , 1986). The 
discrepancy between high FacbR+ expression in patients with 
established RA and the in a b il i ty  to  suppress might therefore be 
explained i f  the former is  seen ju s t as an ind ica to r o f ce ll 
activa tion  and not as ind ica tive  o f the a b i l i ty  to  suppress.
The lack o f Facb suppression at higher concentrations of 
mitogen, as fo r example in normal, early RA positive  and palindromic 
subjects, may be p a rtly  explained by PWM blockade o f Facb receptors, 
though th is  was shown by Facb rosetting  experiments to  be s ig n ifica n t 
only a t P50. I t  is  possible th a t a t the lowest PWM dose ce lls  which 
are not stimulated at higher concentrations o f mitogen come in to  play 
and allow emergence o f suppression. A lte rn a tive ly , a c r i t ic a l 
concentration o f some ce ll modulating mediator may be achieved. For 
example, i t  is  known tha t TRF can bind to  FcR (Schimpl e t a l , 1977). 
During the immune response th is  is  believed to  compete with Fc fo r
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binding to  FcR (Kolsch e t a l , 1980). I t  is  possible tha t PWM stimu­
la tes TRF production and tha t th is  is  greater a t P50 than a t P1000, 
which might explain the emergence o f Facb suppression at the la t te r  
dose. Al-Balaghi e t al (1984) have reported increased production o f 
B ce ll d iffe re n tia tio n  fac to r in  RA. This is  synonymous with TRF and 
might explain why in  established RA subjects FcR-mediated (both Facb 
and Hagg) feedback suppression is  impaired. This, however, assumes 
th a t in  early RA pos itive  and palindromic disease TRF production is  
s im ila r to  healthy contro ls. The s itua tion  fo r  some reason may be 
d iffe re n t in  early RA negative subjects.
Although no s ta t is t ic a l differences were observed between the 
three early RA groups, i t  was found tha t in  contrast to  the other 
groups, IgG production in patients with early RA negative disease was 
not suppressed by Facb fragment, even when the PWM dose was reduced 
to  P1000. I t  has been suggested by some authors (Dojabloug e t a l , 
1980; Alarcon e t a l , 1982a; 1984) th a t seronegative RA is  a d iffe re n t 
disease e n tity  from seropositive disease. With reference to  Facb 
suppression the data obtained here would tend to  support such a 
suggestion. Preliminary data analysis o f Facb suppression in 
patients with established seronegative and seropositive RA, on the 
other hand, revealed no differences between the two subgroups. 
However, th is  is  perhaps not surprising since i t  has been found tha t 
in  the established RA group as a whole very l i t t l e  suppression was 
produced by Facb fragment. Since the m ajority o f the subjects in 
th is  group were seropositive, th is  suggests tha t as the disease 
progresses normal Facb suppression in  early RA positive  disease 
gradually becomes impaired. By th is  token i t  would therefore be 
expected tha t in  F e lty ’ s subjects very l i t t l e  suppression o f IgG 
synthesis would occur. Data a t P1000 unfortunately are not available
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fo r Facb suppression in th is  group, but as fa r as Hagg suppression is  
concerned, Fe lty 's  patients were found to  be well suppressed. 
However, with FacbR+ expression there is  a gradation with developing 
disease, with percentages o f FacbR+ ce lls  varying in the order: 
normals < early RA < established RA < F e lty ’ s patients. The data 
above also suggest tha t in  early RA negative disease Facb suppression 
o f IgG response does not d if fe r  a t a ll from established seronegative 
RA, since in both instances Facb suppression appears to  be impaired. 
This suggests that perhaps FacbR+ ce lls  are a more prominent feature 
o f seropositive disease than seronegative RA. The overall lack o f 
suppression in  the OA group is  hard to  explain but may in part be due 
to  the high v a r ia b ility  o f response in individual patients. The ro le  
o f the immune system in OA is  less marked than in  RA. Perhaps the 
s im ila r ity  in the results  obtained in  OA and RA re fle c ts  any chronic 
disease state.
What produces the gradual impairment in  feedback suppression in  
RA is  not c lear. However, a t least two p o s s ib ilit ie s  e x is t and these 
include old age and some aspect o f disease ch ron ic ity .
Old age was found not to  be responsible fo r the differences 
observed between early RA positive  and established RA patients, since 
the average ages o f these te s t groups were remarkably s im ila r -  56 
and 55 years respectively. Furthermore, when the ages o f onset were 
examined in re la tion  to Facb suppression i t  was found tha t subjects 
w ith early RA positive  disease behaved in a s im ila r fashion, 
regardless o f whether the disease started before or a fte r 60 years o f 
age and that these data d iffe red  from those observed in established 
RA patients who had been s im ila rly  analysed. The la t te r  were found 
to  be less well suppressed irrespective o f the age o f onset. Thus
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these observations seem to suggest tha t changes in the degree o f Facb 
suppression may be re lated to  the developing disease process.
The association between disease duration and Facb suppression 
was therefore investigated. I t  was found tha t though no s ig n ifica n t 
differences were obtained, patients with disease duration o f < 2  
years were better suppressed than those who had had the disease fo r 
> 2 years or fo r > 5 years.
The p o s s ib ility  tha t impaired Facb suppression might become more 
apparent with progressing disease is  fu rthe r indicated by data 
obtained when the e ffe c t o f Facb on spontaneous IgG production was 
examined. Here i t  was found tha t w h ils t Facb was able to  suppress 
antibody production in normals in  a dose-dependent manner, very
l i t t l e  suppression was observed in  the te s t groups. Here, some
degree o f difference was observed with early RA positive  patients but 
not with early RA negative and palindromics compared to normal 
contro ls, w h ils t OA, RA and Fe lty 's  subjects were found to  d if fe r  to 
a s lig h t ly  greater extent. The difference between the early RA 
pos itive  patients and the early RA negative and palindromic groups at 
PO is  probably because the former represent a more exacerbated 
p icture  o f RA than the la t te r  two groups, which exh ib it a milder form 
o f the disease. Comparing these data with observations at P1000, 
these findings seem to  suggest tha t w h ils t early RA positive  and 
palindromic patients cannot suppress well a t PO, they can nonetheless 
be m itogenically stimulated to  suppress. In early RA negative sub­
jec ts  th is  capacity is  impaired fo r some reason. In patients with
established disease no suppression occurs at PO and furthermore,
ce lls  cannot be triggered to  suppression even by mitogen stim ulation. 
So gradually as rheumatoid disease develops the a b il i ty  to  suppress 
becomes impaired.
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In studies investigating T suppressor ce ll function (Sakane e t 
a l , 1982), i t  was found tha t in early RA T ce lls  did not suppress, 
nor were B ce lls  responsive to  suppressor signals, but as disease 
progressed i t  was found that T c e lls  could be induced to  suppressor 
a c t iv ity  by Con A but the B ce lls  s t i l l  remained unresponsive. 
C learly, Facb fragment affects suppression d iffe re n tly  from the 
suppressor T ce lls  since in early RA positive disease B ce lls  are 
responsive to FcR mediated feedback suppression.
Exactly what aspect o f feedback suppression a lte rs  with 
progressing disease is  not c lear. Is i t  tha t the capacity o f FacbR+ 
ce lls  to  suppress is  impaired or do B ce lls  in  established RA become 
less responsive to  FcR-mediated suppression? Mixing experiments 
should have been conducted where Facb rosetting ce lls  and B 
lymphocytes from RA patients were separated and mixed with e ithe r 
normal B ce lls  or normal FacbR+ ce lls  respectively to  determine where 
th is  defect might l ie .  However, one would f i r s t  have to  take MLR 
interactions in to  consideration and ensure tha t these did not 
in te rfe re  with th is  pathway o f suppression.
I t  is  possible tha t in  vivo activa tion  may in fa c t be respon­
s ib le  fo r the impaired FcR-mediated feedback suppression seen in RA. 
There are numerous reports which show tha t in RA, ce lls  are activated 
both in  the jo in t  (Yu e t a l , 1980; Burmester et a l , 1981; G ali1i e t 
a l , 1981; Fox et a l , 1982; Duke e t a l , 1983) and in the c ircu la tio n  
(Yu e t a l , 1980; Burmester e t a l , 1981; Papadimitriou e t a l , 1982). 
This is  indicated by spontaneous 3 H-thymidine uptake (Horwitz e t a l , 
1970; Stratton and Peter, 1978; Froebel e t a l , 1984) and Ig synthesis 
(Al-Balaghi et a l, 1982) as well as by enhanced expression o f HLA-DR 
antigens (Yu et a l , 1980; Burmester e t a l , 1981; Fox e t a l , 1982).
Another explanation comes from the observation tha t SH groups
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are important in  FcR function (Abramson e t a l , 1971). In RA patients 
le /e ls  o f sulphydryl groups are reported to  be reduced (Lorber and 
Chang, 1968), ra is ing  the p o s s ib ility  th a t these may be related to 
the degree o f feedback suppression observed in  these patients.
The e ffects  o f 7-IFN and 2ME on Facb-mediated feedback 
suppression were investigated in a small number o f normal healthy 
controls and established RA pa tien ts . Only lim ited  data are 
available from these experiments because o f a lack o f response to PWM 
stim ulation in  the individuals tested. However, from the information 
available, i t  was found tha t w h ils t both 2ME and 7-IFN enhanced 
FacbR+ expression, these substances appeared to  be having opposing 
e ffe c ts . With the former the degree o f suppression was s lig h tly  
better and with the la t te r  there seemed to  be a negation o f the 
e ffects  of Facb fragment on antibody synthesis. I t  is  reported that 
7-IFN may augment ongoing antibody responses (Taylor-Papadimitriou 
and Rozengurt, 1985). So i t  would appear th a t in  the presence o f 7 -  
IFN and Facb antibody producing c e lls  are subject to  opposing e ffects 
and in the prelim inary experiments reported here, the effects o f 7 -  
IFN appear to  be much more potent than those o f Facb. In RA i t  is  
possible tha t in  areas o f 7-IFN production, FcR mediated feedback 
suppression may be overcome by the stim ulating influences o f 7 -IFN , 
thus leading to  enhanced antibody production. The above experiments 
should be repeated using a much larger sample group.
The re lationships between various c lin ic a l parameters and the 
degree o f Facb suppression were also examined and these were found to 
be in no way re lated to each other. Hall e t al (1980) also reported 
a lack o f corre la tion with FacbR+ expression and laboratory assess­
ment o f c lin ic a l a c t iv ity .  The mechanisms o f Facb-mediated feedback
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suppression were not investigated in the present study. However, i t  
is  known th is  occurs through interference with accessory ce ll 
function (Eales PhD thes is , 1982). Other studies in th is  laboratory 
(Goulding et a l , 1986) have indicated tha t FacbR+ ce lls  are probably 
involved in the early stages o f the immune response. Data presented 
here support th is  since i t  was found tha t Facb fragment had to  be 
present a t Day 0 fo r e ffe c tive  suppression to  occur.
During the course o f th is  study several preparations o f Facb 
were used. Whilst most batches were found to suppress, i t  was 
discovered tha t with one or two preparations, although the Facb 
fragment could be used successfully in the rosette assay to  detect 
FacbR+ ce lls , i t  was not suppressive. Again, th is  emphasises the 
dichotomy between FacbR+ expression and the a b il i ty  to  suppress. 
Thus the experiments conducted using these particu la r batches o f Facb 
were not va lid . I t  is  not clear exactly why th is  varia tion  in  Facb 
preparations should occur. One p o s s ib ility  is  tha t as the serum 
source aged, the immunoglobulin became much more fra g ile  and, under 
the acid ic conditions used in the preparation of Facb, was prone to  
cleavage at amino acid positions other than those normally reactive 
w ith plasmin. This may re su lt in  the loss o f amino acids which, 
w h ils t not a ffecting  the actual binding to  the receptors (since 
rose tting  s t i l l  occurs) may prevent triggering  o f the c e ll fo r 
suppression, possibly by a ffecting  ce ll receptor in teraction  with the 
G proteins in the plasma membrane. Examining the 3D structure o f the 
IgG molecule i t  can be seen tha t the CH3 domains are in  close 
association and th is  is  thought to  s ta b ilise  the C terminal o f the Fc 
region. The CH2 regions d if fe r  by not being s im ila rly  paired, which 
imparts to the region a re la tiv e ly  open structure. This region is
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thus referred to  as 's o f t ' and is  believed to possess a degree of 
inherent in s ta b il i ty  (Burton, 1985). Therefore, i t  is  l ik e ly  tha t 
during preparation damage can occur more read ily  to th is  area. This 
also suggests tha t the structura l nature o f the Facb fragment may in 
addition re su lt in  a looser or less avid binding to  the receptor and 
th is  would make i t  easier to  dislodge i t .  This was found to be true 
when Facb fragment and Hagg were compared fo r th e ir  respective 
a b il i t ie s  to  in h ib it  Facb rosette formation; Hagg was found to  be a 
much more e ffec tive  in h ib ito r .
During the immune response numerous mediators are released and 
some o f these (eg TRF), as mentioned e a r lie r ,  are able to  compete 
with the FcR binding ligand fo r the receptor s ite . Since there are 
l ik e ly  to  be ind iv idua l variations in the amounts o f these competing 
factors generated, d iffe re n t degrees o f competition must ex is t in 
each individual cu ltu re  system between the Facb and the competing 
factors, thus producing a wide range o f responses. This might 
explain why in Facb cultures with a ligand tha t may bind loosely to 
i t s  receptor and therefore be easily replaced, there is  such a wide 
varia tion  in the degree o f suppression produced in immunoglobulin 
synthesis. C learly, an investigation o f association constants would 
be most useful.
Thus in view o f the v a r ia b ility  o f the response observed in  Facb 
cultures and the p o s s ib ility  tha t th is  may in part be due to  the 
nature o f the ligand, another FcR binding ligand was examined. This 
was heat aggregated IgG, which was prepared from myeloma IgG-j ; a 
defined subclass o f IgG was employed rather than a heterogeneous IgG 
preparation in view o f the varying e ffects  d iffe re n t subclasses of 
immunoglobulin have on antibody-mediated feedback suppression (Henry
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and Oerne, 1968; Collisson et a l , 1983). Again i t  was found tha t in 
patients with established RA feedback suppression of immunoglobulin 
synthesis was impaired compared to  young normal healthy controls. 
However, in  comparison to normal subjects over the age o f 60 years, 
s ig n ific a n t differences were not obtained. This seems to  suggest 
tha t age may be p a rtly  responsible fo r the depressed levels o f Hagg- 
mediated suppression in RA. However, th is  does not hold true since 
f i r s t l y ,  no s ig n ifica n t differences existed between young and old 
normal healthy controls and secondly, in  OA patients with an average 
age o f nearly 70 years, the median level o f suppression was greater 
than th a t even in  young normals. However, no s ig n ifica n t differences 
were found between these two groups or between OA and RA subjects. 
This is  probably because o f the high v a r ia b il i ty  o f response observed 
in  th is  group. These data and those obtained with Facb cultures seem 
to  suggest tha t OA subjects possess an innate heterogeneity to FcR 
modulation o f the immune response. The patients in th is  study were 
not divided in to  primary or secondary OA; perhaps th is  has some 
bearing on the outcome o f FcR-mediated feedback suppression. 
S im ila rly  w ith ankylosing spondylitis  patients, though the median 
level o f Hagg suppression was the same as the young normals, the wide 
v a r ia b il i ty  in  response did not allow any s ig n ifica n t differences to 
emerge when compared to  established RA patients. I t  is  f e l t  tha t 
Hagg suppression o f antibody synthesis in  these groups should be 
reassessed using much larger sample groups.
Although no s ig n ifica n t differences were obtained between the OA 
and AS patients and subjects with established RA, the data do 
ind icate tha t the la t te r  are less receptive to  negative feedback 
suppression and tha t th is  is  not made greater by the use o f a much 
more potent FcR ligand. However, in te re s tin g ly , the very small
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number o f F e lty 's  patients examined were found to be well suppressed 
by Hagg, This poses the question as to  whether FcR-mediated 
suppression d iffe rs  between systemic disease and th a t where active 
synovitis ex is ts . Papadimitriou e t al (1982) reported th a t increased 
levels o f c ircu la tin g  low density lymphocytes were only found in 
patients with synovitis  but not in subjects with active EA disease, 
suggesting fu rthe r separation in immunological a c t iv ity  between these 
two phases o f the disease.
Exactly how Hagg-mediated suppression occurs was not 
investigated in the present study. However, i t  was found th a t lik e  
Facb, Hagg had to be present on Day 0 fo r suppression to  occur, but 
the k ine tics d iffe red  in  tha t Hagg suppression emerged e a r lie r ,  on 
Day 10, compared to Facb where suppression was most obvious on Day 
14. This may be because the former is  a much stronger FcR ligand or 
may operate via d iffe re n t pathways to  suppress the immune response 
compared to Facb, since Hagg can bind to  numerous c e ll populations 
w h ils t the Facb fragment binds only to  a selected ce ll type. I t  has 
been suggested tha t Hagg may produce suppression o f Ig synthesis by 
suppressing T helper ce ll a c t iv ity  (Moretta e t a l , 1979) or
trigge ring  phospholipase A2 a c t iv ity  in  macrophages, resu lting  in 
PGE2 generation, which then serves to stimulate T suppressor ce lls  
(Saito-Taki and Nakano, 1983). Le Thi Bich-Thuy and R evilla rd  (1984) 
showed tha t one or the other o f these mechanisms could be activated 
depending on the experimental protocol. Thus in  peripheral blood 
samples where ce lls  had been obtained by de fib rina tion , only IgG sup­
pression occurred and th is  was thought to  happen via T ce ll 
ac tiva tion . Where heparinised blood was used non-isotype suppression 
was found to occur and th is  was thought to  be due to PGE2 generation. 
Although a ll major classes of Ig producing ce lls  were suppressed, the
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degree o f suppression was much greater with IgG synthesising ce lls . 
Prelim inary data presented in Chapters 4 and 5 showed tha t IgNI pro­
duction was not as well suppressed as IgG synthesis by Facb amd Hagg.
B ce lls  are also believed to partic ipa te  in  FcR-mediated 
feedback suppression (Masuda et a l , 1978; Miyama-Inabi et a l , 1982). 
Pisko e t al (1986) showed tha t Hagg stimulated the production o f a
suppressive B ce ll fac to r (SBF) from normal PBMNC. In RA subjects
there is  a decrease in the amount o f SBF produced in response to Hagg
(White e t a l , 1986) compared to levels generated by PBMNC from young
and old normal healthy contro ls . In the te s t system used by White e t 
al (1986) the old normals d iffe red  from young contro ls, suggesting 
the age was an important factor in  the reduction o f SBF production. 
The data obtained by these authors and those presented in the present 
study are not d ire c tly  comparable because o f the differences in 
experimental conditions.
I t  is  f e l t  tha t the Hagg experiments described here should be 
repeated using larger numbers o f te s t individuals and extended to 
include early RA subjects.
The e ffec t o f Facb and Hagg on RhF production was also examined 
since the question arose as to whether the immunoregulatory effects 
o f these ligands affected only IgG production or whether they were 
generalised and extended to  other types o f antibody. Furthermore, 
was autoantibody production modulated d iffe re n tly  from normal 
antibody responses?
Thus, RhF production in the various te s t groups was examined. 
Overall median levels o f RhF production were low in  both Facb and 
Hagg cultures, probably because o f the large number o f non-responders 
in  each group.
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I t  was found tha t w h ils t young and old normal healthy contro ls, 
OA, early RA negative, early  palindromic and AS patients generated 
very l i t t l e  or no RhF spontaneously, both early RA positive  and 
established RA subjects were found to produce RhF at PO. These data 
agree with the findings o f other workers (Koopman and Schrohenloher, 
1980a; Tsoukas e t a l , 1980; Patel e t a l , 1983; Alarcon e t a l ; 1984). 
One explanation fo r  unstimulated autoantibody production in  these 
patients comes from the work o f Patel and Panayi (1984) who reported 
th a t in  RA there exists increased T helper ce ll a c t iv ity  fo r the 
production o f RhF. Examination o f the re la tive  proportions o f 
patients generating spontaneous RhF showed them to  be 22% and 7.4% in 
the early RA pos itive  and established RA subjects respectively. 
Higher values (40 -  50%) have been reported in  RA by other workers 
(Koopman and Schrohenloher, 1980a; Olsen e t a l , 1982) and the 
differences between th e ir  data and those presented in th is  thesis are 
most probably due to  pa tien t selection.
With PWM stim u la tion , RhF production was stimulated in  a ll 
groups. No s ig n ifica n t differences were found in the percentage o f 
subjects responding to  PWM in the various te s t groups. However, in 
agreement with data reported in  the lite ra tu re  (Koopman and 
Schrohenloher, 1980b; Alarcon e t a l, 1984) 50% o f young normal 
healthy controls ( in  the Facb study) were stimulated to  autoantibody 
production a t P200. The percentage fo r early RA positive  was 
s lig h t ly  higher compared to  controls and those fo r early RA negative, 
palindromics, OA and F e lty 's  subjects were lower. Whilst some 
reports (Alarcon e t a l , 1982b) show tha t seronegative patients are 
s im ila r to controls in  th e ir  a b il i ty  to  produce RhF in v itro  
fo llow ing ce ll s tim ula tion, others have reported tha t these patients 
have s ig n ific a n tly  decreased levels o f RhF production compared to
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controls (Pasquali et a l , 1981). Pasquali et al (1984) re la te  th is  
to  the presence of a n ti- id io ty p ic  antibodies in  seronegative 
subjects. However, i t  is  possible tha t th is  d ifference may be 
re lated to  the choice o f stim ulating agent, ie  EBV versus PWM, since 
each o f these polyclonal activators has been found to  activate 
d iffe re n t, non-overlapping populations o f B ce lls  (reviewed Olsen and 
Oasin, 1985).
The percentages o f responding subjects in the OA, F e lty 's , 
palindromic and early RA negative groups reported in the current work 
are probably a r t i f i c ia l ly  high because o f the small number o f 
patients examined compared to  the main groups o f young normals, early 
RA positive  and established RA.
Rodriguez et al (1982) reported tha t the a b il i ty  to  generate RhF 
in v it ro  became greater with age. However, th is  was not found to  be 
true  in the current investigation: levels o f RhF production in young 
and old normals were comparable.
Suppression o f PWM-driven RhF production by Facb was examined 
and found not to  vary with the dose o f PWM as reported fo r IgG 
synthesis. Although the e ffects o f th is  fragment on autoantibody 
production were variable, i t  was found tha t the lower doses o f Facb 
were suppressive w h ils t with increasing concentration o f the ligand 
the RhF levels e ithe r returned to  the response observed where no 
ligand was present or were enhanced. This is  in  contrast to  the data 
obtained fo r IgG synthesis where higher concentration o f ligand 
produced greater suppression. In the small number o f ind iv idua ls 
examined both Facb and Hagg were found not to  s ig n if ic a n tly  suppress 
IgM production and w h ils t the e ffects produced by Facb on IgM RhF 
were more akin to  those seen with IgM production, they were not
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always observed to  be s im ila r, ind ica ting  tha t RhF production may be 
d iffe re n tly  modulated from the generalised IgM response. This is  
fu rthe r emphasised by the observation th a t in  some subjects whose 
ce lls  did not produce RhF with PWM alone, the presence o f Facb led to 
autoantibody production. Thus i t  would appear tha t Facb can induce 
RhF synthesis. In the jo in t  where numerous enzymes are present, 
p a r t ia lly  degraded IgG molecules may enhance autoantibody production. 
Morgan and Weigle (1983) reported th a t a peptide derived by 
macrophages from Fc fragment could act as an adjuvant in  antibody 
response. I t  is  possible that a s im ila r a c t iv ity  may be generated 
from Facb fragment here and also in v ivo . Oxygen free radical 
damaged IgG may also stimulate RhF production in  the rheumatoid 
jo in t .
Whilst s im ila r e ffects were produced by Facb in a ll te s t groups 
and in PWM-stimulated and unstimulated cu ltu res, those seen with Hagg 
were found to be more d e fin it iv e .
In a ll patients spontaneous RhF production was completely 
eliminated or strongly suppressed by Hagg. However, with PWM-driven 
cultures results were variable. In most groups RhF levels of 
production were found to  be suppressed or unchanged. Only in  RA 
subjects was a two-fold enhancement seen in the level o f RhF 
synthesis in the presence o f Hagg.
I t  would therefore appear tha t w h ils t Facb fragment does not 
vary in  the e ffects  i t  produces in  d if fe re n t groups, Hagg has a 
d iffe re n t e ffec t on RA PBMNC compared to  those from other te s t 
groups.
I t  is  possible tha t RA ce lls  may be sensitised to  Hagg already 
and therefore see i t  not as an FcR immunomodulator but as an antigen. 
TaO et al (1984) have recently reported th a t at concentrations as low
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as 0.1 ug/ml, Hagg behaves as a stimulant fo r RhF production by RA 
c e lls . This is  not found in normal controls and th is  e ffe c t is  
d iffe re n t from tha t observed by Pisko et al (1982) who employed much 
higher concentrations o f Hagg (100 ug/ml). Here Hagg was found to  
behave as a polyclonal stim ulator o f immunoglobulin production, 
during the course o f which RhF was also generated. C learly, the data 
and the conditions presented in th is  thesis are s im ila r to  those o f 
TaO and co-workers (1984). However, whatever the concentrations o f 
Hagg, in  view o f the large numbers o f immune complexes present in  the 
jo in t  (Winchester et a l , 1970; Z va ifle r, 1973; McDuffie, 1978), the 
potential fo r antibody production exists in  the synovial compartment.
• Mechanisms con tro lling  RhF production are not c le a rly  
understood. However, i t  is  known tha t RhF generation in v it ro  is  
susceptible to  TH and Ts influences (Tsoukas e t a l , 1980). What ro le  
feedback suppression plays is  not cl ear,but the very nature o f the 
anti-IgG antibody may not allow pa rtic ipa tion  in  th is  control 
mechanism. I t  is  well established tha t IgM antibodies have a 
potentiating e ffec t on the immune response, thus i t  is  possible th a t 
IgM RhF may serve to  enhance i t s  own production in  vivo ra ther than 
suppress i t .  This production is  probably increased by two fac to rs . 
F irs t ly ,  there is  a lack o f T ce ll suppressor influences in  the 
synovial jo in t  and secondly, much o f the IgG produced in the synovial 
compartment has RhF a c t iv ity .  IgG RhF is  known to  self-associate and 
th is  would remove much o f the Fc necessary fo r FcR-mediated 
suppression. IgM RhF w ill furthermore prevent other non RhF IgG from 
mediating th is  process by complexing with th e ir  Fc regions. C learly, 
fo r  the in  v itro  assay system described in  the present investiga tion , 
th is  is  not a consideration because o f the very low amounts o f IgM 
RhF generated in the cu ltures. The lack o f suppressor influences in
252
the RA jo in t  would thus allow expansion o f a precommitted RhF
producing ce ll population.
I t  has recently been reported tha t RA subjects possess higher 
numbers o f CD5+ B ce lls  compared to  normal controls (Plater-Zyberk e t 
a l , 1985). These are thought to  be committed to  autoantibody
formation (Hardy e t a l, 1987). I t  is  possible also tha t ce lls  such 
as these may be modulated s lig h t ly  d iffe re n tly  from the PWM- 
stimulated ce lls  examined in  the current investiga tion , since CD5+ 
c e lls  are thought to  represent a re la tiv e ly  immature subpopulation o f 
the B ce ll reperto ire , w h ils t ce lls  responsive to PWM are mature 
lymphocytes which are committed to  high rates o f immunoglobulin 
production (Au lt and Towle, 1981). S im ila rly , the data presented in  
th is  thesis should be regarded in  the l ig h t  o f the observation by 
A u lt and Towle (1981) tha t only a small percentage o f the to ta l B 
ce ll population is  stimulated by PWM and the p o s s ib ility  exists tha t 
normal Ig production by other classes o f B ce lls  may vary in  k ine tics  
o f or su sce p tib ility  to  FcR-mediated feedback suppression. Thus 
other B ce ll activators should be also be used to  more fu l ly  assess 
th is  mechanism in  RA.
In view o f the questions asked at the in it ia t io n  o f th is  
investiga tion , the fo llow ing may be concluded:-
1. FcR-mediated feedback suppression in early RA positive  and
palindromic RA patients is  not impaired and tha t defect o f th is
control mechanism develops w ith progressive disease.
2. Data suggest tha t Facb feedback mediated suppression may be more 
pertinent to  seropositive disease than to seronegative disease, 
since the resu lts  obtained in the present study indicate tha t
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IgG synthesis by PBMNC o f seronegative patients is  not 
susceptible to  suppression by Facb.
3. Defects in  FcR feedback suppression cannot be used to  separate 
RA from d iffe re n t disease e n titie s  or from some subsets o f early 
disease because o f the wide v a r ia b ility  observed in  response to 
FcR binding ligands.
4. Modulation o f RhF production by FcR ligands is  complex. 
Certainly in  RA the p o s s ib ility  tha t these ligands may behave as 
antigens cannot be ruled out. Furthermore, i t  is  l ik e ly  tha t 
other immunoregulatory pathways, eg those involving a n ti-  
id io typ ic  antibodies or T suppressor ce lls , are much more 
relevant to  control o f IgM RhF synthesis rather than the non­
spec ific  suppression mediated by Facb fragment and Hagg.
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